Steroid derivative modulators, method for preparing the same, and application thereof

Novel steroidal derivative GABA A Receptor modulators offer rapid antidepressant effects, overcoming the slow onset of traditional antidepressants by providing immediate relief for MDD patients.

JP2024163113AActive Publication Date: 2024-11-21JIANGSU HANSOH PHARMA CO LTD +1
View PDF 15 Cites 0 Cited by

Patent Information

Application Number
JP2024111699
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-11-23
Filing Date
2024-07-11
Publication Date
2024-11-21
Estimated Expiration
2039-01-31

AI Technical Summary

Technical Problem

Current antidepressants take weeks to show efficacy, necessitating a rapid-acting mechanism for treating major depressive disorder (MDD), particularly for patients with suicidal tendencies, and existing GABA A Receptor modulators have not addressed this need effectively.

Method used

Development of novel steroidal derivative modulators represented by specific compounds of general formula (I) and their stereoisomers or pharmacologically acceptable salts, which act as GABA A Receptor modulators, offering rapid antidepressant effects within 24 hours.

Benefits of technology

The compounds provide swift antidepressant effects lasting several days to two weeks, addressing the slow onset of traditional antidepressants and meeting the urgent treatment needs of MDD patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024163113000001
    Figure 2024163113000001
  • Figure 2024163113000002
    Figure 2024163113000002
  • Figure 2024163113000003
    Figure 2024163113000003
Patent Text Reader

Abstract

To provide steroid derivative modulators, a method for preparing the same, and uses thereof.SOLUTION: The invention relates to steroid derivative modulators, a method for preparing the same, and uses thereof. In particular, the invention relates to a compound represented by the general formula (I), a method for preparing the same, a pharmaceutical composition containing the compound, and applications thereof as a GABAA receptor modulator in treating depression, convulsion, Parkinson's disease, and nervous system diseases, where the substituents in the general formula (I) are the same as defined in the specification.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention is in the field of drug synthesis, specifically, it relates to steroid derivative modulators, their preparation and use. [Background technology]

[0002] GABA A The receptors are chemically gated channels on the cell membrane and belong to the ionotropic receptors. They are widely distributed in the nervous system and bind to the inhibitory neurotransmitter GABA (gamma-aminobutyric acid) to open chloride ion channels, causing neuronal inhibition. GABAA receptor modulators (tetrahydroprogesterone) inhibit the GABA A It is a positive modulator of the receptor. Tetrahydroprogesterone and GABA in the synapse A The binding of tetrahydroprogesterone with the receptor modulator increases the opening frequency of the chloride ion channel on the receptor, and increases the internal flow of chloride ions, thereby increasing the phasic current, achieving a rapid inhibitory effect, and reducing neuroexcitability, thereby achieving anxiolytic and antidepressant effects. The binding of tetrahydroprogesterone with the GABAA receptor modulator in synapse generates a sustained chloride ion current, mediating a long-lasting inhibitory effect. Tetrahydroprogesterone can also increase the content of neurotrophic factor (BDNF), promote the regeneration of hippocampal neurons, and play a neuroprotective role, thereby improving the symptoms of anxiety and depression, but the specific mechanism of action is unclear.

[0003] Major depressive disorder (MDD) is a common, chronic, relapsing illness with increasingly severe disease burdens and adverse events. Although there have been great advances in the research, development and clinical use of antidepressants over the past 40 years, most antidepressants (e.g., fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram) take 2-4 weeks to take effect, and the clinical treatment of major depressive disorder, especially for patients with suicidal depression, often requires timely and rapid clinical treatment, so there is an urgent need to develop fast-acting antidepressants.

[0004] Over the past 20 years, there has been little innovation in the discovery and development of treatments for depression, with GABA being the only treatment. A The goal of developing receptor modulators is to change patients' expectations by altering their MDD treatment regimens. A Receptor modulators may be the first drugs in the last couple of decades to offer a truly novel mechanism of action for the treatment of depression. Currently, overseas pharmaceutical companies, including Sage Therapeutics and Marinus, are developing GABA receptor modulators. A Every effort is being made to develop receptor modulators.

[0005] Currently disclosed, GABA A Patent applications for receptor modulators include WO2003077919, WO2014169833, WO2016061537, WO2015180679, and WO2015027227.

[0006] GABA A Receptor modulators have good prospects for use as popular drug targets in the pharmaceutical industry.

[0007] Number one, GABA A Receptor modulators can be applied to major depressive disorder (MDD), the annual incidence of MDD in China is about 2%, and there is huge market potential.

[0008] Second, traditional antidepressants have a slow onset of action, usually taking 3-4 weeks, a high failure rate of up to 40%, and require long-term medication. A Receptor modulators can exert a pronounced antidepressant effect within 24 hours, and the effects of the medication can last from a few days to two weeks.

[0009] Number three: GABA A Receptor modulators may meet the daily oral treatment needs of MDD patients. [Prior art documents] [Patent documents]

[0010] [Patent Document 1] International Publication No. 2003077919 [Patent Document 2] International Publication No. 2014169833 [Patent Document 3] International Publication No. 2016061537 [Patent Document 4] International Publication No. 2015180679 [Patent Document 4] International Publication No. 2015027227 Summary of the Invention [Problem to be solved by the invention]

[0011] An object of the present invention is to provide a compound represented by general formula (I), a stereoisomer thereof, or a pharmacologically acceptable salt thereof, and the structure of the compound represented by general formula (I) is as shown below. [Means for solving the problem]

[0012] [ka] (In the formula, X is -CR 17 -or -N-; Y is -CR 23R 24 -, -S(CH2) n1 -, -P(CH2) n1 -, -O(CH2) n1 -, -(CH2) n1 NR 22 -, [ka] is selected from R x , R y , R z and R f are the same or different and each independently represent a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a mercapto group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH2) n1 R 23 , -(CH2) n1 OR 23 , -(CH2) n1 S.R. 23 , -(CH2) n1 C(O)R 23 , -(CH2) n1 C(O)OR 23 , -(CH2) n1 S(O) m1 R 23 , -(CH2) n1 NR 23 R 24 , -(CH2) n1 C(O)NR 23 R 24 , -(CH2) n1 NR 23 C(O)R 24 or -(CH2) n1 NR 23 S(O) m1 R 24wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, a mercapto group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH2) n1 R 25 , -(CH2) n1 OR 25 , -(CH2) n1 S.R. 25 , -(CH2) n1 C(O)R 25 , -(CH2) n1 C(O)OR 25 , -(CH2) n1 S(O) m1 R 25 , -(CH2) n1 NR 25 R 26 , -(CH2) n1 C(O)NR 25 R 26 , -(CH2) n1 C(O)NHR 25 , -(CH2) n1 NR 25 C(O)R 26 and -(CH2) n1 NR 25 S(O) m1 R 26 may be substituted with one or more substituents selected from Or, R x , R y , R z and R fAny two adjacent or non-adjacent groups among the above may be combined to form a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, in which the cycloalkyl group, the heterocyclyl group, the aryl group, and the heteroaryl group may further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH2) n1 R 23 , -(CH2) n1 OR 23 , -(CH2) n1 S.R. 23 , -(CH2) n1 C(O)R 23 , -(CH2) n1 C(O)OR 23 , -(CH2) n1 S(O) m1 R 23 , -(CH2) n1 NR 23 R 24 , -(CH2) n1 C(O)NR 23 R 24 , -(CH2) n1 NR 23 C(O)R 24 and -(CH2) n1 NR 23 S(O) m1 R 24 may be substituted with one or more substituents selected from Or, R x , R y , R z and R f Any two adjacent groups among R 21is a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH2) n1 R 23 , -(CH2) n1 OR 23 , -(CH2) n1 S.R. 23 , -(CH2) n1 C(O)R 23 , -(CH2) n1 C(O)OR 23 , -(CH2) n1 S(O) m1 R 23 , -(CH2) n1 NR 23 R 24 , -(CH2) n1 C(O)NR 23 R 24 , -(CH2) n1 NR 23 C(O)R 24 or -(CH2) n1 NR 23 S(O) m1 R 24 wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH2) n1 R 25 , -(CH2) n1 OR 25 , -(CH2) n1 S.R. 25 , -(CH2) n1 C(O)R 25 , -(CH2) n1 C(O)OR 25 , -(CH2)n1 S(O) m1 R 25 , -(CH2) n1 NR 25 R 26 , -(CH2) n1 C(O)NR 25 R 26 , -(CH2) n1 C(O)NHR 25 , -(CH2) n1 NR 25 C(O)R 26 and -(CH2) n1 NR 25 S(O) m1 R 26 may be substituted with one or more substituents selected from X is -CR 17 - R 17 is selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, a hydroxyl group, an amino group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group may be further substituted with one or more substituents selected from a deuterium atom, a substituted or unsubstituted alkyl group, a halogen, a hydroxyl group, a substituted or unsubstituted amino group, an oxo group, a nitro group, a cyano group, an alkenyl group, an alkynyl group, an alkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group and a substituted or unsubstituted heteroaryl group; Or, R 17 is R x , R y , R z and R fcan be combined with any of the groups listed above to form a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, and the cycloalkyl group, the heterocyclyl group, the aryl group, and the heteroaryl group can further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH2) n1 R 23 , -(CH2) n1 OR 23 , -(CH2) n1 S.R. 23 , -(CH2) n1 C(O)R 23 , -(CH2) n1 C(O)OR 23 , -(CH2) n1 S(O) m1 R 23 , -(CH2) n1 NR 23 R 24 , -(CH2) n1 C(O)NR 23 R 24 , -(CH2) n1 NR 23 C(O)R 24 and -(CH2) n1 NR 23 S(O) m1 R 24 may be substituted with one or more substituents selected from R 22 is a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH2) n1 R 23 , -(CH2) n1 OR 23 , -(CH2) n1 S.R.23 , -(CH2) n1 C(O)R 23 , -(CH2) n1 C(O)OR 23 , -(CH2) n1 S(O) m1 R 23 , -(CH2) n1 NR 23 R 24 , -(CH2) n1 C(O)NR 23 R 24 , -(CH2) n1 NR 23 C(O)R 24 or -(CH2) n1 NR 23 S(O) m1 R 24 wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH2) n1 R 25 , -(CH2) n1 OR 25 , -(CH2) n1 S.R. 25 , -(CH2) n1 C(O)R 25 , -(CH2) n1 C(O)OR 25 , -(CH2) n1 S(O) m1 R 25 , -(CH2) n1 NR 25 R 26 , -(CH2) n1 C(O)NR 25 R 26 , -(CH2) n1 C(O)NHR 25 , -(CH2) n1 NR 25C(O)R 26 and -(CH2) n1 NR 25 S(O) m1 R 26 may be substituted with one or more substituents selected from R 23 , R 24 , R 25 and R 26 are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, a hydroxyl group, an amino group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group are optionally further substituted with one or more substituents selected from a deuterium atom, a substituted or unsubstituted alkyl group, a halogen, a hydroxyl group, a substituted or unsubstituted amino group, an oxo group, a nitro group, a cyano group, an alkenyl group, an alkynyl group, an alkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group and a substituted or unsubstituted heteroaryl group; m is an integer of 0, 1, 3, 4, 5, 6, 7, 8, 9, or 10; n is an integer of 0, 1, 2 or 3; o is an integer of 0, 1, 2, 3, 4 or 5; p is an integer of 0, 1, 2, 3, 4, 5, or 6; q is an integer of 0, 1, 2, 3, 4, 5, or 6; m1 is an integer of 0, 1 or 2; and n1 is an integer of 0, 1, 2, 3, 4, or 5.

[0013] In a preferred embodiment of the present invention, the compound represented by the general formula (I) is a compound represented by the general formula (III), a stereoisomer thereof, or a pharmacologically acceptable salt thereof. [ka] (In the formula, Y is [ka] is selected from R 3a is selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a mercapto group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, or an alkynyl group; R5 is selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, or an alkynyl group; R 15a is selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, or an alkynyl group; R 16a is selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, or an alkynyl group; Or, R 15a and R 16a are bonded to form a cycloalkyl or heteroalkyl group, and the cycloalkyl or heteroalkyl group formed may be further substituted with one or more substituents selected from a hydrogen atom, a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, or a heteroaryl group; R 19is a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a mercapto group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a hydroxyalkyl group, -(CH2) n1 OR 23 , -(CH2) n1 S.R. 23 , -(CH2) n1 C(O)OR 23 , -(CH2) n1 S(O) m1 R 23 , -(CH2) n1 S(O)(=NR 23 )R 24 or -(CH2) n1 C(O)NR 23 R 24 is selected from Alternatively, R5 and R 19 are bonded to form a cycloalkyl or heteroalkyl group, and the cycloalkyl or heteroalkyl group formed may be further substituted with one or more substituents selected from a hydrogen atom, a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, or a heteroaryl group; R 21 is a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH2) n1 R 23 , -(CH2) n1 OR 23 , -(CH2) n1 S.R. 23 , -(CH2) n1 C(O)R 23 , -(CH2) n1 C(O)OR 23, -(CH2) n1 S(O) m1 R 23 , -(CH2) n1 NR 23 R 24 , -(CH2) n1 C(O)NR 23 R 24 , -(CH2) n1 NR 23 C(O)R 24 or -(CH2) n1 NR 23 S(O) m1 R 24 wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH2) n1 R 25 , -(CH2) n1 OR 25 , -(CH2) n1 S.R. 25 , -(CH2) n1 C(O)R 25 , -(CH2) n1 C(O)OR 25 , -(CH2) n1 S(O) m1 R 25 , -(CH2) n1 NR 25 R 26 , -(CH2) n1 C(O)NR 25 R 26 , -(CH2) n1 C(O)NHR 25 , -(CH2) n1 NR 25 C(O)R 26 and -(CH2) n1 NR 25 S(O) m1 R 26may be substituted with one or more substituents selected from R 23 , R 24 , R 25 and R 26 are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, a hydroxyl group, an amino group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group are optionally further substituted with one or more substituents selected from a deuterium atom, a substituted or unsubstituted alkyl group, a halogen, a hydroxyl group, a substituted or unsubstituted amino group, an oxo group, a nitro group, a cyano group, an alkenyl group, an alkynyl group, an alkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group and a substituted or unsubstituted heteroaryl group; n is an integer of 1 or 2, m1 is an integer of 0, 1 or 2; and n1 is an integer of 0, 1, 2, 3, 4, or 5.

[0014] In a preferred embodiment of the present invention, the compound represented by the general formula (II) is a compound represented by the general formula (III-A), a stereoisomer thereof, or a pharmacologically acceptable salt thereof. [ka] (In the formula, Z is -CR 23 R 24 -, -NR 23 -, -(CH2) n1 O(CH2) n2 - or -O-, preferably a methylene group; Ring C is selected from a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, of which the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group, and the heteroaryl group can further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH2) n1 R 25 , -(CH2) n1 OR 25 , -(CH2) n1 S.R. 25 , -(CH2) n1 C(O)R 25 , -(CH2) n1 C(O)OR 25 , -(CH2) n1 S(O) m1 R 25 , -(CH2) n1 NR 25 R 26 , -(CH2) n1 C(O)NR 25 R 26 , -(CH2) n1 C(O)NHR 25 , -(CH2) n1 NR 25 C(O)R 26 and -(CH2) n1 NR 25 S(O) m1 R 26 may be substituted with one or more substituents selected from R c are the same or different and are a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH2) n1 R 23 , -(CH2)n1 OR 23 , -(CH2) n1 S.R. 23 , -(CH2) n1 C(O)R 23 , -(CH2) n1 C(O)OR 23 , -(CH2) n1 S(O) m1 R 23 , -(CH2) n1 S(O)NR 23 , -(CH2) n1 NR 23 R 24 , -(CH2) n1 C(O)NR 23 R 24 , -(CH2) n1 NR 23 C(O)R 23 or -(CH2) n1 NR 23 S(O) m1 R 24 wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH2) n1 R 25 , -(CH2) n1 OR 25 , -(CH2) n1 S.R. 25 , -(CH2) n1 C(O)R 25 , -(CH2) n1 C(O)OR 25 , -(CH2) n1 S(O) m1 R 25 , -(CH2) n1 NR 25 R 26 , -(CH2) n1 C(O)NR 25 R26 , -(CH2) n1 C(O)NHR 25 , -(CH2) n1 NR 25 C(O)R 26 and -(CH2) n1 NR 25 S(O) m1 R 26 may be substituted with one or more substituents selected from z is an integer of 0, 1, 3, 4, or 5; and R 3a , R 3b , R5, R 19 , R 23 ~R 26 , n, m1 and n1 are as defined for the compound represented by formula (II).

[0015] In a preferred embodiment of the present invention, the compound represented by the general formula (II), its stereoisomer or its pharmacologically acceptable salt is a compound represented by the general formula (V-7) and the general formula (V-8), its stereoisomer or its pharmacologically acceptable salt. [ka] (In the formula, Ring A is selected from a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, of which the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group, and the heteroaryl group can further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH2) n1 R 25 , -(CH2) n1 OR 25 , -(CH2) n1 S.R. 25 , -(CH2) n1 C(O)R 25, -(CH2) n1 C(O)OR 25 , -(CH2) n1 S(O) m1 R 25 , -(CH2) n1 NR 25 R 26 , -(CH2) n1 C(O)NR 25 R 26 , -(CH2) n1 C(O)NHR 25 , -(CH2) n1 NR 25 C(O)R 26 and -(CH2) n1 NR 25 S(O) m1 R 26 may be substituted with one or more substituents selected from R a are the same or different and are a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH2) n1 R 23 , -(CH2) n1 OR 23 , -(CH2) n1 S.R. 23 , -(CH2) n1 C(O)R 23 , -(CH2) n1 C(O)OR 23 , -(CH2) n1 S(O) m1 R 23 , -(CH2) n1 S(O)NR 23 , -(CH2) n1 NR 23 R 24 , -(CH2) n1 C(O)NR 23 R 24 , -(CH2) n1 NR 23 C(O)R 23 or -(CH2) n1 NR23 S(O) m1 R 24 wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH2) n1 R 25 , -(CH2) n1 OR 25 , -(CH2) n1 S.R. 25 , -(CH2) n1 C(O)R 25 , -(CH2) n1 C(O)OR 25 , -(CH2) n1 S(O) m1 R 25 , -(CH2) n1 NR 25 R 26 , -(CH2) n1 C(O)NR 25 R 26 , -(CH2) n1 C(O)NHR 25 , -(CH2) n1 NR 25 C(O)R 26 and -(CH2) n1 NR 25 S(O) m1 R 26 may be substituted with one or more substituents selected from R 19 is a hydrogen atom, an alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH2) n1 R 23 , -(CH2) n1 OR 23, -(CH2) n1 S.R. 23 , -(CH2) n1 C(O)R 23 , -(CH2) n1 C(O)OR 23 , -(CH2) n1 S(O) m1 R 23 , -(CH2) n1 S(O)NR 23 , -(CH2) n1 NR 23 R 24 , -(CH2) n1 C(O)NR 23 R 24 , -(CH2) n1 NR 23 C(O)R 23 , -(CH2) n1 S(O)(=NR 23 )R 24 or -(CH2) n1 NR 23 S(O) m1 R 24 wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH2) n1 R 25 , -(CH2) n1 OR 25 , -(CH2) n1 S.R. 25 , -(CH2) n1 C(O)R 25 , -(CH2) n1 C(O)OR 25 , -(CH2) n1 S(O) m1 R 25 , -(CH2) n1 NR 25 R 26 , -(CH2)n1 C(O)NR 25 R 26 , -(CH2) n1 C(O)NHR 25 , -(CH2) n1 NR 25 C(O)R 26 and -(CH2) n1 NR 25 S(O) m1 R 26 may be substituted with one or more substituents selected from x, m1 and n1 are as defined in general formula (II).

[0016] In a preferred embodiment of the present invention, the compound represented by the general formula (II) is a compound represented by the general formula (III-B), a stereoisomer thereof, or a pharmacologically acceptable salt thereof. [ka] (In the formula, R5 is a hydrogen atom, C 1-6 Alkyl group, C 1-6 Halogenated alkyl group or C 1-6 alkoxy groups, R 19 is a hydrogen atom, C 1-6 Alkyl group, C 1-6 Halogenated alkyl groups, C 1-6 Alkoxy group, -(CH2) n1 OR 23 or -(CH2) n1 S.R. 23 is selected from R c is a hydrogen atom, a cyano group or C 1-6 alkyl groups, z is an integer of 0, 1 or 2; and n is 0, 1 or 2.

[0017] In a preferred embodiment of the present invention, the compound represented by the general formula (I), its stereoisomer or its pharmacologically acceptable salt is a compound represented by the general formulas (IV-A) and (IV-B), its stereoisomer or its pharmacologically acceptable salt. [ka] (In the formula, R 3a is C 1-6 Alkyl group, C 1-6 Halogenated alkyl group or C 1-6 alkoxy groups, R 19 is a cyano group, halogen, C 1-6 Alkyl group, C 1-6 Halogenated alkyl groups, C 1-6 Alkoxy group, -(CH2) n1 OR 23 , -(CH2) n1 S(O) m1 R 23 , -(CH2) n1 S(O)(=NR 23 )R 24 or -(CH2) n1 S.R. 23 is selected from R a is a hydrogen atom, a cyano group, a halogen atom, a nitro group, an alkyl group, an alkoxy group, a halogenated alkyl group, a cycloalkyl group, a hydroxyalkyl group, a heterocyclyl group, a heteroaryl group, -(CH2) n1 CR 23 R 24 R 25 , -(CH2) n1 S.R. 23 , -(CH2) n1 C(O)OR 23 , -(CH2) n1 S(O) m1 R 23 , -(CH2) n1 S(O)(=NR 23 )R 24 , -(CH2) n1 C(O)NR 23 R 24wherein the alkyl, cycloalkyl, heterocyclyl or heteroaryl group may be further substituted with one or more substituents selected from a hydrogen atom, an alkyl group, a halogen, a cyano group, a hydroxyl group, a cycloalkyl group, a heterocyclyl group and a heteroaryl group; x is an integer of 0, 1, or 2; and R5, m1 and n1 are as defined in claim 2.

[0018] In a preferred embodiment of the present invention, the compound represented by the general formula (I), its stereoisomer or its pharmacologically acceptable salt is a compound represented by the general formula (VIII), its stereoisomer or its pharmacologically acceptable salt. [ka] (In the formula, Rings A, Z, R a and x are as defined in general formula (III). In a preferred embodiment of the present invention, the compound represented by the general formula (I), its stereoisomer or its pharmacologically acceptable salt is a compound represented by the general formula (VI), its stereoisomer or its pharmacologically acceptable salt. [ka] (In the formula, Z is -CR 23 R 24 -, -(CH2) n1 NR 23 -, -(CH2) n1 O(CH2) n2 - or -O-, preferably a methylene group; Ring B is selected from a cycloalkyl group, a heterocyclyl group, an aryl group, or a heteroaryl group, wherein the cycloalkyl group, the heterocyclyl group, the aryl group, and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH2) n1 R 25 , -(CH2) n1 OR 25 , -(CH2) n1 S.R. 25 , -(CH2) n1 C(O)R 25 , -(CH2) n1 C(O)OR 25 , -(CH2) n1 S(O) m1 R 25 , -(CH2) n1 NR 25 R 26 , -(CH2) n1 C(O)NR 25 R 26 , -(CH2) n1 C(O)NHR 25 , -(CH2) n1 NR 25 C(O)R 26 and -(CH2) n1 NR 25 S(O) m1 R 26 may be substituted with one or more substituents selected from R b are the same or different and are a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH2) n1 R 23 , -(CH2) n1 OR23 , -(CH2) n1 S.R. 23 , -(CH2) n1 C(O)R 23 , -(CH2) n1 C(O)OR 23 , -(CH2) n1 S(O) m1 R 23 , -(CH2) n1 S(O)NR 23 , -(CH2) n1 NR 23 R 24 , -(CH2) n1 C(O)NR 23 R 24 , -(CH2) n1 NR 23 C(O)R 23 or -(CH2) n1 NR 23 S(O) m1 R 24 wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH2) n1 R 25 , -(CH2) n1 OR 25 , -(CH2) n1 S.R. 25 , -(CH2) n1 C(O)R 25 , -(CH2) n1 C(O)OR 25 , -(CH2) n1 S(O) m1 R 25 , -(CH2) n1 NR 25 R 26 , -(CH2) n1 C(O)NR 25 R 26, -(CH2) n1 C(O)NHR 25 , -(CH2) n1 NR 25 C(O)R 26 and -(CH2) n1 NR 25 S(O) m1 R 26 and y is an integer selected from 0, 1, 2, 3, or 4.

[0019] In a preferred embodiment of the present invention, the compound represented by the general formula (I), its stereoisomer or its pharmacologically acceptable salt is a compound represented by the general formula (VIII), its stereoisomer or its pharmacologically acceptable salt. [ka] (In the formula, R 21 is a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH2) n1 R 23 , -(CH2) n1 OR 23 , -(CH2) n1 S.R. 23 , -(CH2) n1 C(O)R 23 , -(CH2) n1 C(O)OR 23 , -(CH2) n1 S(O) m1 R 23 , -(CH2) n1 NR 23 R 24 , -(CH2) n1 C(O)NR 23 R 24 , -(CH2) n1 NR 23 C(O)R 24 or -(CH2) n1NR 23 S(O) m1 R 24 wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH2) n1 R 25 , -(CH2) n1 OR 25 , -(CH2) n1 S.R. 25 , -(CH2) n1 C(O)R 25 , -(CH2) n1 C(O)OR 25 , -(CH2) n1 S(O) m1 R 25 , -(CH2) n1 NR 25 R 26 , -(CH2) n1 C(O)NR 25 R 26 , -(CH2) n1 C(O)NHR 25 , -(CH2) n1 NR 25 C(O)R 26 and -(CH2) n1 NR 25 S(O) m1 R 26 may be substituted with one or more substituents selected from R 23 ~R 26 , m1 and n1 are as defined in claim 1.

[0020] In a preferred embodiment of the present invention, the compound represented by the general formula (I), its stereoisomer or its pharmacologically acceptable salt is a compound represented by the general formula (X): [ka] (In the formula, M is -CR 23 - or an oxygen atom, Y is -S(CH2) n1 -, [ka] is selected from R 21 is a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH2) n1 R 23 , -(CH2) n1 OR 23 , -(CH2) n1 S.R. 23 , -(CH2) n1 C(O)R 23 , -(CH2) n1 C(O)OR 23 , -(CH2) n1 S(O) m1 R 23 , -(CH2) n1 NR 23 R 24 , -(CH2) n1 C(O)NR 23 R 24 , -(CH2) n1 NR 23 C(O)R 24 or -(CH2) n1 NR 23 S(O) m1 R 24wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH2) n1 R 25 , -(CH2) n1 OR 25 , -(CH2) n1 S.R. 25 , -(CH2) n1 C(O)R 25 , -(CH2) n1 C(O)OR 25 , -(CH2) n1 S(O) m1 R 25 , -(CH2) n1 NR 25 R 26 , -(CH2) n1 C(O)NR 25 R 26 , -(CH2) n1 C(O)NHR 25 , -(CH2) n1 NR 25 C(O)R 26 and -(CH2) n1 NR 25 S(O) m1 R 26 may be substituted with one or more substituents selected from R 22 ~R 26 , m1 and n1 are as defined in claim 1.

[0021] In a preferred embodiment of the present invention, in the compound represented by the general formula (I), its stereoisomer, or its pharmacologically acceptable salt, the ring A, ring B, and ring C are [ka] is selected from the group:

[0022] In a preferred embodiment of the present invention, the compound represented by the general formula (I), its stereoisomer or its pharmacologically acceptable salt is R a , R b and R c is a hydrogen atom, a cyano group, a halogen, a nitro group, C 1-6 Alkyl group, C 2-6 Alkynyl group, C 1-6 Alkoxy group, C 1-6 Halogenated alkyl groups, C 3-6 Cycloalkyl groups, C 1-6 Hydroxyalkyl groups, 5-10 membered heterocyclyl groups, 5-10 membered heteroaryl groups, -(CH2) n1 OR 23 , -(CH2) n1 S.R. 23 , -(CH2) n1 C(O)R 23 , -(CH2) n1 C(O)NR 23 R 24 , -(CH2) n1 C(O)OR 23 or -(CH2) n1 S(O) m1 R 23 Among these, C 1-6 Alkynyl group, C 1-6 Alkoxy group, C 1-6 Halogenated alkyl groups, C 3-6 Cycloalkyl groups, C 1-6 The hydroxyalkyl group, the 5- to 10-membered heterocyclyl group and the 5- to 10-membered heteroaryl group may further include a hydrogen atom, 1-6 Alkynyl group, halogen, cyano group, hydroxyl group, C 3-6 Cycloalkyl groups, C 1-6 optionally substituted with one or more substituents selected from hydroxyalkyl groups, 5- to 10-membered heterocyclyl groups, and 5- to 10-membered heteroaryl groups; R 23 and R 24 are each independently a hydrogen atom, C 1-6It is selected from an alkyl group or a 3-8 membered heterocyclyl group.

[0023] In a preferred embodiment of the present invention, the compound represented by the general formula (I), its stereoisomer or its pharmacologically acceptable salt is Z is selected from -CH2-, -CH2NH-, -CH2O-, -CH2-, -NH- or -NHSO2-; R 3a is C 1-6 Alkyl group, C 1-6 Halogenated alkyl group or C 1-6 alkoxy groups, preferably C 1-3 Alkyl group or C 1-3 an alkoxy group, more preferably a methyl group or a methoxymethyl group; R5 is a hydrogen atom, a halogen, a cyano group, or C 1-6 Alkyl group, C 1-6 Halogenated alkyl group or C 1-6 alkoxy groups, preferably hydrogen atoms and C 1-3 is an alkyl group, R 19 is a cyano group, halogen, C 1-6 Alkyl group, C 1-6 Halogenated alkyl groups, C 1-6 Alkoxy group, -(CH2) n1 OR 23 , -(CH2) n1 S(O) m1 R 23 , -(CH2) n1 S(O)(=NR 23 )R 24 or -(CH2) n1 S.R. 23 Preferably, the cyano group, halogen, C 1-3 Alkoxy group, C 1-3 Halogenated alkyl groups, -(CH2) n1 S.R. 23 , -(CH2) n1 S(O) m1 R 23 or -(CH2) n1 S(O)(=NR 23 )R 24and more preferably halogen. Alternatively, R5 and R 19 Any two adjacent groups in 3-6 It can form a cycloalkyl group, preferably a cyclopropyl group.

[0024] In a preferred embodiment of the present invention, [ka] [ka] [ka] [ka] [ka] [ka] [ka] The compound represented by the above general formula (I), its stereoisomer or its pharmacologically acceptable salt is selected from the group consisting of compounds represented by the above general formula (I),

[0025] The present invention further relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound represented by general formula (I), its stereoisomer or a pharmacologically acceptable salt thereof, and one or more pharma- ceutically acceptable carriers, diluents or excipients.

[0026] The present invention further relates to a compound represented by any one of general formula (I), its stereoisomer or a pharmacologically acceptable salt thereof, or said pharmaceutical composition, A The present invention relates to use in the manufacture of receptor modulators.

[0027] The present invention further relates to the use of a compound represented by general formula (I), its stereoisomer or a pharmacologically acceptable salt thereof, or a pharmaceutical composition thereof, in the manufacture of a medicament for treating a CNS-related disease, wherein the CNS-related disease is selected from sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, memory and / or cognition disorders, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, or tinnitus.

[0028] The present invention further relates to a method of treating a CNS-related disease with a compound represented by general formula (I), a stereoisomer thereof, or a pharmacologically acceptable salt thereof, or a pharmaceutical composition thereof.

[0029] The present invention further relates to a method for preventing and / or treating a CNS-related disease, comprising administering to a patient a therapeutically effective amount of a compound represented by general formula (I), a stereoisomer thereof or a pharmacologically acceptable salt thereof, or a pharmaceutical composition thereof. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0030] Unless otherwise specified to the contrary, terms used in the specification and claims have the following meanings.

[0031] The term "alkyl group" refers to a saturated aliphatic hydrocarbon group that is a straight or branched chain group containing from 1 to 20 carbon atoms, preferably an alkyl group containing from 1 to 8 carbon atoms, more preferably an alkyl group containing from 1 to 6 carbon atoms, and most preferably an alkyl group containing from 1 to 3 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 6-methylhexyl, 7-methylhexyl, 8-methylhexyl, 9-methylhexyl, 10-methylhexyl, 11-methylhexyl, 12-methylhexyl, 13-methylhexyl, 14-methylhexyl, 15-methylhexyl, 16-methylhexyl, 17-methylhexyl, 18-methylhexyl, 19-methylhexyl, 22-methylhexyl, 23-methylhexyl, 24-methylhexyl, 25-methylhexyl, 26-methylhexyl, 27-methylhexyl, 28-methylhexyl, 29-methylhexyl, 30-methylhexyl, 31-methylhexyl, 32-methylhexyl, 33-methylhexyl, 34-methylhexyl, 35-methylhexyl, 36-methylhexyl, 37-methylhexyl, 38-methylhexyl, 39-methylhexyl, 40-methylhexyl, 41-methylhexyl, 42-methylhexyl, 43-methylhexyl, 44-methylhexyl, 45-methylhex Examples of such groups include 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl and various branched chain isomers thereof.The alkyl group may be substituted or unsubstituted, and when substituted, the substituent may be substituted at any available attachment point, and the substituent is preferably one or more groups independently selected from alkyl groups, alkenyl groups, alkynyl groups, alkoxy groups, alkylthio groups, alkylamino groups, halogens, mercapto groups, hydroxyl groups, nitro groups, cyano groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, cycloalkoxy groups, heterocycloalkoxy groups, cycloalkylthio groups, heterocycloalkylthio groups, oxo groups, carboxyl groups, or carboxylate groups, and in the present invention is preferably a methyl group, an ethyl group, an isopropyl group, a tert-butyl group, a halogenated alkyl group, a deuterated alkyl group, an alkyl group substituted with an alkoxy group, and an alkyl group substituted with a hydroxyl group.

[0032] The term "alkylene group" refers to an alkyl group in which one hydrogen atom has been further substituted, for example, a "methylene group" is -CH2-, an "ethylene group" is -(CH2)2-, a "propylidene group" is -(CH2)3-, and a "butylidene" is -(CH2)4-. The term "alkenyl group" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, such as vinyl, 1-propenyl, 2-propenyl, 1-, 2-, or 3-butenyl groups. An alkenyl group may be substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkyl groups, alkenyl groups, alkynyl groups, alkoxy groups, alkylthio groups, alkylamino groups, halogens, mercapto groups, hydroxyl groups, nitro groups, cyano groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, cycloalkoxy groups, heterocycloalkoxy groups, cycloalkylthio groups, and heterocycloalkylthio groups.

[0033] The term "cycloalkyl group" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, where the cycloalkyl ring contains 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, and more preferably 3 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, and the like, and polycyclic cycloalkyl groups include spirocyclic, fused, and bridged cyclic cycloalkyl groups, preferably cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, and cycloheptyl.

[0034] The term "spirocycloalkyl group" refers to a polycyclic group that shares one carbon atom (called a spiro atom) between 5-20 membered monocyclic rings and may contain one or more double bonds, but no ring has a fully conjugated π-electron system. It is preferably 6-14 membered, more preferably 7-10 membered. Depending on the number of spiro atoms shared between the rings, spirocycloalkyl groups are divided into monocyclic spirocycloalkyl groups, bicyclic spirocycloalkyl groups, or polycyclic spirocycloalkyl groups, with monocyclic spirocycloalkyl groups and bicyclic spirocycloalkyl groups being preferred. More preferred are 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered, or 5-membered / 6-membered monocyclic spirocycloalkyl groups. Non-limiting examples of spirocycloalkyl groups are: [ka] Including, Also included are spirocycloalkyl groups in which the monocyclic spirocycloalkyl groups and heterocycloalkyl groups share a spiro atom, non-limiting examples of which are: [ka] Includes.

[0035] The term "fused cycloalkyl group" refers to an all-carbon polycyclic group having 5 to 20 members, in which each ring in the system shares an adjacent pair of carbon atoms with the other rings in the system, and one or more rings may contain one or more double bonds, but no ring has a completely conjugated π-electron system. It is preferably 6 to 14 members, more preferably 7 to 10 members. Depending on the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic fused cycloalkyl groups, but is preferably bicyclic or tricyclic, and more preferably 5-membered / 5-membered or 5-membered / 6-membered bicycloalkyl groups. Non-limiting examples of fused cycloalkyl groups are: [ka] Includes.

[0036] The term "bridged cyclic cycloalkyl group" refers to a 5-20 member all-carbon polycyclic group in which any two rings share two carbon atoms that are not directly bonded, and may contain one or more double bonds, but no ring has a completely conjugated π-electron system. It is preferably 6-14 membered, more preferably 7-10 membered. Depending on the number of rings that it comprises, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged cyclic cycloalkyl groups, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of bridged cyclic cycloalkyl groups are: [ka] Includes. The cycloalkyl ring may be fused to an aryl group, a heteroaryl group, or a heterocycloalkyl ring, in which the ring attached to the parent structure is a cycloalkyl group, non-limiting examples include indanyl, tetrahydronaphthyl, benzocycloheptane, etc. The alkynyl group may be optionally substituted or unsubstituted, and if substituted, the substituents are preferably one or more groups independently selected from alkyl groups, alkenyl groups, alkynyl groups, alkoxy groups, alkylthio groups, alkylamino groups, halogens, mercapto groups, hydroxyl groups, nitro groups, cyano groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, cycloalkoxy groups, heterocycloalkoxy groups, cycloalkylthio groups, heterocycloalkylthio groups, oxo groups, carboxyl groups, or carboxylic acid ester groups.

[0037] The term "heterocyclyl group" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent that contains 3 to 20 ring atoms, at least one of which is nitrogen, oxygen or S(O). m(where m is an integer of 0 to 2), but does not include the ring moiety of -OO-, -OS-, or -SS-, and the remaining ring atoms are carbon. Preferably, it contains 3 to 12 ring atoms, of which 1 to 4 ring atoms are heteroatoms, more preferably 3 to 8 ring atoms, and most preferably 3 to 8 ring atoms. Non-limiting examples of monocyclic heterocyclyl groups include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolo, dihydropyrrole, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, pyranyl, and 1,4-diazacyclo groups, and preferably tetrahydrofuranyl, pyrazolidinyl, morpholinyl, 1,4-diazacyclo, piperazinyl, and pyranyl. Polycyclic heterocyclyl groups include spirocyclic, fused and bridged heterocyclyl groups, which may be connected to other groups via a single bond or further connected in parallel rings to other cycloalkyl, heterocyclyl, aryl and heteroaryl groups via any two or more atoms on the ring.

[0038] The term "spiroheterocyclyl group" refers to a polycyclic heterocyclyl group that shares one atom (called a spiro atom) between the 5- to 20-membered monocyclic rings, and one or more of the ring atoms is nitrogen, oxygen, or S(O). m(where m is an integer from 0 to 2), and the remaining ring atoms are carbon. It may contain one or more double bonds, but there is no ring with a completely conjugated π-electron system. It is preferably 6 to 14-membered, more preferably 7 to 10-membered. Depending on the number of spiro atoms shared by the rings, spiroheterocyclyl groups are divided into monocyclic spiroheterocyclyl groups, bicyclic spiroheterocyclyl groups, and polycyclic spiroheterocyclyl groups, preferably monocyclic spiroheterocyclyl groups and bicyclic spiroheterocyclyl groups. More preferably, it is a 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered, or 5-membered / 6-membered monocyclic spiroheterocyclyl group. Non-limiting examples of spiroheterocyclyl groups are: [ka] Includes.

[0039] The term "fused heterocyclyl group" refers to a 5- to 20-membered polycyclic heterocyclyl group in which each ring in the system shares an adjacent pair of carbon atoms with each other ring in the system, and one or more rings may contain one or more double bonds, but no ring has a completely conjugated pi-electron system, and one or more ring atoms is not nitrogen, oxygen, or S(O). m (wherein m is an integer of 0 to 2), and the remaining ring atoms are carbon. Preferably, it is 6 to 14-membered, more preferably 7 to 10-membered. Depending on the number of constituting rings, it can be classified as a bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclyl group, preferably a bicyclic or tricyclic group, more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclyl group. Non-limiting examples of fused heterocyclyl groups are: [ka] Includes.

[0040] The term "bridged heterocyclyl group" refers to a 5-14 membered polycyclic heterocyclyl group in which any two rings share two carbon atoms that are not directly bonded and may contain one or more double bonds, but no ring has a completely conjugated pi electron system, and one or more ring atoms is not nitrogen, oxygen or S(O). m (wherein m is an integer of 0 to 2), and the remaining ring atoms are carbon. Preferably, it is 6 to 14-membered, more preferably 7 to 10-membered. Depending on the number of constituting rings, it can be classified as a bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclyl group, preferably a bicyclic, tricyclic or tetracyclic group, more preferably a bicyclic or tricyclic group. Non-limiting examples of bridged heterocyclyl groups are: [ka] Includes.

[0041] The heterocyclic ring may be fused to an aryl group, a heteroaryl group, or a cycloalkyl ring, where the ring attached to the parent structure is a heterocyclyl group, non-limiting examples are: [ka] etc.

[0042] The heterocyclyl group may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkyl groups, alkenyl groups, alkynyl groups, alkoxy groups, alkylthio groups, alkylamino groups, halogens, mercapto groups, hydroxyl groups, nitro groups, cyano groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, cycloalkoxy groups, heterocycloalkoxy groups, cycloalkylthio groups, heterocycloalkylthio groups, oxo groups, carboxyl groups, or carboxylic acid ester groups.

[0043] The term "aryl group" refers to a 6-14 membered all carbon monocyclic or fused polycyclic (i.e. rings sharing adjacent pairs of carbon atoms) group having a conjugated pi electron system, preferably 6-10 membered, such as phenyl and naphthyl groups. More preferably, it is a phenyl group. The aryl ring may be fused to a heteroaryl group, heterocyclyl group, or cycloalkyl ring, in which the ring attached to the parent structure is an aryl ring, non-limiting examples are: [ka] Includes.

[0044] The aryl group may be substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkyl groups, alkenyl groups, alkynyl groups, alkoxy groups, alkylthio groups, alkylamino groups, halogens, mercapto groups, hydroxyl groups, nitro groups, cyano groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, cycloalkoxy groups, heterocycloalkoxy groups, cycloalkylthio groups, heterocycloalkylthio groups, carboxyl groups, or carboxylic acid ester groups.

[0045] The term "heteroaryl group" refers to a heteroaromatic system containing from 1 to 4 heteroatoms and 5 to 14 ring atoms, where the heteroatoms are selected from oxygen, sulfur and nitrogen. The heteroaryl group is preferably 5- to 10-membered, more preferably 5- or 6-membered, and is, for example, an imidazolyl group, a furyl group, a thienyl group, a thiazolyl group, a pyrazolyl group, an oxazolyl group, a pyrrolyl group, a triazolyl group, a tetrazolyl group, a pyridyl group, a pyrimidinyl group, a thiadiazole group, a pyrazinyl group, etc., and is preferably a triazolyl group, a tetrazolyl group, a thienyl group, an imidazolyl group, a pyrazolyl group, a pyridazine group, a pyrimidinyl group, a thiazolyl group, an oxazolyl group, an isoxazolyl group, or a pyrimidinyl group, and more preferably a triazolyl group, a tetrazolyl group, a pyrazolyl group, a pyridyl group, a pyridazine group, a pyrimidinyl group, a thiazolyl group, an oxazolyl group, an isoxazolyl group, or an imidazolyl group. The heteroaryl ring may be fused to an aryl group, a heterocyclyl group, or a cycloalkyl ring, where the ring attached to the parent structure is an aryl ring, non-limiting examples include: [ka] Includes.

[0046] A heteroaryl group may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkyl groups, alkenyl groups, alkynyl groups, alkoxy groups, alkylthio groups, alkylamino groups, halogens, mercapto groups, hydroxyl groups, nitro groups, cyano groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, cycloalkoxy groups, heterocycloalkoxy groups, cycloalkylthio groups, heterocycloalkylthio groups, carboxyl groups, or carboxylic acid ester groups.

[0047] The term "alkoxy group" refers to -O-(alkyl group) and -O-(unsubstituted cycloalkyl group), where the alkyl group is defined above. Non-limiting examples of alkoxy groups include methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, and cyclohexyloxy groups. An alkoxy group may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkyl groups, alkenyl groups, alkynyl groups, alkoxy groups, alkylthio groups, alkylamino groups, halogens, mercapto groups, hydroxyl groups, nitro groups, cyano groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, cycloalkoxy groups, heterocycloalkoxy groups, cycloalkylthio groups, heterocycloalkylthio groups, carboxyl groups, or carboxylic acid ester groups.

[0048] "Halogenated alkyl group" refers to an alkyl group that is substituted with one or more halogens, where alkyl group is as defined above.

[0049] A "haloalkoxy group" refers to an alkoxy group substituted with one or more halogens, where alkoxy is as defined above.

[0050] "Hydroxyalkyl group" refers to an alkyl group substituted with a hydroxyl group, where alkyl group is as defined above.

[0051] "Alkenyl group" refers to an olefin also referred to as an alkene, which may be further substituted with other related groups, such as alkyl groups, alkenyl groups, alkynyl groups, alkoxy groups, alkylthio groups, alkylamino groups, halogens, mercapto groups, hydroxyl groups, nitro groups, cyano groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, cycloalkoxy groups, heterocycloalkoxy groups, cycloalkylthio groups, heterocycloalkylthio groups, carboxyl groups, or carboxylic acid ester groups.

[0052] "Alkynyl group" refers to (CH≡C-), which may be further substituted with other related groups, such as alkyl groups, alkenyl groups, alkynyl groups, alkoxy groups, alkylthio groups, alkylamino groups, halogens, mercapto groups, hydroxyl groups, nitro groups, cyano groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, cycloalkoxy groups, heterocycloalkoxy groups, cycloalkylthio groups, heterocycloalkylthio groups, carboxyl groups, or carboxylic acid ester groups.

[0053] "Hydroxyl" refers to an -OH group.

[0054] "Halogen" refers to fluorine, chlorine, bromine or iodine.

[0055] An "amino group" refers to -NH2.

[0056] A "cyano group" refers to -CN.

[0057] A "nitro group" refers to --NO.sub.2.

[0058] A "carboxyl group" refers to -C(O)OH.

[0059] "THF" refers to tetrahydrofuran.

[0060] "EtOAc" refers to ethyl acetate.

[0061] "MeOH" refers to methanol.

[0062] "DMF" refers to N,N-dimethylformamide.

[0063] "DIPEA" refers to diisopropylethylamine.

[0064] "TFA" refers to trifluoroacetic acid.

[0065] "MeCN" refers to acetonitrile.

[0066] "DMA" refers to N,N-dimethylacetamide.

[0067] "Et2O" refers to ethyl ether.

[0068] "DCE" refers to 1,2 dichloroethane.

[0069] "DIPEA" refers to N,N-diisopropylethylamine.

[0070] "NBS" refers to N-bromosuccinimide.

[0071] "NIS" refers to N-iodosuccinimide.

[0072] "Cbz-Cl" refers to benzyl chloroformate.

[0073] "Pd2(dba)3" refers to tris(dibenzylideneacetone)dipalladium.

[0074] "Dppf" refers to 1,1'-bis(diphenylphosphino)ferrocene.

[0075] "HATU" refers to O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate.

[0076] "KHMDS" refers to potassium hexamethyldisilazide.

[0077] "LiHMDS" refers to lithium bis(trimethylsilyl)amide.

[0078] "MeLi" refers to methyllithium.

[0079] "nBuLi" refers to n-butyllithium.

[0080] "NaBH(OAc)3" refers to sodium triacetoxyborohydride.

[0081] The different terms "X is selected from A, B, or C", "X is selected from A, B and C", "X is A, B or C", and "X is A, B and C" all have the same meaning, i.e., X may be any one or more of A, B, and C.

[0082] Any of the hydrogen atoms of the present invention may be replaced with its isotope, deuterium, and any one of the hydrogen atoms of the compounds according to the examples of the present invention may be replaced with a deuterium atom.

[0083] "May" or "may" means that the subsequently described event or circumstance may occur, but does not necessarily occur, and the description includes cases where the event or circumstance occurs or does not occur. For example, "a heterocyclic group preferably substituted with an alkyl group" indicates that an alkyl group may be present, but is not necessarily present, and the description includes cases where the heterocyclic group is substituted with an alkyl group and cases where the heterocyclic group is not substituted with an alkyl group.

[0084] "Substituted" refers to one or more hydrogen atoms in a group, preferably up to 5, more preferably 1 to 3 hydrogen atoms, each independently replaced with a corresponding number of substituents. It goes without saying that the substituents are only present at possible chemical sites, and a person skilled in the art can determine (by experiment or theory) without much effort which substitutions are possible or impossible. For example, when an amino group or a hydroxyl group having a free hydrogen is combined with a carbon atom having an unsaturated (e.g., ethylenic) bond, it may become unstable.

[0085] "Pharmaceutical composition" refers to a mixture of one or more compounds described herein or their physiologically / pharmaceutical acceptable salts or prodrugs with other chemical components, and other components such as physiologically / pharmaceutical acceptable carriers and excipients. Pharmaceutical compositions are intended to exert their physiological activity by facilitating administration to the body and facilitating absorption of the active ingredients.

[0086] "Pharmaceutically acceptable salt" means a salt of a compound of the present invention, which is safe and effective when administered to a mammalian body, and which possesses the desired biological activity. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0087] The present invention will be further described below with reference to examples, but these examples are not intended to limit the scope of the present invention.

[0088] Working Example The structures of the compounds of the present invention are determined by nuclear magnetic resonance (NMR) or / and liquid chromatography-mass spectrometry (LC-MS). NMR chemical shifts (δ) are given in parts per million (ppm). NMR was measured using a Bruker AVANCE-400 nuclear magnetometer, with deuterated dimethylsulfoxide (DMSO-d6), deuterated methanol (CD3OD) and deuterated chloroform (CDCl3) as solvents and tetramethylsilane (TMS) as internal standard.

[0089] For liquid chromatography-mass spectrometry (LC-MS), an Agilent 1200 Infinity Series mass spectrometer is used. For HPLC, an Agilent 1200DAD high performance liquid chromatograph (Sunfire C18 150×4.6 mm chromatography column) and a Waters 2695-2996 high performance liquid chromatograph (Gimini C18 150×4.6 mm chromatography column) are used.

[0090] Thin layer chromatography silica gel plate uses Yantai Yellow Sea HSGF254 or Qingdao GF254 silica gel plate, the silica gel plate used in TLC has a size of 0.15mm-0.20mm, and the silica gel plate used to separate and purify products by thin layer chromatography has a size of 0.4mm-0.5mm. Column chromatography generally uses Yantai Yellow Sea silica gel 200-300 mesh silica gel as the carrier.

[0091] The starting materials for the examples of the present invention are known and can be purchased commercially or synthesized according to methods known in the art.

[0092] Unless otherwise noted, all reactions of the present invention are carried out under a dry nitrogen or argon atmosphere with continuous magnetic stirring, solvents are dry solvents, and reaction temperatures are in degrees Celsius.

[0093] Example 1 1-((3R,5R,8S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone [ka] Step 1: (8S,9S,10S,13S,14S)-10-Fluoro-13-methyl-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-diketone [ka] In a 100mL three-neck flask, (8R,9S,13S,14S)-3-hydroxyl-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthrene-17-ketone (2.7g, 10mmol) and acetonitrile (100mL) were added in order, and 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo2.2.2octane bis(tetrafluoroborate) salt (3.6g, 10mmol) was added while stirring. The mixture was heated to 45°C in an oil bath and reacted for 5 hours, then cooled to room temperature. The reaction solution was concentrated, dissolved in dichloromethane (100mL), washed with saturated saline (30mLx3), and the organic phase was dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was separated and purified by column chromatography (petroleum ether / ethyl acetate: 3 / 1) to obtain (8S,9S,10S,13S,14S)-10-fluoro-13-methyl-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-diketone (1.8 g, pale yellow solid, yield: 62.5%).

[0094] MS m / z (ESI): 289.1[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.12-7.05 (m, 1 H), 6.30-6.19 (m, 1H), 6.04 (s, 1H), 2.70-2.60 (m, 1H), 2.52-2.45 (m, 2H), 2.16-1.86 (m, 7H), 1.65-1.18 (m, 5H), 0.98 (s, 3H). 19 F NMR (376 MHz, CDCl3) δ -165.20. Step 2: (5R,8S,9S,10R,13S,14S)-10-Fluoro-13-methyltetradecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-diketone [ka] In a 100 mL single-neck flask, (8S,9S,10S,13S,14S)-10-fluoro-13-methyl-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-diketone (1.8 g, 6.25 mmol) was added and dissolved in ethanol (50 mL). The mixture was stirred at room temperature for 2 to 3 minutes, and then palladium-barium sulfate catalyst (300 mg) was added. After the addition was completed, the mixture was stirred at room temperature under a hydrogen gas atmosphere for 5 hours. The reaction mixture was filtered and dissolved in 20 mL of dichloromethane to precipitate a white solid, which was then filtered and the filtrate was spin-dried. The crude product was separated and purified by column chromatography (petroleum ether / ethyl acetate: 3 / 1) to obtain (5R,8S,9S,10R,13S,14S)-10-fluoro-13-methyltetradecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-diketone (600 mg, white solid, yield: 32.9%).

[0095] 1 H NMR (400 MHz, CDCl3) δ 2.63-2.45 (m, 2H), 2.43-2.33 (m, 3H), 2.30-1.80 (m, 8H),1.75-1.55 (m, 5H), 1.45-1.35 (m, 3H), 1.25-1.18 (m, 1H), 0.94 (s, 3H). 19 F NMR (376 MHz, CDCl3) δ -159.89 . Step 3: (3R,5R,8S,10R,13S,14S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-17H-cyclopenta[a]phenanthrene-17-ketone [ka] 2,6-di-tert-butyl-4-methylphenol (1.45g, 6.6mmol) was added to a 100mL three-neck flask and dissolved in anhydrous toluene (15mL). The mixture was cooled to 0-5℃ in an ice bath, and trimethylaluminum (1.7mL, 2M, 3.3mmol) was added dropwise under nitrogen gas protection. After the addition was completed, the mixture was allowed to naturally warm to room temperature and stirred for 1 hour. The reaction solution was cooled to -78℃, and a toluene (5mL) solution of (5R,8S,9S,10R,13S,14S)-10-fluoro-13-methyltetradecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-diketone (320mg, 1.1mmol) was added dropwise to the reaction solution, and the reaction solution was reacted at -78℃ for 1 hour. Then, methyl magnesium bromide (1.0 mL, 3 M, 3 mmol) was added dropwise, and the reaction solution was reacted at -78 ° C for 1 hour. The reaction solution was quenched with a saturated aqueous ammonium chloride solution, extracted with ethyl acetate (20 mL), and a large amount of white solid was precipitated. The reaction solution was filtered, the filtrate was separated, and the organic phase was dried with anhydrous sodium sulfate, spin-dried, and separated and purified by column chromatography (petroleum ether / ethyl acetate: 2 / 1) to obtain (3R, 5R, 8S, 10R, 13S, 14S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-17H-cyclopenta [a] phenanthrene-17-ketone (250 mg, white solid, yield: 74.0%).

[0096] 1 H NMR (400 MHz, CDCl3) δ 2.46 (dd, J = 19.3, 8.7 Hz, 1H), 2.17 - 1.72 (m, 8H), 1.71 - 1.44 (m, 10H), 1.38 (s, 3H), 1.34 - 1.11 (m, 3H), 0.90 (s, 3H). 19 F NMR (376 MHz, CDCl3) δ -158.16 . Step 4: (3R,5R,8S,10R,13S,14S)-17-Ethylene-10-fluoro-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3-phenol [ka] In a 100 mL three-neck flask, potassium t-butoxide (500 mg, 4.5 mmol) and tetrahydrofuran (15 mL) were added in this order, the reaction solution was cooled to 0°C, ethyltriphenylphosphonium bromide (1.82 g, 4.8 mmol) was added in several portions, the reaction solution was stirred at 60°C for 2 hours, (3R,5R,8S,10R,13S,14S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-17H-cyclopenta[a]phenanthrene-17-ketone (250 mg, 0.75 mmol) was added to the above reaction solution, and the reaction solution was reacted at 60°C for 8 hours. The reaction mixture was quenched with saturated ammonium chloride solution, extracted with ethyl acetate (20 mL), washed with saturated saline (10 mL x 2), and the organic phase was dried over anhydrous sodium sulfate, filtered, spin-dried, and separated by column chromatography (petroleum ether / ethyl acetate: 5 / 1) to give (3R,5R,8S,10R,13S,14S)-17-ethylene-10-fluoro-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3-phenol (110 mg, white solid, yield 42%).

[0097] 1 H NMR (400 MHz, CDCl3) δ 5.15-5.08 (m, 1H), 2.40-1.80 (m, 8H), 1.65 - 1.45 (m, 13H), 1.36 (s, 3H), 1.31 - 1.05 (m, 4H), 0.89 (s, 3H). 19 F NMR (376 MHz, CDCl3) δ -157.91 . Step 5: (3R,5R,8S,10R,13S,14S)-10-Fluoro-17-(1-hydroxyethyl)-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3-phenol [ka] (3R,5R,8S,10R,13S,14S)-17-Ethylene-10-fluoro-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3-phenol (110 mg, 0.35 mmol) was dissolved in dry tetrahydrofuran (5 mL), and borane-tetrahydrofuran complex (1.1 mL, 1 M, 1.05 mmol) was added at room temperature. After the addition was completed, the mixture was stirred for 1 hour. The reaction solution was cooled in an ice-water bath, NaOH (10%, 1.5 mL) was slowly added dropwise to release a large amount of gas, and then hydrogen peroxide solution (30%, 2 mL) was slowly added dropwise, the reaction solution was stirred at room temperature for 1 hour, the reaction solution was extracted with ethyl acetate (10 mL x 2), washed with 10% sodium thiosulfate, the organic phase was dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give (3R,5R,8S,10R,13S,14S)-10-fluoro-17-(1-hydroxyethyl)-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3-phenol (100 mg, white solid).

[0098] Step 6: 1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone [ka] (3R,5R,8S,10R,13S,14S)-10-fluoro-17-(1-hydroxyethyl)-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3-phenol (100 mg, 0.3 mmol) was dissolved in dichloromethane (5 mL), pyridinium chlorochromate (130 mg, 0.6 mmol) was added, and the mixture was stirred at room temperature for 12 hours. The reaction solution was filtered, concentrated under reduced pressure, and separated by column chromatography (petroleum ether / ethyl acetate: 5 / 1) to obtain 1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-17-yl)ethane-1-ketone (80 mg, white solid, yield: 81%). 1 H NMR (400 MHz, CDCl3) δ 2.53 (t, J = 9.0 Hz, 1H), 2.23-2.16 (m, 1H), 2.12 (s, 3H), 2.10 - 1.83 (m, 5H), 1.73 - 1.42 (m, 12H), 1.38 (s, 3H), 1.35 - 1.02 (m, 4H), 0.64 (s, 3H).

[0099] Example 2 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-4-carbonitrile [ka] Step 1: 2-Bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone [ka] 1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (80 mg, 0.25 mmol) was dissolved in methanol (5 mL), and 3 drops of hydrogen bromide and 3 drops of liquid bromine were added, followed by stirring at room temperature for 12 hours. The reaction mixture was added to ice water and extracted with ethyl acetate (10 mL x 2). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (80 mg, 81%), which was used directly in the next reaction.

[0100] Step 2: 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-4-carbonitrile [ka] 2-Bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (80 mg, 0.2 mmol) was dissolved in tetrahydrofuran (5 mL), 4-cyanopyrazole (46 mg, 0.5 mmol) and potassium carbonate (84 mg, 0.6 mmol) were added, and the reaction mixture was stirred at room temperature for 5 h. The reaction mixture was filtered, concentrated, and separated by prep-HPLC to obtain the product (25 mg, white solid, 30.3% yield).

[0101] MS m / z (ESI): 428.3[M+H] + . 1H NMR (400 MHz, CDCl3) δ 7.87 (s, 1H), 7.81 (s, 1H), 5.10-4.83 (m, 2H), 2.60 (t, J = 8.8 Hz, 1H), 2.28-2.18 (m, 1H), 2.15-2.07 (m, 2H), 2.05 -~ 1.75 (m, 5H), 1.69 - 1.45 (m, 10H), 1.38 (s, 3H), 1.35 - 1.23 (m, 3H), 1.19 - 1.07 (m, 1H), 0.70 (s, 3H). 19 F NMR (376 MHz, CDCl3) δ -158.28 .

[0102] Examples 3 and 4 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-3-carbonitrile (3) 1-(2-((3R,5R,8S,9S,10R,13S,14S,17R)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-3-carbonitrile (4) [ka] 2-Bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (80 mg, 0.2 mmol) was dissolved in tetrahydrofuran (5 mL), 3-cyanopyrazole (46 mg, 0.5 mmol) and potassium carbonate (84 mg, 0.6 mmol) were added, and the reaction solution was stirred at room temperature for 5 h. The reaction mixture was filtered, concentrated, and separated by prep-HPLC to give the product 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-3-carbonitrile (3) (18 mg, white). The product 1-(2-((3R,5R,8S,9S,10R,13S,14S,17R)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-3-carbonitrile (4) (5 mg, white solid, 6.0% yield) was obtained.

[0103] Example 3: MS m / z (ESI): 428.1[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.50 (d, J =2.4 Hz, 1H), 6.74 (d, J =2.4 Hz, 1H), 5.15-4.85 (m, 2H), 2.60 (t, J = 8.9 Hz, 1H), 2.26-2.16 (m, 1H), 2.05-1.90 (m, 2H), 1.85 - 1.73 (m, 3H), 1.67 - 1.43 (m, 12H), 1.38 (s, 3H), 1.38 - 1.25 (m, 3H), 1.18 - 1.06 (m, 1H), 0.71 (s, 3H). 19 F NMR (376 MHz, CDCl3) δ -158.21 .

[0104] Example 4: MS m / z (ESI): 428.1[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.50 (d, J =2.4 Hz, 1H), 6.76 (d, J =2.4 Hz, 1H), 5.15-4.85 (m, 2H), 2.78 (dd, J = 8.0,2.8 Hz, 1H), 2.10-1.73 (m, 7H), 1.70 - 1.36 (m, 11H), 1.35 (s, 3H), 1.32 - 1.10(m, 4H), 0.98 (s, 3H). 19 F NMR (376 MHz, CDCl3) δ -158.42 .

[0105] Examples 5 and 6 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)ethane-1-ketone (5) 1-((3R,5R,8S,9S,10R,13S,14S,17R)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)ethane-1-ketone (6) [ka] Using 2-bromo-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, referring to step 2 of Example 2, the product 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren- 17-yl)-2-(1H-tetrazol-1-yl)ethane-1-ketone (5) (35.5 mg, white solid, 43% yield) and 1-((3R,5R,8S,9S,10R,13S,14S,17R)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)ethane-1-ketone (6) (12.3 mg, white solid, 14.9% yield) were obtained.

[0106] Example 5: MS m / z (ESI): 471.3[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.48 (s, 1H), 6.59 (d, J = 2.1 Hz, 1H), 5.05-4.92 (m, 2H), 2.59 (t, J = 8.8 Hz, 1H), 2.25-2.15 (m, 1H), 2.15-2.05 (m, 2H), 2.03 - 1.69 (m, 5H), 1.70 - 1.41 (m, 12H), 1.38 (s, 3H), 1.06 (m, 4H), 0.71 (s, 3H).

[0107] Example 6: MS m / z (ESI): 471.3[M+H] + . 1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 1.3 Hz, 1H), 6.61 (d, J = 2.3 Hz, 1H), 5.07-4.90 (m, 2H), 2.77 (dd, J = 7.9, 3.0 Hz, 1H), 2.12 - 1.72 (m, 9H), 1.72 - 1.38 (m, 11H), 1.34(s, 3H), 1.33-1.04(m, 4H), 0.96 (s, 3H). Examples 7 and 8 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4-(trifluoromethyl)-1H-pyrazol-1-yl)ethane-1-ketone (7) 1-((3R,5R,8S,9S,10R,13S,14S,17R)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4-(trifluoromethyl)-1H-pyrazol-1-yl)ethane-1-ketone (8) [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, product 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(2-bromo-1-ketone)-2 ... -(4-(trifluoromethyl)-1H-pyrazol-1-yl)ethane-1-ketone (7) (22 mg, white solid, 32.9% yield) and the product 1-((3R,5R,8S,9S,10R,13S,14S,17R)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4-(trifluoromethyl)-1H-pyrazol-1-yl)ethane-1-ketone (8) (8 mg, white solid, 11.5% yield) were obtained.

[0108] Example 7: MS m / z (ESI): 471.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.72 (s, 2H), 5.05 - 4.85(m, 2H), 2.60 (t, J = 8.0 Hz, 1H), 2.30-2.15 (m, 1H), 2.15-2.05 (m, 2H), 2.01 - 1.93 (m, 2H), 1.92 - 1.83 (m, 1H), 1.81 - 1.71 (m, 2H),1.71 - 1.43 (m, 10H), 1.38 (s, 3H), 1.35 - 1.25 (m, 3H), 1.19 - 1.10 (m, 1H), 0.71 (s, 3H). 19 F NMR (376 MHz, CDCl3) δ -56.44, -158.26 .

[0109] Example 8: MS m / z (ESI): 471.3[M+H]+ . 1 H NMR (400 MHz, CDCl3) δ 7.74 (s, 1H), 7.73 (s, 1H), 5.29 - 5.19 (m, 2H), 2.79 (dd, J = 7.9,2.7 Hz, 1H), 2.10-2.03 (m, 1H), 1.95-1.75 (m, 6H), 1.65 - 1.25 (m, 17H), 1.19 - 1.10 (m, 1H), 0.98 (s, 3H). 19 F NMR (376 MHz, CDCl3) δ -56.42, -158.43 .

[0110] Examples 9 and 10 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(1H-1,2,3-triazol-1-yl)ethane-1-ketone (9) 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(2H-1,2,3-triazol-2-yl)ethane-1-ketone (10) [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-17-yl)ethane-1-ketone as raw material, the product 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-17-yl)ethane-1-ketone was obtained by referring to step 2 of Example 6. 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(2H-1,2,3-triazol-2-yl)ethane-1-ketone (10) (20 mg, white solid, 20.5% yield) was obtained.

[0111] Example 9: MS m / z (ESI): 404.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.76 (s, 1H), 7.65 (s, 1H), 5.30 - 5.13 (m, 2H), 2.65 (t, J = 8.0 Hz, 1H), 2.25-2.15 (m, 1H), 2.13-2.03 (m, 2H), 2.05 - 1.75 (m, 5H), 1.68 - 1.43 (m, 10H), 1.38 (s, 3H), 1.35 - 1.25 (m, 3H), 1.19 - 1.10 (m, 1H), 0.71 (s, 3H). 19 F NMR (376 MHz, CDCl3) δ -158.26 .

[0112] Example 10: MS m / z (ESI): 404.2[M+H] + . 1H NMR (400 MHz, CDCl3) δ 7.69 (s, 2H), 5.24 (s, 2H), 2.57 (t, J = 8.0 Hz, 1H), 2.27-2.16 (m, 1H), 2.15-2.07 (m, 2H), 2.05 - 1.75 (m, 5H), 1.68 - 1.43 (m, 10H), 1.38 (s, 3H), 1.35 - 1.25 (m, 3H), 1.19 - 1.05 (m, 1H), 0.74 (s, 3H). 19 F NMR (376 MHz, CDCl3) δ -158.24 .

[0113] Example 11 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4-methyl-1H-pyrazol-1-yl)ethane-1-ketone [ka] Using 2-bromo-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as the raw material, and referring to step 8 of Example 6, the product 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4-methyl-1H-pyrazol-1-yl)ethane-1-ketone (11) (24 mg, white solid, yield 29%) was obtained.

[0114] MS m / z (ESI): 417.3[M+H] + . 1H NMR (400 MHz, CDCl3) δ 7.35 (s, 1H), 7.18 (s, 1H), 4.90-4.79 (m, 2H), 2.56 (t, J = 8.9 Hz, 1H), 2.27-2.13 (m, 1H), 2.11 (s, 3H), 2.06-1.80 (m, 4H), 1.80-1.40 (m, 11H), 1.38 (s, 3H), 1.35- 1.19 (m, 5H), 1.18 - 1.03 (m, 1H), 0.71 (s, 3H).

[0115] Example 12 and Example 13 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(2H-tetrazol-2-yl)ethane-1-ketone (12) 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(1H-tetrazol-1-yl)ethane-1-ketone (13) [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as the raw material, the product 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone was obtained by referring to step 2 of Example 2. 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(1H-tetrazol-1-yl)ethane-1-ketone (13) (9 mg, white solid, 12% yield) was obtained.

[0116] Example 12: MS m / z (ESI): 405.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 8.57 (s, 1H), 5.46 (s, 2H), 2.64 (t, J = 8.0 Hz, 1H), 2.28-2.19 (m, 1H), 2.18-2.07 (m, 2H), 2.05 - 1.75 (m, 4H), 1.71 - 1.43 (m, 11H), 1.38 (s, 3H), 1.34 - 1.26 (m, 3H), 1.21 - 1.11 (m, 1H), 0.75 (s, 3H).

[0117] Example 13: MS m / z (ESI): 405.2[M+H] + . 1H NMR (400 MHz, CDCl3) δ 8.75 (s, 1H), 5.35 - 5.15 (m, 2H), 2.67 (t, J = 8.0 Hz, 1H), 2.30-2.19 (m, 1H), 2.15-2.07 (m, 1H), 2.05 - 1.75 (m, 4H), 1.68 - 1.45 (m, 11H), 1.39 (s, 3H), 1.35 - 1.25 (m, 4H), 1.20 - 1.10 (m, 1H), 0.71 (s, 3H).

[0118] Examples 14 and 15 2-(2H-benzo[d][1,2,3]triazol-2-yl)-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (15) 2-(1H-benzo[d][1,2,3]triazol-1-yl)-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (16) [ka] Using 2-bromo-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, the product 2-(2H-benzo[d][1,2,3]triazol-2-yl)-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone was obtained by referring to step 8 of Example 6. Dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (14) (11 mg, 14% yield) and 2-(1H-benzo[d][1,2,3]triazol-1-yl)-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (15) (31 mg, 41% yield) were obtained.

[0119] Example 14: MS m / z (ESI): 453.3[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.88 (dd, J = 6.6, 3.0 Hz, 2H), 7.40 (dd, J = 6.6, 3.0 Hz, 2H), 5.53 (t, J = 4.7 Hz, 2H), 2.64 (t, J = 8.9 Hz, 1H), 2.34 - 1.41 (m, 16H), 1.38 (s, 3H), 1.35 - 0.97 (m, 6H), 0.78 (s, 3H).

[0120] Example 15: MS m / z (ESI): 453.3[M+H] + . 1H NMR (400 MHz, CDCl3) δ 8.11 (d, J = 7.5 Hz, 1H), 7.50 (t, J = 7.5 Hz, 1H), 7.46 -~ 7.30 (m, 2H), 5.42 (s, 2H), 2.70 (t, J = 8.5 Hz, 1H), 2.35 - 1.42 (m, 16H), 1.38 (s, 3H), 1.35 - 1.01 (m, 6H), 0.77 (s, 3H).

[0121] Example 16 and Example 17 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(2H-pyrazolo[3,4-c]pyridyl-2-yl)ethane-1-ketone (16) 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(1H-pyrazolo[3,4-c]pyridyl-1-yl)ethane-1-ketone (17) [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as the raw material, the product 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone was obtained by referring to step 2 of Example 6. 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(2H-tetrazol-2-yl)ethane-1-ketone (17) (16 mg, white solid, 18.3% yield) was obtained.

[0122] Example 16: MS m / z (ESI): 454.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 9.33 (s, 1H), 8.19 (s, 1H), 8.13 (s, 1H), 7.72 (s, 1H), 5.42 - 5.25 (m, 2H), 2.70 (t, J = 8.0 Hz, 1H), 2.30-2.10 (m, 3H), 2.05-1.85 (m, 8H), 1.70 - 1.45 (m, 7H), 1.39 (s, 3H), 1.32 - 1.25 (m, 3H), 0.90-0.85 (m, 1H), 0.75 (s, 3H).

[0123] Example 17: MS m / z (ESI): 454.2[M+H] + . 1H NMR (400 MHz, CDCl3) δ 8.88 (s, 1H), 8.36 (s, 1H), 8.13 (s, 1H), 7.71 (s, 1H), 5.32 - 5.25 (m, 2H), 2.69 (t, J = 8.0 Hz, 1H), 2.25-2.10 (m, 3H), 2.05-1.75 (m, 5H), 1.70 - 1.45 (m, 10H), 1.39 (s, 3H), 1.35 - 1.25 (m, 3H), 1.20-1.10 (m, 1H), 0.76 (s, 3H).

[0124] Example 18, Example 19 and Example 20 2-(5-fluoro-2H-benzo[d][1,2,3]triazol-2-yl)-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (18) 2-(6-fluoro-1H-benzo[d][1,2,3]triazol-1-yl)-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (19) 2-(5-fluoro-1H-benzo[d][1,2,3]triazol-1-yl)-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (20) [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as a raw material, 2-(5-fluoro-2H-benzo[d][1,2,3]triazol-2-yl)-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (18) (20 mg, white solid, yield 14.9%), 2-(6-fluoro-1H-benzo[d][1 ,2,3]triazol-1-yl)-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (19) (18 mg, white solid, 13.1% yield) and 2-(5-fluoro-1H-benzo[d][1,2,3]triazol-1-yl)-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (20) (19 mg, white solid, 13.9% yield).

[0125] Example 18: MS m / z (ESI): 472.3[M+H] + . 11H NMR (400 MHz, CDCl3) δ 7.86 (dd, J = 9.3, 4.7 Hz, 1H), 7.47 (dd, J = 8.7, 1.9 Hz, 1H), 7.21 (m, 1H), 5.55 - 5.45 (m, 2H), 2.65 (t, J = 8.8 Hz, 1H), 2.32 - 2.08 (m, 3H), 2.04 - 1.45 (m, 15H), 1.38 (s, 3H), 1.35 - 1.23 (m, 3H), 1.20 - 1.10 (m, 1H), 0.78 (s, 3H).

[0126] Example 19: MS m / z (ESI): 472.3[M+H] + . 1 1H NMR (400 MHz, CDCl3) δ 8.04 (dd, J = 8.9, 4.4 Hz, 1H), 7.20 - 7.10 (m, 1H), 6.99 (d, J = 7.6 Hz, 1H), 5.45 - 5.35 (m, 2H), 2.69 (d, J = 8.7 Hz, 1H), 2.31 - 2.08 (m, 3H), 2.04 - 1.45 (m, 15H), 1.39 (s, 3H), 1.35 - 1.25 (m, 3H), 1.20 - 1.10 (m, 1H), 0.76 (s, 3H).

[0127] Example 20: MS m / z (ESI): 472.3[M+H] + . 1 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 7.9 Hz, 1H), 7.35 - 7.28 (m, 2H), 5.45 - 5.35 (m, 2H), 2.69 (d, J = 8.7 Hz, 1H), 2.31 - 2.08 (m, 3H), 2.04 - 1.45 (m, 15H), 1.39 (s, 3H), 1.35 - 1.25 (m, 3H), 1.20 - 1.10 (m, 1H), 0.76 (s, 3H).

[0128] Example 21 and Example 22 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4,5,6,7-tetrahydro-2H-indazol-2-yl)ethane-1-ketone (21) 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4,5,6,7-tetrahydro-1H-indazol-1-yl)ethane-1-ketone (22) [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as a raw material, 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4, 5,6,7-Tetrahydro-2H-indazol-2-yl)ethane-1-ketone (21) (15.0 mg, white solid, yield 27.2%) and 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4,5,6,7-tetrahydro-1H-indazol-1-yl)ethane-1-ketone (22) (8.0 mg, white solid, yield 12.1%) were obtained.

[0129] Example 21: MS m / z (ESI): 457.2[M+H] + . 1H NMR (400 MHz, CDCl3) δ 7.10 (s, 1H), 4.90 - 4.85 (m, 2H), 2.72-2.66 (m, 2H), 2.62-2.52 (m, 3H), 2.25-1.40 (m, 22H), 1.37 (s, 3H), 1.33 - 1.23 (m, 3H), 1.17-1.07 (m, 1H), 0.71 (s, 3H).

[0130] Example 22: MS m / z (ESI): 457.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.31 (s, 1H), 4.85 -~ 4.75 (m, 2H), 2.60-2.50 (m, 3H), 2.45-2.39 (m, 2H), 2.25-1.40 (m, 22H), 1.37 (s, 3H), 1.33 - 1.23 (m, 3H), 1.15-1.05 (m, 1H), 0.71 (s, 3H).

[0131] Example 23 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-((4-fluorophenyl)amino)ethane-1-ketone [ka] 2-Bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (80 mg, 0.2 mmol) was dissolved in tetrahydrofuran (5 mL), and 4-fluoroaniline (42 mg, 0.4 mmol) and triethylamine (60 mg, 0.6 mmol) were added. The reaction solution was stirred at room temperature for 5 h. The reaction solution was concentrated and separated by prep-HPLC to obtain the product (18 mg, white solid, 21% yield).

[0132] MS m / z (ESI): 446.3[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 6.94-6.88 (m, 2H), 6.58 - 6.53(m, 2H), 3.96 -~ 3.85(m, 2H), 2.57 (t, J = 8.0 Hz, 1H), 2.30-2.20 (m, 1H), 2.15-2.06 (m, 1H), 2.05 -~ 1.71 (m, 6H), 1.68 - 1.43 (m, 10H), 1.38 (s, 3H), 1.34 - 1.20 (m, 3H), 1.18 - 1.07 (m, 1H), 0.68 (s, 3H).

[0133] Example 24 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-((2-fluorophenyl)amino)ethane-1-ketone [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as the raw material, and referring to Example 23, the product 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-((2-fluorophenyl)amino)ethane-1-ketone (11 mg, white solid, yield 20.5%) was obtained.

[0134] MS m / z (ESI): 446.2[M+H] + . 1H NMR (400 MHz, CDCl3) δ 7.04 - 6.92 (m, 2H), 6.71 - 6.61 (m, 1H), 6.60 - 6.52 (m, 1H), 4.03 - 3.86 (m, 2H), 2.58 (t, J = 8.8 Hz, 1H), 2.33 -~ 1.44 (m, 18H), 1.38 (s, 3H), 1.33 - 1.05 (m, 4H), 0.69 (s, 3H).

[0135] Example 25 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-((3-fluorophenyl)amino)ethane-1-ketone [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as the raw material, and referring to Example 23, the product 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-((3-fluorophenyl)amino)ethane-1-ketone (4.5 mg, white solid, yield 7.0%) was obtained.

[0136] MS m / z (ESI): 446.2[M+H] + . 1H NMR (400 MHz, CDCl3) δ 7.15 - 7.07 (m, 1H), 6.51 - 6.38 (m, 2H), 6.30 (d, J = 11.4 Hz, 1H), 3.98 - 3.85 (m, 2H), 2.57 (t, J = 8.8 Hz, 1H), 2.12 - 1.64 (m, 18H), 1.38 (s, 3H), 1.30 - 1.26 (m, 3H), 1.18 - 1.11 (m, 1H), 0.68 (s, 3H).

[0137] Example 26 2-((2,4-difluorophenyl)amino)-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone [ka] 2-Bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (80 mg, 0.193 mmol) was dissolved in tetrahydrofuran (3 mL), 2,4-difluoroaniline (37 mg, 0.289 mmol) and potassium carbonate (53 mg, 0.438 mmol) were added, and the mixture was stirred at room temperature for 16 h. Water (15 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phase was washed with saturated saline (15 mL), the organic phase was dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and separated by preparative chromatography to obtain a white solid 2-((2,4-difluorophenyl)amino)-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (7 mg, yield: 7.8%).

[0138] MS m / z (ESI): 464.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 6.84 - 6.70 (m, 2H), 6.50-6.45 (m, 1H), 3.98-3.88 (m, 2H), 2.57 (t, J = 8.9 Hz, 1H), 2.31 - 2.19 (m, 1H), 2.10 (m, 1H), 2.04 - 1.74 (m, 7H), 1.51 - 1.44 (m, 5H), 1.38 (s, 3H), 1.37 - 1.20 (m, 8H), 1.13 (m, 2H), 0.69 (s, 3H).

[0139] Example 27 5-Fluoro-2-((2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)amino)benzonitrile [ka] 2-Amino-5-fluorobenzonitrile (147 mg, 1.08 mmol) was dissolved in tetrahydrofuran (5 mL) at 0° C., then sodium hydride (29 mg, 0.72 mmol) was added and stirred at 0° C. for 40 minutes, and a mixture of 2-bromo-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (150 mg, 0.36 mmol) and tetrahydrofuran (2 mL) was stirred at 0° C. for 30 minutes, and the reaction solution was diluted with water. (20mL) was added, followed by extraction with ethyl acetate (20mLx3), the combined organic phase was washed with saturated saline (30mL), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure, followed by separation and purification by preparative chromatography to obtain 5-fluoro-2-((2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)amino)benzonitrile (10mg, white solid, yield: 6%).

[0140] MS m / z (ESI): 471.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.62 (dd, J = 9.6, 3.0 Hz, 1H), 7.10 -~ 7.01 (m, 1H), 6.62 (dd, J = 9.1, 4.5 Hz, 1H), 4.90 - 4.73 (m, 2H), 2.58 (t, J = 8.8 Hz, 1H), 2.28-1.78 (m, 9H), 1.65-1.58 (m, 3H), 1.61-1.44 (m, 4H),1.38(s, 3H), 1.31-1.26 (m, 4H), 1.15-1.09 (m, 2H), 0.90-0.86 (m, 2H), 0.73 (s, 3H).

[0141] Example 28 1-((3S,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-((3-fluoropyridin-4-yl)amino)ethane-1-ketone [ka] 4-Amino-3-fluoropyridine (32.4 mg, 0.28 mmol), 2-bromo-1-((3S,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (60 mg, 0.14 mmol) were dissolved in N,N-dimethylformamide (5 mL), triethylamine (42.5 mg, 0.42 mmol) was added, and the mixture was stirred at room temperature overnight. 5 mL of water was added, extracted with ethyl acetate (30 mL x 3), washed once with saturated brine (20 mL), and the organic phase was dried over anhydrous sodium sulfate, spin-dried, and separated by prep-HPLC to obtain the product 1-((3S,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-((3-fluoropyridin-4-yl)amino)ethane-1-ketone (6.1 mg, white solid, 9.7% yield).

[0142] MS m / z (ESI): 447.2[M+H] + .

[0143] Example 29 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(pyridazin-4-oxy)ethane-1-ketone [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 2 of Example 2, product 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(pyridazin-4-oxy)ethane-1-ketone (19 mg, white solid, yield 30.5%) was obtained.

[0144] MS m / z (ESI): 431.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.92 (s, 1H), 7.72 (s, 1H), 6.60 (s, 1H), 4.99 - 4.73 (m, 2H), 2.67 - 2.54 (m, 1H), 2.32 - 1.49 (m, 18H), 1.38 (s, 3H), 1.31 - 1.01 (m, 4H), 0.71 (s, 3H).

[0145] Example 30 and Example 32 5-Fluoro-2-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethoxy)benzonitrile (30) 5-Fluoro-2-(2-((3R,5R,8S,9S,10R,13S,14S,17R)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethoxy)benzonitrile (32) [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, the product 5-fluoro-2-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone was obtained by referring to step 2 of Example 2. [a]phenanthren-17-yl)-2-carbonylethoxy)benzonitrile (30) (14.5 mg, white solid, yield 21.2%) and 5-fluoro-2-(2-((3R,5R,8S,9S,10R,13S,14S,17R)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethoxy)benzonitrile (32) (13.5 mg, white solid, yield 19.8%) were obtained.

[0146] Example 30: 1 H NMR (400 MHz, CDCl3) δ 7.31 (dd, J = 7.4, 3.1 Hz, 1H), 7.25 - 7.18 (m, 1H), 6.74 (dd, J = 9.3, 4.0 Hz, 1H), 4.69 - 4.53 (m, 2H), 2.90 (t, J = 8.7 Hz, 1H), 2.32 - 1.43 (m, 18H), 1.37 (s, 3H), 1.31 - 1.03 (m, 4H), 0.70 (s, 3H). Example 32: 1 H NMR (400 MHz, CDCl3) δ 7.37 - 7.32 (m, 1H), 7.25 - 7.17 (m, 2H), 5.67 - 5.40 (m, 2H), 3.40 (t, J = 8.9 Hz, 1H), 2.44 - 1.08 (m, 25H), 0.73 (s, 3H).

[0147] Example 31 3-Fluoro-4-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethoxy)benzonitrile [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 2 of Example 2, the product 3-fluoro-4-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethoxy)benzonitrile (13 mg, white solid, yield 19.0%) was obtained.

[0148] 1 H NMR (400 MHz, CDCl3) δ 7.50 - 7.34 (m, 2H), 6.86 (t, J = 8.4 Hz, 1H), 4.76 - 4.59 (m, 2H), 2.79 (t, J = 8.9 Hz, 1H), 2.29 - 1.42 (m, 17H), 1.38 (s, 3H), 1.34 - 1.07 (m, 5H), 0.70 (s, 3H).

[0149] Example 33 4-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethoxy)benzonitrile [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 2 of Example 2, product 4-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethoxy)benzonitrile (27.5 mg, white solid, yield 41.9%) was obtained.

[0150] 1 H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 8.8 Hz, 2H), 6.92 (d, J = 8.8 Hz, 2H), 4.65 - 4.52 (m, 2H), 2.77 (t, J = 8.7 Hz, 1H), 2.24 - 1.49 (m, 18H), 1.38 (s, 3H), 1.32 - 1.25 (m, 3H), 1.18 -1.06 (m, 1H), 0.71 (s, 3H).

[0151] Example 34 4-Fluoro-3-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethoxy)benzonitrile [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 2 of Example 2, the product 4-fluoro-3-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethoxy)benzonitrile (32 mg, white solid, yield 46.9%) was obtained.

[0152] 1 H NMR (400 MHz, CDCl3) δ 7.36 - 7.27 (m, 1H), 7.20 (dd, J = 10.6, 8.4 Hz, 1H), 7.11 (dd, J = 7.6, 1.9 Hz, 1H), 4.76 - 4.51 (m, 2H), 2.77 (t, J = 8.9 Hz, 1H), 2.24 - 1.51 (m, 18H), 1.38 (s,3H), 1.32 - 1.23 (m, 3H), 1.19 - 1.06 (m, 1H), 0.71 (s, 3H).

[0153] Example 35 2-Fluoro-4-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethoxy)benzonitrile [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 2 of Example 2, the product 2-fluoro-4-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethoxy)benzonitrile (23 mg, white solid, yield 33.7%) was obtained.

[0154] 1 H NMR (400 MHz, CDCl3) δ 7.36 - 7.27 (m, 1H), 7.20 (dd, J = 10.6, 8.4 Hz, 1H), 7.11 (dd, J = 7.6, 1.9 Hz, 1H), 4.76 - 4.51 (m, 2H), 2.77 (t, J = 8.9 Hz, 1H), 2.24 - 1.51 (m, 18H), 1.38 (s,3H), 1.32 - 1.23 (m, 3H), 1.19 - 1.06 (m, 1H), 0.71 (s, 3H).

[0155] Example 36 2-(2,4-difluorophenoxy)-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone [ka] Using 2-bromo-1-((3R,5R,8R,9R,10S,13S,14S,15R,17S)-3-hydroxyl-3,13,15-trimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 2 of Example 2, the product 2-(2,4-difluorophenoxy)-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (16.4 mg, white solid, yield 24.4%) was obtained.

[0156] 1 H NMR (400 MHz, Chloroform-d) δ 6.95 - 6.83 (m, 2H), 6.82 - 6.69 (m, 1H), 4.67 - 4.45 (m, 2H), 2.81 (t, J = 8.8 Hz, 1H), 2.36 - 2.16 (m, 1H), 2.14 - 2.04 (m, 1H), 2.03 - 1.78 (m, 4H), 1.76 - 1.69 (m, 1H), 1.65 - 1.44 (m, 11H), 1.37 (s, 3H), 1.32 - 1.21 (m, 3H), 1.19 - 0.99 (m, 1H), 0.69 (s, 3H).

[0157] Example 37 2-(4-chloro-1H-pyrazol-1-yl)-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 2 of Example 2, the product 2-(4-chloro-1H-pyrazol-1-yl)-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (22 mg, white solid, yield 34.9%) was obtained.

[0158] MS m / z (ESI): 437.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.46 (s, 1H), 7.42 (s, 1H), 5.04-4.62 (m, 2H), 2.57 (t, J = 8.8 Hz, 1H), 2.31-1.45 (m, 18H), 1.38 (s, 3H), 1.33-1.23 (m, 3H), 1.18-1.05 (m, 1H), 0.70 (s, 3H).

[0159] Example 38 and Example 39 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-3-methyl-1H-pyrazole-4-carbonitrile (38) 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-5-methyl-1H-pyrazole-4-carbonitrile (39) [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-17-yl)ethane-1-ketone as raw material, the product 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-17-yl)ethane-1-ketone was obtained by referring to step 2 of Example 2. 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-5-methyl-1H-pyrazole-4-carbonitrile (39) (9.5 mg, white solid, 11% yield) was obtained.

[0160] Example 38: MS m / z (ESI): 442.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.75 (s, 1H), 4.96 -~ 4.79 (m, 2H), 2.65 - 2.54 (m, 1H), 2.38 (s, 3H), 2.17 - 1.58 (m, 18H), 1.38 (s, 3H), 1.33 - 1.24 (m, 3H), 1.18 - 1.06 (m, 1H), 0.70 (s, 3H).

[0161] Example 39: MS m / z (ESI): 442.2[M+H] + . 1H NMR (400 MHz, CDCl3) δ 7.71 (s, 1H), 4.86 - 4.80 (m, 2H), 2.61 - 2.54 (m, 1H), 2.33 (s, 3H), 2.23 - 1.55 (m, 18H), 1.38 (s, 3H), 1.30 - 1.27 (m, 3H), 1.15 - 1.11 (m, 1H), 0.71 (s, 3H).

[0162] Example 40 3-Cyclopropyl-1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-4-carbonitrile [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 2 of Example 2, the product 3-cyclopropyl-1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-4-carbonitrile (15 mg, white solid, yield 22.2%) was obtained.

[0163] MS m / z (ESI): 468.2[M+H] + . 1H NMR (400 MHz, CDCl3) δ 7.72 (s, 1H), 4.92 - 4.72 (m, 2H), 2.57 (t, J = 8.8 Hz, 1H), 2.26 - 1.40 (m, 19H), 1.38 (s, 3H), 1.37 - 1.05 (m, 4H), 1.05 - 0.91 (m, 4H), 0.69 (s, 3H).

[0164] Example 41 and Example 42 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(5-methyl-2H-tetrazol-2-yl)ethane-1-ketone (41) 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(5-methyl-1H-tetrazol-1-yl)ethane-1-ketone (42) [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, the product 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone was obtained by referring to step 2 of Example 2. 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(5-methyl-1H-tetrazol-1-yl)ethane-1-ketone (42) (6.5 mg, white solid, 6.5% yield) was obtained.

[0165] Example 41: MS m / z (ESI): 419.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 5.46 - 5.27 (m, 2H), 2.63 (d, J = 8.5 Hz, 1H), 2.57 (s, 3H), 2.31 - 1.46 (m, 18H), 1.38 (s, 3H), 1.35 - 1.03 (m, 4H), 0.75 (s, 3H).

[0166] Example 42: MS m / z (ESI): 419.2[M+H] + . 1H NMR (400 MHz, CDCl3) δ 5.19 - 5.02 (m, 2H), 2.66 (t, J = 8.5 Hz, 1H), 2.48 (s, 3H), 2.30 - 1.48 (m, 18H), 1.39 (s, 3H), 1.33 - 1.07 (m, 4H), 0.72 (s, 3H).

[0167] Example 43 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(thiazolyl-2-ylamino)ethane-1-ketone [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 2 of Example 2, product 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(thiazolyl-2-ylamino)ethane-1-ketone (13 mg, white solid, yield 20.7%) was obtained.

[0168] MS m / z (ESI): 435.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 6.37 (d, J = 4.9 Hz, 1H), 5.92 (d, J = 4.9 Hz, 1H), 4.70 - 4.46 (m, 2H), 2.68 (t, J = 8.9 Hz, 1H), 2.32 - 1.46 (m, 17H), 1.37 (s, 3H), 1.35 - 1.20 (m, 4H), 1.16 - 1.06 (m, 1H), 0.70 (s, 3H).

[0169] Example 44 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)ethane-1-ketone [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as the raw material, and referring to Example 23, the product 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)ethane-1-ketone (8.2 mg, white solid, yield 13.2%) was obtained.

[0170] MS m / z (ESI): 432.3[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.30 (s, 1H), 7.26 (s, 1H), 3.94 -~ 3.88 (m, 2H), 3.83 (s, 3H), 2.52 (t, J = 8.7 Hz, 1H), 2.27 - 1.46 (m, 16H), 1.37 (s, 3H), 1.33 - 1.05 (m, 6H), 0.65 (s, 3H).

[0171] Example 45 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(isothiazol-4-ylamino)ethane-1-ketone [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 2 of Example 2, product 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(isothiazol-4-ylamino)ethane-1-ketone (8.5 mg, white solid, yield 14.0%) was obtained.

[0172] MS m / z (ESI): 419.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 8.08 (s, 1H), 7.91 (s, 1H), 3.85 - 3.65 (m, 2H), 2.53 (t, J = 8.7 Hz, 1H), 2.23 - 1.72 (m, 8H), 1.51 - 1.13 (m, 17H), 0.67 (s, 3H).

[0173] Example 46, Example 47 and Example 48 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(5-methoxy-2H-benzo[d][1,2,3]triazol-2-yl)ethane-1-ketone (46) 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(6-methoxy-1H-benzo[d][1,2,3]triazol-1-yl)ethane-1-ketone (47) 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(5-methoxy-1H-benzo[d][1,2,3]triazol-1-yl)ethane-1-ketone (48) [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 2 of Example 2, the product 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(5-methoxy-2H-benzo[d][1,2,3]triazol-2-yl)ethane-1-ketone (46) (13.5 mg, white solid, yield 11.6%), 1-((3R,5R,8S,9S,10R ,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(6-methoxy-1H-benzo[d][1,2,3]triazol-1-yl)ethane-1-ketone (47) (14 mg, white solid, 12.0% yield) and 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(5-methoxy-1H-benzo[d][1,2,3]triazol-1-yl)ethane-1-ketone (48) (14 mg, white solid, 12.0% yield).

[0174] Example 46: MS m / z (ESI): 484.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.75 - 7.70 (m, 1H), 7.11 - 7.04 (m, 2H), 5.49 - 5.40 (m, 2H), 3.88 (s, 3H), 2.62 (t, J = 8.8 Hz, 1H), 2.30 - 1.46 (m, 18H), 1.38 (s, 3H), 1.34 - 1.10 (m, 4H), 0.78 (s, 3H).

[0175] Example 47: MS m / z (ESI): 484.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.39 (d, J = 2.2 Hz, 1H), 7.22 (d, J = 9.0 Hz, 1H), 7.15 (dd, J = 9.0, 2.2 Hz, 1H), 5.39 - 5.35 (m, 2H), 3.90 (s, 3H), 2.70 - 2.64 (m, 1H), 2.26 - 1.45 (m, 18H), 1.38 (s, 3H), 1.32 - 1.12 (m, 4H), 0.76 (s, 3H).

[0176] Example 48: MS m / z (ESI): 484.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.92 (d, J = 9.1 Hz, 1H), 7.01 (dd, J = 9.1, 2.2 Hz, 1H), 6.60 (d, J = 2.2 Hz, 1H), 5.35 - 5.31 (m, 2H), 3.87 (s, 3H), 2.73 - 2.65 (m, 1H), 2.26 - 1.46 (m, 18H), 1.38 (s, 3H), 1.34 - 1.10 (m, 4H), 0.77 (s, 3H).

[0177] Example 49 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(pyrimidin-5-oxy)ethane-1-ketone [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 2 of Example 2, product 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(pyrimidin-5-oxy)ethane-1-ketone (10.3 mg, white solid, yield 20.0%) was obtained.

[0178] MS m / z (ESI): 431.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 8.92 (s, 1H), 8.44 (s, 2H), 4.78 - 4.63 (m, 2H), 2.75-2.70 (m, 1H), 2.29-2.20 (m, 1H), 2.15-2.05 (m, 3H), 2.02-1.93 (m, 3H), 1.92 - 1.82 (m, 1H), 1.81-1.73 (m, 2H), 1.62-1.60 (m, 2H), 1.59 - 1.43 (m, 6H), 1.38 (s, 3H), 1.35-1.25 (m, 3H), 1.20-1.07 (m, 1H), 0.72 (s, 3H).

[0179] Example 50 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-3,5-dicarbonitrile [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 2 of Example 2, the product 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-3,5-dicarbonitrile (26 mg, white solid, yield 39.7%) was obtained.

[0180] MS m / z (ESI): 451.2[MH] - . 1 H NMR (400 MHz, CDCl3) δ 7.21 (s, 1H), 5.19 - 5.14 (m, 2H), 2.63 (t, J = 8.9 Hz, 1H), 2.29 - 1.49 (m, 18H), 1.38 (s, 3H), 1.32 - 1.30 (m, 3H), 1.20 - 1.10 (m, 1H), 0.75 (s, 3H).

[0181] Example 51 3-Chloro-1-(2-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-4-carbonitrile [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, refer to step 2 of Example 2 to obtain product 3-chloro-1-(2-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-4-carbonitrile (12 mg, white solid, yield: 22%).

[0182] MS m / z (ESI): 462.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.82 (s, 1H), 4.98-4.85 (m, 2H), 2.58 (t, J = 8.5 Hz, 1H), 2.26-2.18 (m, 1H), 2.15 - 1.75 (m, 7H), 1.66 - 1.45 (m, 10H), 1.40 - 1.25 (m, 7H), 1.15-1.09 (m, 1H), 0.70 (s, 3H).

[0183] Example 52 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4-(oxazolyl-2-yl)-1H-pyrazol-1-yl)ethane-1-ketone [ka] Step 1: Preparation of 2-(1H-pyrazol-4-yl)oxazolyl [ka] A mixture of 1H-pyrazole-4-carbaldehyde (0.8 g, 8.33 mmol), 1-((isocyanomethyl)sulfonyl)-4-toluene (1.79 g, 9.16 mmol), potassium carbonate (2.53 g, 18.33 mmol) and methanol (20 mL) was stirred at 70° C. for 16 hours, and the reaction solution was concentrated to dryness under reduced pressure, separated and purified by column chromatography (dichloromethane / methanol=10:1) to obtain a white solid 2-(1H-pyrazol-4-yl)oxazolyl (160 mg, yield: 14%).

[0184] MS m / z (ESI): 136.2[M+H] + . 1 H NMR (400 MHz, DMSO) δ 13.19 (s, 1H), 8.30 (s, 1H), 8.15 (s, 1H), 7.83 (s, 1H), 7.26 (s, 1H). Step 2: 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4-(oxazolyl-2-yl)-1H-pyrazol-1-yl)ethane-1-ketone [ka] A mixture of 2-bromo-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (60 mg, 0.14 mmol), 2-(1H-pyrazol-4-yl)oxazolyl (28 mg, 0.21 mmol), potassium carbonate (39 mg, 0.28 mmol) and tetrahydrofuran (3 mL). The mixture was stirred at room temperature for 16 hours, and the reaction mixture was concentrated to dryness under reduced pressure, and separated and purified by preparative chromatography to obtain 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4-(oxazolyl-2-yl)-1H-pyrazol-1-yl)ethane-1-ketone (13 mg, white solid, yield: 20%).

[0185] MS m / z (ESI): 470.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.85 (s, 1H), 7.76 (s, 1H), 7.69 (s, 1H), 7.13 (s, 1H), 4.99-4.89 (m, 2H), 2.61 (t, J = 8.8 Hz, 1H), 2.28 - 2.18 (m, 1H), 2.15 - 2.08 (m, 2H), 2.03 - 1.82 (m, 4H), 1.78-1.76(m, 2H), 1.64-1.62 (m, 3H), 1.52 - 1.43 (m, 5H), 1.38 (s, 3H), 1.31-1.26 (m, 4H), 1.16-1.11 (m, 2H), 0.73 (s, 3H).

[0186] Example 53 and Example 54 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(6-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-1-yl)ethane-1-ketone (53) 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(5-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-1-yl)ethane-1-ketone (54) [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as a raw material, 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(6-(2-hydroxypropanediol)-1,4-diol)-2,4-diol was prepared by referring to step 2 of Example 2. 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(5-(2-hydroxypropan-2-yl)-1H-benzo[d]imidazol-1-yl)ethane-1-ketone (54) (15 mg, white solid, 20.3% yield) was obtained.

[0187] Example 53: MS m / z (ESI): 511.3[M+H] + . 1H NMR (400 MHz, Chloroform-d) δ 7.93 (s, 1H), 7.87 (s, 1H), 7.51 (d, J = 8.5 Hz, 1H), 7.14 (d, J = 8.5 Hz, 1H), 4.96 - 4.84 (m, 2H), 2.64 (t, J = 8.7 Hz, 1H), 2.31 - 2.17 (m, 1H), 2.16 -~ 2.06 (m, 2H), 2.04 - 1.93 (m, 2H), 1.92 -~ 1.75 (m, 2H), 1.71 - 1.43 (m, 15H), 1.39 (s, 3H), 1.35 - 1.20 (m, 5H), 1.18 - 1.05 (m, 1H), 0.75 (s, 3H).

[0188] Example 54: MS m / z (ESI): 511.3[M+H] + . 1 H NMR (400 MHz, Chloroform-d) δ 8.19 (s, 1H), 7.77 (d, J = 8.5 Hz, 1H), 7.46 (s, 1H), 7.39 (d, J = 8.1 Hz, 1H), 5.12 - 4.89 (m, 2H), 2.68 (t, J = 8.2 Hz, 1H), 2.31 - 2.06 (m, 7H), 2.04 - 1.47 (m, 15H), 1.38 (s, 3H), 1.35 - 1.21 (m, 5H), 1.20 - 1.02 (m, 1H), 0.75 (s, 3H).

[0189] Example 55 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4-(methylthio)-1H-pyrazol-1-yl)ethane-1-ketone [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 2 of Example 2, product 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4-(methylthio)-1H-pyrazol-1-yl)ethane-1-ketone (25 mg, white solid, yield 38%) was obtained.

[0190] MS m / z (ESI): 449.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.53 (s, 1H), 7.43 (s, 1H), 4.95-4.85 (m, 2H), 2.58 (t, J = 8.9 Hz, 1H), 2.35 (s, 3H), 2.25-2.17 (m, 1H), 2.10 (d, J = 11.4 Hz, 2H), 2.02 - 1.82 (m, 4H), 1.77-1.74 (m, 2H), 1.68 - 1.42 (m, 9H), 1.38 (s, 3H), 1.35 - 1.21 (m, 4H), 1.17 - 1.04 (m, 1H), 0.71 (s, 3H).

[0191] Example 56 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4-(methylsulfinyl<sulfinyl>)-1H-pyrazol-1-yl)ethane-1-ketone [ka] 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4-(methylthio)-1H-pyrazol-1-yl)ethane-1-ketone (35 mg, 0.078 mmol) was dissolved in dichloromethane (3 mL), followed by addition of metachloroperbenzoic acid (17 mg, 0.0858 mmol) and stirring at -78 °C for 2 h, quenching with saturated sodium sulfite solution, and extracting with ethyl acetate (20 mL x 3), affording the product. The organic phase was combined and washed with saturated saline (30 mL), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure, and then separated and purified by preparative chromatography to obtain a white solid 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4-(methylsulfinyl<sulfinyl>)-1H-pyrazol-1-yl)ethane-1-ketone (25 mg, white solid, yield: 69%). MS m / z (ESI): 465.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.81 (d, J = 4.6 Hz, 2H), 4.96-4.85 (m, 2H), 2.90 (s, 3H), 2.61 (t, J = 8.7 Hz, 1H), 2.27 - 2.17 (m, 1H), 2.13-2.07 (m, 2H), 2.04 - 1.73 (m, 4H), 1.66-1.62 (m, 4H), 1.50-1.48 (m, 5H), 1.38 (s, 3H), 1.33 - 1.22 (m, 5H), 1.14-1.11(m, 2H), 0.71 (s, 3H).

[0192] Example 57 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4-(methanesulfonyl)-1H-pyrazol-1-yl)ethane-1-ketone [ka] 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4-(methylthio)-1H-pyrazol-1-yl)ethane-1-ketone (15 mg, 0.033 mmol) was dissolved in dichloromethane (3 mL), and then metachloroperbenzoic acid (17 mg, 0.1 mmol) was added at room temperature for 6 h. The reaction mixture was stirred for 2 hours, and then concentrated to dryness under reduced pressure. The mixture was separated and purified by preparative chromatography to obtain 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4-(methanesulfonyl)-1H-pyrazol-1-yl)ethane-1-ketone (10 mg, white solid, yield: 63%).

[0193] MS m / z (ESI): 481.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.93 (s, 1H), 7.87 (s, 1H), 4.99-4.90 (m, 2H), 3.13 (s, 3H), 2.62 (t, J = 8.7 Hz, 1H), 2.24-2.20 (m, 1H), 2.12-2.09 (m, 2H), 2.03 - 1.74 (m, 5H), 1.66-1.63 (m, 4H), 1.53 - 1.42 (m, 6H), 1.38 (s, 3H), 1.28 -1.26(m, 3H), 1.15 (m, 1H), 0.89-0.86 (m, 1H), 0.71 (s, 3H).

[0194] Example 58 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4-nitro-1H-pyrazol-1-yl)ethane-1-ketone [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 2 of Example 2, product 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4-nitro-1H-pyrazol-1-yl)ethane-1-ketone (39 mg, white solid, yield: 60.3%) was obtained.

[0195] MS m / z (ESI): 448.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 8.18 (s, 1H), 8.08 (s, 1H), 5.08 - 4.81 (m, 2H), 2.62 (t, J = 8.7 Hz, 1H), 2.30 - 1.46 (m, 16H), 1.38 (s, 3H), 1.34 - 1.04 (m, 6H), 0.71 (s, 3H).

[0196] Example 59 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 2 of Example 2, the product 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-4-carboxylic acid ethyl ester (32 mg, white solid, yield 46.6%) was obtained. MS m / z (ESI): 475.3[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.94 (s, 1H), 7.92 (s, 1H), 5.04 - 4.80 (m, 2H), 4.38 - 4.19 (m, 2H), 2.60 (t, J = 8.7 Hz, 1H), 2.27 - 1.45 (m, 21H), 1.38 (s, 3H), 1.37 - 1.25 (m, 3H), 1.20 - 1.07 (m, 1H), 0.71 (s, 3H).

[0197] Example 60 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-N,N-dimethyl-1H-pyrazole-4-carboxamide [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 2 of Example 2, the product 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-N,N-dimethyl-1H-pyrazole-4-carboxamide (10 mg, white solid, yield 14.6%) was obtained.

[0198] MS m / z (ESI): 474.3[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.75 (s, 2H), 5.09 - 4.82 (m, 2H), 3.16 (s, 6H), 2.69 - 2.53 (m, 1H), 2.30 - 1.45 (m, 18H), 1.38 (s, 3H), 1.32 - 1.05 (m, 4H), 0.72 (s, 3H).

[0199] Example 61 N-Ethyl-1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-N-methyl-1H-pyrazole-4-carboxamide [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 2 of Example 2, the product N-ethyl-1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-N-methyl-1H-pyrazole-4-carboxamide (14 mg, white solid, yield 19.8%) was obtained.

[0200] MS m / z (ESI): 488.3[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.76 (s, 1H), 7.73 (s, 1H), 5.02 - 4.80 (m, 2H), 3.66 - 3.44 (m, 2H), 3.28 - 2.93 (m, 3H), 2.60 (t, J = 8.6 Hz, 1H), 2.30 - 1.45 (m, 18H), 1.38 (s, 3H), 1.34 - 1.06 (m, 7H), 0.71 (s, 3H).

[0201] Example 62 2-(4-(azetidine-1-carbonyl)-1H-pyrazol-1-yl)-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as the raw material, and referring to step 2 of Example 2, the product 2-(4-(azetidine-1-carbonyl)-1H-pyrazol-1-yl)-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (12 mg, white solid, yield: 17.1%) was obtained.

[0202] MS m / z (ESI): 486.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.87 (s, 1H), 7.76 (s, 1H), 5.02 - 4.82 (m, 2H), 4.39 - 4.21 (m, 4H), 2.59 (t, J = 8.5 Hz, 1H), 2.46 - 1.59 (m, 20H), 1.38 (s, 3H), 1.34 - 1.19 (m, 3H), 1.17 - 1.05 (m, 1H), 0.71 (s, 3H).

[0203] Example 63 and Example 64 2-(4-Cyclopropyl-2H-1,2,3-triazol-2-yl)-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (63) 2-(4-Cyclopropyl-1H-1,2,3-triazol-1-yl)-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (64) [ka] Step 1: Preparation of 4,5-dibromo-2H-1,2,3-triazole [ka] Liquid bromine (3 mL) was slowly added dropwise to a solution of 2H-1,2,3-triazole (3 g, 43.43 mmol) in water (30 mL) at 0° C., a pale yellow solid precipitated, and the mixture was stirred at room temperature for 16 hours. The reaction solution was filtered, the cake was washed with water (20 mL), and the cake was dried. The mixture was used in the next step without purification to obtain 4,5-dibromo-2H-1,2,3-triazole (5.7 g, white solid, yield: 58%).

[0204] MS m / z (ESI): 227.2[M+H] + . Step 2: Preparation of 4-bromo-2H-1,2,3-triazole [ka] 4,5-Dibromo-2H-1,2,3-triazole (5.7 g, 25.13 mmol) was suspended in water (50 mL), followed by the addition of sodium sulfite (9.5 g, 75.38 mmol) and stirring at 100° C. for 3 days, the reaction solution was cooled to room temperature, extracted with ethyl acetate (30 mL×6), the organic phases were combined and washed with saturated saline (100 mL), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure to obtain 4-bromo-2H-1,2,3-triazole (3 g, white solid, yield: 81%).

[0205] MS m / z (ESI): 148.2 [M+H] + , 150.2 [M+2+H] + . Step 3: Preparation of 4-bromo-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-1,2,3-triazole [ka] Sodium hydride (760 mg, 18.9 mmol) was gradually added to tetrahydrofuran (20 mL) of 4-bromo-2H-1,2,3-triazole (2 g, 13.51 mmol) at 0 ° C., then stirred at 0 ° C. for 0.5 hours, after which 2-(trimethylsilyl)ethoxymethyl chloride (2.48 g, 14.86 mmol) was added dropwise, and after the dropwise addition was completed, the mixture was stirred at room temperature for 2 hours, and water (50 mL) was added to the reaction solution to quench the reaction, and the mixture was extracted with ethyl acetate (30 mL x 3). The organic phase was combined and washed with saturated saline (50 mL), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure, and the mixture was separated and purified by column chromatography to obtain 4-bromo-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-1,2,3-triazole (1.4 g, white solid, yield: 38%).

[0206] MS m / z (ESI): 278.2 [M+H] + , 280.2 [M+2+H] + . Step 4: Preparation of 4-cyclopropyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-1,2,3-triazole [ka] 4-Bromo-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-1,2,3-triazole (0.5 g, 1.79 mmol) and potassium cyclopropyltrifluoroborate (530 mg, 3.58 mmol) were dissolved in 1,4-dioxane (10 mL), and then [1,1'-bis(diphenylphosphine)ferrocene]palladium subchloride (0.5 g, 1.79 mmol) and sodium carbonate (0.5 g, 1.79 mmol) were added. After replacing with nitrogen gas three times, the mixture was stirred at 100° C. under nitrogen gas protection for 16 hours, and the mixture was cooled to room temperature. The mixture was filtered through a layer of soil, and the filtrate was concentrated under reduced pressure to obtain a residue. Water (30 mL) was added to the residue, followed by extraction with ethyl acetate (30 mL x 3). The combined organic phase was washed with saturated saline (50 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure. The mixture was separated and purified by column chromatography (petroleum ether / ethyl acetate = 4:1) to obtain 4-cyclopropyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-1,2,3-triazole (70 mg, pale yellow oil, yield: 16%).

[0207] MS m / z (ESI): 240.2 [M+H] + . Step 5: Preparation of 4-cyclopropyl-2H-1,2,3-triazole [ka] 4-Cyclopropyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-1,2,3-triazole (50 mg, 0.208 mmol) was dissolved in dichloromethane (1 mL), then trifluoroacetic acid (1 mL) was added and stirred at room temperature for 3 hours, water (10 mL) was added to the reaction solution, and a saturated sodium carbonate solution was added to adjust the pH to 8, followed by extraction with ethyl acetate (20 mL x 3), the organic phase was combined and washed with saturated saline (50 mL), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure to obtain 4-cyclopropyl-2H-1,2,3-triazole (35 mg, white solid, crude product).

[0208] MS m / z (ESI): 110.2 [M+H] + . Step 6: Preparation of 2-(4-cyclopropyl-2H-1,2,3-triazol-2-yl)-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (63) and 2-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (64) [ka] A mixture of 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (80mg, 0.193mmol) and tetrahydrofuran (3mL) was added to potassium carbonate (80mg, 0.579mmol), and then stirred at room temperature for 16 hours. Water (20mL) was added to the reaction solution, followed by extraction with ethyl acetate (20mLx3), and the combined organic phase was washed with saturated saline (30mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure. The mixture was separated and purified by preparative chromatography to obtain a white solid 2-(4-cyclopropanediol). Pyl-2H-1,2,3-triazol-2-yl)-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (63) (34 mg, white solid, yield 39.8%) and white solid 2-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (64) (14 mg, white solid, yield 16.4%) were obtained.

[0209] Example 63: MS m / z (ESI): 444.2 [M+H] + . 1H NMR (400 MHz, CDCl3) δ 7.35 (s, 1H), 5.15-5.05 (m, 2H), 3.91 (d, J = 3.0 Hz, 1H), 2.61 - 2.47 (m, 1H), 2.25-2.08 (m, 4H), 2.04 - 1.81 (m, 5H), 1.78-1.71 (m, 2H), 1.54 - 1.42 (m, 6H), 1.37 (s, 3H), 1.33 - 1.20 (m, 4H), 1.18 - 1.04 (m, 2H), 0.99-0.96 (m, 2H), 0.80 - 0.75 (m, 2H), 0.73 (s, 3H).

[0210] Example 64: MS m / z (ESI): 444.2 [M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.35 (s, 1H), 5.16-5.06 (m, 2H), 3.91 (d, J = 3.0 Hz, 1H), 2.54 (t, J = 8.8 Hz, 1H), 2.24-2.09 (m, 4H), 2.04 - 1.81 (m, 5H), 1.78-1.70 (m, 2H), 1.54- 1.42 (m, 6H), 1.37 (s, 3H), 1.31-1.22 (m, 4H), 1.18 - 1.04 (m, 2H), 0.99 - 0.96 (m, 2H), 0.80-0.76(m, 2H), 0.73 (s, 3H).

[0211] Example 66 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-((2-(trifluoromethyl)pyrimidin-5-yl)oxo)ethane-1-ketone [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 2 of Example 2, product 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-((2-(trifluoromethyl)pyrimidin-5-yl)oxo)ethane-1-ketone (39.2 mg, white solid, yield 65.5%) was obtained.

[0212] MS m / z (ESI): 499.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 8.45 (s, 2H), 4.84 - 4.70 (m, 2H), 2.68 (t, J = 8.9 Hz, 1H), 2.23 (m, 1H), 2.09 (d, J = 10.8 Hz, 1H), 1.98 (t, J = 12.6 Hz, 3H), 1.91 - 1.83 (m, 1H), 1.79 (t, J = 8.4 Hz, 2H), 1.60 - 1.52 (m, 4H), 1.48 (dd, J = 19.5, 12.9 Hz, 5H), 1.38 (s, 3H), 1.35 - 1.21 (m, 4H), 1.20 - 1.05 (m, 1H), 0.73 (s, 3H). Example 67 3-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)thiazolidine-2,4-diketone [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 2 of Example 2, the product 3-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)thiazolidine-2,4-diketone (18.5 mg, white solid, yield 28.3%) was obtained.

[0213] 1 H NMR (400 MHz, CDCl3) δ 4.43 - 4.32 (m, 2H), 4.03 (s, 2H), 2.56 (t, J = 8.7 Hz, 1H), 2.21 - 1.54 (m, 18H), 1.37 (s, 3H), 1.32 - 1.25 (m, 3H), 1.17 - 1.08 (m, 1H), 0.68 (s, 3H).

[0214] Example 68 (1R,3R,5R)-2-(2-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-2-azabicyclo[3.1.0]hexane-3-carbonitrile [ka] Step 1: Preparation of tert-butyl (1R,3R,5R)-3-cyano-2-azabicyclo[3.1.0]hexane-2-carboxylate [ka] Trifluoroacetic anhydride (5 mL, 35.3 mmol) was slowly added dropwise to a suspension of tert-butyl (1R,3R,5R)-3-carbamyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (2 g, 8.85 mmol) and pyridyl (25 mL) at -20°C, then stirred at -20°C for 1 h, and then allowed to warm to room temperature and stirred for 8 h. The reaction was quenched by adding ice water, followed by extraction with ethyl acetate (3 The organic phase was combined, washed with dilute hydrochloric acid (10%) and saturated saline, the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure, and separated and purified by column chromatography (petroleum ether / ethyl acetate=4:1) to obtain tert-butyl (1R,3R,5R)-3-cyano-2-azabicyclo[3.1.0]hexane-2-carboxylate (1.5 g, white solid, yield: 83%).

[0215] 1 H NMR (400 MHz, CDCl3) δ 4.71 (dd, J = 41.1, 9.6 Hz, 1H), 3.58 (d, J = 33.8 Hz, 1H), 2.63 - 2.47 (m, 1H), 2.35 (d, J = 12.7 Hz, 1H), 1.70-1.60 (m, 1H), 1.52 (s, 9H), 1.02 (s, 1H), 0.90-0.81 (m, 1H). Step 2: Preparation of (1R,3R,5R)-2-azabicyclo[3.1.0]hexane-3-carbonitrile [ka] tert-Butyl (1R,3R,5R)-3-cyano-2-azabicyclo[3.1.0]hexane-2-carboxylate (0.8g, 3.85mmol) was dissolved in dioxane (2mL), then hydrochloric acid-dioxane (8mL) was added, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated to dryness under reduced pressure, water (50mL) was added to the residue, followed by extraction with (dichloromethane / methanol=10:1), and the organic phases were combined and washed with saturated saline, the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure to obtain (1R,3R,5R)-2-azabicyclo[3.1.0]hexane-3-carbonitrile (0.5g, brown oil, crude product).

[0216] Step 3: Preparation of (1R,3R,5R)-2-(2-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-2-azabicyclo[3.1.0]hexane-3-carbonitrile [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as the raw material, and referring to step 2 of Example 2, the product (1R,3R,5R)-2-(2-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-2-azabicyclo[3.1.0]hexane-3-carbonitrile (12 mg, white solid, yield: 23%) was obtained.

[0217] MS m / z (ESI): 443.2 [M+H] + . 1H NMR (400 MHz, CDCl3) δ 4.08 (s, 2H), 3.70 (s, 2H), 2.49 (t, J = 8.7 Hz, 1H), 2.24 - 2.16 (m, 2H), 2.12 - 1.82 (m, 11H), 1.74-1.70(m, 2H), 1.60-1.48(m, 6H), 1.37 (s, 3H), 1.31-1.25 (m, 6H), 1.12-1.07 (m, 1H), 0.65 (s, 3H).

[0218] Example 69 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-((1-methyl-1H-pyrazol-4-yl)oxo)ethane-1-ketone [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 2 of Example 2, product 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-((1-methyl-1H-pyrazol-4-yl)oxo)ethane-1-ketone (20 mg, white solid, yield 32.0%) was obtained.

[0219] MS m / z (ESI): 433.3[M+H] + . 1H NMR (400 MHz, CDCl3) δ 7.21 (s, 1H), 7.08 (s, 1H), 4.48 - 4.28 (m, 2H), 3.82 (s, 3H), 2.74 (t, J = 8.9 Hz, 1H), 2.22 - 1.50 (m, 18H), 1.37 (s, 3H), 1.30 - 1.10 (m, 4H), 0.68 (s, 3H).

[0220] Example 70 7-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethoxy)quinoline-1-nitrogen oxide [ka] Step 1: Preparation of 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(quinolin-7-oxy)ethane-1-ketone [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 2 of Example 2, product 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(quinolin-7-oxy)ethane-1-ketone (60.0 mg, white solid, yield 52.1%) was obtained.

[0221] MS m / z (ESI): 480.2[M+H] + . Step 2: Preparation of 7-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethoxy)quinoline-1-nitrogen oxide [ka] To a 100 ml single-neck flask was added 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(quinolin-7-oxy)ethane-1-ketone (60 mg, 0.125 mmol) and dichloromethane (10 ml), followed by metachloroperbenzoic acid (78 mg, 0.313 mmol). The reaction was stirred at room temperature overnight. The reaction was washed with saturated sodium bicarbonate solution and then concentrated. The concentrated crude product was purified by prep-HPLC to obtain 7-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethoxy)quinoline-1-nitrogen oxide (29.2 mg, white solid, yield 47.1%).

[0222] MS m / z (ESI): 496.2[M+H] + . 1H NMR (400 MHz, CDCl3) δ 8.59 (d, J = 6.0 Hz, 1H), 7.97 (d, J = 2.2 Hz, 1H), 7.83 (d, J = 9.0 Hz, 1H), 7.78 (d, J = 8.3 Hz, 1H), 7.43 (dd, J = 9.0, 2.4 Hz, 1H), 7.26 - 7.20 (m, 1H), 4.87 - 4.73 (m, 2H), 2.83-2.75 (m, 1H), 2.33-2.21 (m, 1H), 2.13-2.07 (m, 1H), 2.06-1.95 (m, 4H), 1.94-1.84 (m, 2H), 1.82-1.74 (m, 2H), 1.62-1.42 (m, 8H), 1.38 (s, 3H), 1.35 - 1.25 (m, 3H), 1.20-1.06 (m, 1H), 0.75 (s, 3H).

[0223] Example 71 N-(2-((3S,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)benzenesulfonamide [ka] Benzenesulfonamide (28 mg, 0.18 mmol) was dissolved in N,N-dimethylformamide (5 mL), sodium hydride (7.2 mg, 0.18 mmol) was added at 0 °C, and the mixture was stirred at 0 °C for 0.5 h. 2-Bromo-1-((3S,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (50 mg, 0.12 mmol) was added at 0 °C, and the mixture was stirred at room temperature overnight. 5 mL of water was added, and the mixture was extracted with ethyl acetate (30 mL x 3), washed once with saturated saline (20 mL), and the organic phase was dried over anhydrous sodium sulfate, spin-dried, and separated by prep-HPLC to obtain the product (7.1 mg, white solid, 12% yield).

[0224] 1 H NMR (400 MHz, CDCl3) δ 7.86 (d, J = 7.2 Hz, 2H), 7.58 (t, J = 7.4 Hz, 1H), 7.51 (t, J = 7.5 Hz, 2H), 5.48 (s, 1H), 3.87 - 3.68 (m, 2H), 2.36 (t, J = 8.9 Hz, 1H), 2.06-2.08 (m, 2H), 1.94-1.97 (m, 2H), 1.90-1.80 (m, 1H), 1.71 - 1.62 (m, 4H), 1.52 - 1.39 (m, 6H), 1.37 (s, 3H), 1.34 - 1.25 (m, 4H), 1.24 - 1.01 (m, 3H), 0.38 (s, 3H).

[0225] Example 72 (3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-N-(4-fluorophenyl)-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-17-carboxamide [ka] Step 1: Preparation of (3R,5R,8S,9S,10R,13S,14S)-10-fluoro-3,13-dimethyl-17-methylenehexadecahydro-1H-cyclopenta[a]phenanthrene-3-phenol [ka] To a solution of methyltriphenylphosphonium bromide (13.9 g, 38.961 mmol) and tetrahydrofuran (50 mL), add potassium tert-butoxide (4.36 g, 38.961 mmol), then stir at 65 ° C for 1 hour, add a mixture of (3R, 5R, 8S, 9S, 10R, 13S, 14S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-17H-cyclopenta[a]phenanthrene-17-ketone (2 g, 6.494 mmol) and tetrahydrofuran (30 mL) dropwise, and stir at 65 ° C for 1 hour. The reaction mixture was cooled to room temperature and quenched by adding water, followed by extraction with ethyl acetate (50mLx3). The combined organic phase was washed with saturated saline, the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure. The mixture was separated and purified by column chromatography (petroleum ether / ethyl acetate=10:1) to obtain (3R,5R,8S,9S,10R,13S,14S)-10-fluoro-3,13-dimethyl-17-methylenehexadecahydro-1H-cyclopenta[a]phenanthrene-3-phenol (1.8g, white solid, yield: 90%).

[0226] Step 2: Preparation of (3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-17-(hydroxymethyl)-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3-phenol [ka] (3R,5R,8S,9S,10R,13S,14S)-10-Fluoro-3,13-dimethyl-17-methylenehexadecahydro-1H-cyclopenta[a]phenanthrene-3-phenol (0.5 g, 1.634 mmol) was dissolved in tetrahydrofuran (8 mL), then borane-tetrahydrofuran (8.2 mL, 8.169 mmol) was added dropwise, stirred at room temperature for 1.5 hours, and cooled to 0° C., and a solution of sodium hydroxide (327 mg, 8.169 mmol) in water (3 mL) was added dropwise, followed by hydrogen peroxide solution (3 mL). , 30%) was slowly added dropwise, followed by stirring at room temperature for 1.5 hours. Water (50 mL) was added to the reaction solution, which was then extracted with ethyl acetate (50 mL x 3). The organic phases were combined and washed with saturated saline, the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure to obtain (3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-17-(hydroxymethyl)-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3-phenol (600 mg, crude product).

[0227] Step 3: Preparation of (3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-17-carboxylic acid [ka] Pyridinium dichromate (4.6 g, 12.34 mmol) was added to a mixture of (3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-17-(hydroxymethyl)-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3-phenol (400 mg, 1.234 mmol), N,N-dimethylformamide (15 mL) and water (1 mL), and the mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with saturated sodium sulfite solution (50 The reaction mixture was quenched by addition of 1,000 mL of ethyl acetate, followed by extraction with ethyl acetate (40 mL×3). The combined organic phase was washed with saturated brine, the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure to give a pale yellow solid (3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-17-carboxylic acid (400 mg, pale yellow solid, crude product).

[0228] 1 H NMR (400 MHz, DMSO) δ 11.92 (s, 1H), 4.38 (s, 1H), 2.90-2.70 (m, 2H), 2.05 - 1.52 (m, 9H), 1.39-1.19(m, 15H), 0.61 (s, 3H). Step 4: Preparation of (3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-N-(4-fluorophenyl)-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-17-carboxamide [ka] A mixture of 3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-17-carboxylic acid (200 mg, 0.592 mmol), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (270 mg, 0.71 mmol), triethylamine (119 mg, 1.18 mmol) and dichloromethane (5 mL) was stirred at room temperature for 30 min, followed by addition of 4-fluoroaniline (79 mg, 0.71 mmol). l) was added and stirred at room temperature for 3 hours, water (30 mL) was added to the reaction solution, followed by extraction with dichloromethane (40 mL x 3), the organic phases were combined and washed with saturated saline, the organic phase was dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated to dryness under reduced pressure, and separated and purified by preparative chromatography to obtain (3R, 5R, 8S, 9S, 10R, 13S, 14S, 17S)-10-fluoro-N-(4-fluorophenyl)-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-17-carboxamide (25 mg, white solid, yield: 10%).

[0229] MS m / z (ESI): 432.2 [M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.51 - 7.41 (m, 2H), 7.05-6.95 (m, 2H), 2.43 - 2.17 (m, 2H), 2.14 - 1.80 (m, 8H), 1.72-1.69 (m, 3H), 1.51 - 1.11 (m, 15H), 0.93 (s, 3H).

[0230] Example 73 2-((4-fluoro-2-methoxyphenyl)amino)-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone [ka] Using 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as the raw material, and referring to Example 23, the product 2-((4-fluoro-2-methoxyphenyl)amino)-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (29 mg, white solid, yield 42.2%) was obtained.

[0231] MS m / z (ESI): 476.3[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 6.61 - 6.49 (m, 2H), 6.40 - 6.31 (m, 1H), 3.91 (d, J = 6.3 Hz, 2H), 3.87 - 3.82 (m, 3H), 2.58 (t, J = 8.8 Hz, 1H), 2.31 - 1.42 (m, 18H), 1.38 (s, 3H), 1.35 - 1.03 (m, 4H), 0.69 (s, 3H).

[0232] Example 79A 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-(fluoromethyl)-3-hydroxyl-3,13-dimethylhexahydrodecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)-1H-pyrazole-4-carbonitrile [ka] This Example 79A is synthesized according to the following specific embodiment. [ka]

[0233] Example 82A 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-(difluoromethyl)-3-hydroxyl-3,13-dimethylhexahydrodecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)-1H-pyrazole-4-carbonitrile [ka] This Example 82A is synthesized according to the following specific embodiment.

[0234] [ka]

[0235] Example 90 1-(2-((2R,4aR,4bS,6aS,8bS,8cR,10aR)-2-hydroxymethyl-4a-(methoxymethyl)-2,6a-dimethylhexadecahydrocyclopentadiene[4,5]cyclopenta[1,2-α]phenanthren-7-yl)-2-oxoethyl)-1H-pyrazole-4-carbonitrile [ka] This Example 90 is synthesized according to the following specific embodiment. [ka] MS m / z (ESI): 465.3 [M] + .

[0236] Example 91 1-(2-((2R,4aR,4bS,6aS,8bS,8cR,10aR)-2-hydroxymethyl-4a-(methoxymethyl)-2,6a-dimethylhexadecahydrocyclopentadiene[4,5]cyclopenta[1,2-α]phenanthren-7-yl)-2-oxoethyl)-1H-pyrazole-3-carbonitrile [ka] MS m / z (ESI): 465.3 [M] + .

[0237] Example 92 1-(2-((2R,4aR,4bS,6aS,8bS,8cR,10aR)-2-thiomethyl-4a-(methoxymethyl)-2,6a-dimethylhexadecahydrocyclopentadiene[4,5]cyclopenta[1,2-α]phenanthren-7-yl)-2-oxoethyl)-1H-pyrazole-4-carbonitrile [ka] This Example 92 is synthesized according to the following specific embodiment. [ka] MS m / z (ESI): 469.3 [M] + .

[0238] Example 93 2-(5-chloro-1H-benzo[d][1,2,3]triazol-1-yl)-1-((3R,5R,8S,9S,10R,13S,14S,17S)-3-((methylthio)methyl)hexahydrodecahydro-1H-cyclopenta[a]phenanthren-17-yl)eth-1-ketone [ka] MS m / z (ESI): 529.3 [M] + .

[0239] Example 94 2-(4,5-difluoro-1H-benzo[d][1,2,3]triazol-1-yl)-1-((3R,5R,8S,9S,10R,13S,14S,17S)-3-hydroxyl-3,13-dimethyl-10-((methylthio)methyl)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)eth-1-ketone [ka] MS m / z (ESI): 531.3 [M] + .

[0240] Example 95 2-(3H-[1,2,3]triazolo[4,5-b]pyridyl-3-yl)-1-((3R,5R,8S,9S,10R,13S,14S,17S)-3-hydroxyl-3,13-dimethyl-10-((methylthio)methyl)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)eth-1-ketone [ka] MS m / z (ESI): 496.3 [M] + .

[0241] Example 96 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-3-hydroxyl-3,13-dimethyl-10-((methylsulfonyl)methyl)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)-1H-pyrazole-4-carbonitrile [ka] MS m / z (ESI): 501.3 [M] + .

[0242] Example 97 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-3-hydroxyl-3,13-dimethyl-10-((S-methylsulfonimidoyl)methyl)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)-1H-pyrazole-4-carbonitrile [ka] MS m / z (ESI): 500.3 [M] + . MS m / z (ESI): 456.3 [M] + .

[0243] Example 114 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3-(methoxymethyl)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-4-carbonitrile [ka] Step 1: (5R,8S,10R,13S,14S)-10-Fluoro-13-methyltetradecahydrospiro[cyclopenta[a]phenanthro-3,2'-oxiranyl]-17(2H)-ketone [ka] In a 100 mL three-neck flask, trimethylsulfoxonium iodide (2.65 g, 12 mmol) and tetrahydrofuran (50 mL) were added in order, and potassium t-butoxide (1.35 g, 12 mmol) was added with stirring, and the reaction was stirred at room temperature for 0.5 hours. (5R,8S,9S,10R,13S,14S)-10-fluoro-13-methyltetradecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-diketone (3.0 g, 10 mmol) was added to the reaction, and the reaction was allowed to react at room temperature for 2 hours. The reaction was quenched with saturated aqueous ammonium chloride, extracted with ethyl acetate (30 mL), washed with brine (10 mL x 3), and the organic phase was dried over anhydrous sodium sulfate, filtered, and spun dry. The crude product was purified by column chromatography (petroleum ether / ethyl acetate: 3 / 1) to obtain (5R,8S,10R,13S,14S)-10-fluoro-13-methyltetradecahydrospiro[cyclopenta[a]phenanthro-3,2'-oxiranyl]-17(2H)-ketone (2.5 g, pale yellow solid, yield: 79.5%).

[0244] 1 H NMR (400 MHz, CDCl3) δ 2.72 - 2.67 (m, 2H), 2.52 - 2.43 (m, 1H), 2.31 - 1.06 (m, 21H), 0.92 (s, 3H). Step 2: (3R,5R,8S,10R,13S,14S)-10-Fluoro-3-hydroxyl-3-(methoxymethyl)-13-methylhexadecahydro-17H-cyclopenta[a]phenanthrene-17-ketone [ka] In a 100 mL one-neck flask, (5R,8S,10R,13S,14S)-10-fluoro-13-methyltetradecahydrospiro[cyclopenta[a]phenanthro-3,2'-oxiranyl]-17(2H)-ketone (2.5 g, 7.5 mmol) was added and dissolved in methanol (50 mL), stirred at room temperature for 2-3 minutes, sodium methoxide (1.25 g, 22.5 mmol) was added, and after the addition was completed, the mixture was stirred at 60 ° C for 5 hours. The reaction solution was cooled to room temperature, quenched with saturated aqueous ammonium chloride solution, extracted with ethyl acetate (30 mL), washed with brine (10 mL x 3), and the organic phase was dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was purified by column chromatography (petroleum ether / ethyl acetate: 3 / 1) to obtain (3R,5R,8S,10R,13S,14S)-10-fluoro-3-hydroxyl-3-(methoxymethyl)-13-methylhexadecahydro-17H-cyclopenta[a]phenanthrene-17-ketone (1.6 g, pale yellow solid, yield: 57.9%).

[0245] 1 H NMR (400 MHz, CDCl3) δ 3.39 (s, 3H), 3.21 (s, 2H), 2.51 - 2.40 (m, 1H), 2.37 - 1.04 (m, 21H), 0.90 (s, 3H). Step 3: (3R,5R,8S,10R,13S,14S)-17-Ethylene-10-fluoro-3-(methoxymethyl)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthrene-3-phenol [ka] Using (3R,5R,8S,10R,13S,14S)-10-fluoro-3-hydroxyl-3-(methoxymethyl)-13-methylhexadecahydro-17H-cyclopenta[a]phenanthrene-17-ketone as raw material, and referring to step 4 of Example 1, the product (3R,5R,8S,10R,13S,14S)-17-ethylene-10-fluoro-3-(methoxymethyl)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthrene-3-phenol (600 mg, white solid, yield 36.2%) was obtained.

[0246] 1 H NMR (400 MHz, CDCl3) δ 5.18 - 4.96 (m, 1H), 3.39 (s, 3H), 3.20 (s, 2H), 2.44 - 0.99 (m, 25H), 0.90 (s, 3H). Step 4: (3R,5R,8S,10R,13S,14S,17R)-10-fluoro-17-(1-hydroxyethyl)-3-(methoxymethyl)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthrene-3-phenol [ka] Using (3R,5R,8S,10R,13S,14S)-17-ethylene-10-fluoro-3-(methoxymethyl)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthrene-3-phenol as raw material, and referring to step 5 of Example 1, the product (3R,5R,8S,10R,13S,14S,17R)-10-fluoro-17-(1-hydroxyethyl)-3-(methoxymethyl)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthrene-3-phenol (600 mg, white solid, yield 95.1%) was obtained.

[0247] Step 5: 1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3-(methoxymethyl)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone [ka] Using (3R,5R,8S,10R,13S,14S,17R)-10-fluoro-17-(1-hydroxyethyl)-3-(methoxymethyl)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthrene-3-phenol as raw material and referring to step 6 of Example 1, the product 1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3-(methoxymethyl)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthrene-17-yl)ethane-1-ketone (500 mg, white solid, yield 83.7%) was obtained.

[0248] 1 H NMR (400 MHz, CDCl3) δ 3.40 (s, 3H), 3.21 (s, 2H), 2.56 - 2.47 (m, 1H), 2.39 - 2.16 (m, 4H), 2.12 (s, 3H), 2.07 - 0.98 (m, 18H), 0.65 (s, 3H). Step 6: 2-Bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3-(methoxymethyl)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone [ka] Using 1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3-(methoxymethyl)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material and referring to step 1 of Example 2, product 2-bromo-1-((3R,5R,8S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3-(methoxymethyl)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone (500 mg, white solid, yield 82.2%) was obtained.

[0249] Step 7: 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3-(methoxymethyl)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-4-carbonitrile [ka] Using 2-bromo-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3-(methoxymethyl)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material and referring to step 2 of Example 2, product 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3-(methoxymethyl)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-4-carbonitrile (11 mg, white solid, yield 17.8%) was obtained.

[0250] MS m / z (ESI): 458.3[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.87 (s, 1H), 7.82 (s, 1H), 5.04 - 4.90 (m, 2H), 3.40 (s, 3H), 3.22 (s, 2H), 2.58 (t, J = 8.9 Hz, 1H), 2.22 - 1.01 (m, 22H), 0.71 (s, 3H).

[0251] Example 115 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-Fluoro-3-hydroxyl-3-(methoxymethyl)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4-(trifluoromethyl)-1H-pyrazol-1-yl)ethane-1-ketone [ka] Using 2-bromo-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3-(methoxymethyl)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material and referring to step 2 of Example 2, product 1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3-(methoxymethyl)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(4-(trifluoromethyl)-1H-pyrazol-1-yl)ethane-1-ketone (25 mg, white solid, yield 37.0%) was obtained. MS m / z (ESI): 501.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.74 (s, 2H), 5.05 - 4.82 (m, 2H), 3.40 (s, 3H), 3.22 (s, 2H), 2.59 (t, J = 8.6 Hz, 1H), 2.45 - 1.05 (m, 22H), 0.72 (s, 3H).

[0252] Example 116 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3-(methoxymethyl)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-3-carbonitrile [ka] Starting from 2-bromo-1-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3-(methoxymethyl)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1-ketone and referring to step 2 of Example 2, product 1-(2-((3R,5R,8S,9S,10R,13S,14S,17S)-10-fluoro-3-hydroxyl-3-(methoxymethyl)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-3-carbonitrile (19 mg, white solid, yield 30.8%). MS m / z (ESI): 458.3[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 2.4 Hz, 1H), 6.74 (d, J = 2.4 Hz, 1H), 5.03 - 4.88 (m, 2H), 3.39 (s, 3H), 3.22 (s, 2H), 2.59 (t, J = 8.8 Hz, 1H), 2.38 - 1.05 (m, 22H), 0.71 (s, 3H).

[0253] Example 117 1-(2-((3R,5S,8S,9S,10S,13S,14S,17S)-3-hydroxyl-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-4-carbonitrile [ka] Step 1: ((8R,9S,10S,13S,14S)-13-Methyl-3,17-dicarbonyl-1,2,3,6,7,8,9,11,12,13,14,15,16,17-tetradecahydro-10H-cyclopenta[a]phenanthren-10-yl)methyl 4-methylbenzenesulfonate [ka] Pyridyl (20 mL) and (8R,9S,10S,13S,14S)-10-(hydroxymethyl)-13-methyl-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-diketone (6.0 g, 20 mmol) were added to a 100 mL three-neck flask in this order, and 4-methylbenzenesulfonyl chloride (11.4 g, 60 mmol) was obtained with stirring. After stirring at room temperature for 12 hours, the mixture was placed in an ice-water bath, and a white solid precipitated. The solid was filtered, washed with water, and dried to obtain the product ((8R,9S,10S,13S,14S)-13-methyl-3,17-dicarbonyl-1,2,3,6,7,8,9,11,12,13,14,15,16,17-tetradecahydro-10H-cyclopenta[a]phenanthren-10-yl)methyl 4-methylbenzenesulfonate (8.0 g, white solid, yield: 88%).

[0254] MS m / z (ESI): 457.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 8.0 Hz, 2 H), 7.36 (d, J = 8.0 Hz, 2 H), 5.87 (s, 1H), 4.39-4.23 (m, 2H), 2.52-2.47 (m, 1H), 2.46 (s, 3H), 2.38-2.25 (m, 5H), 2.12-1.70 (m, 7H), 1.65-1.40 (m, 2H), 1.30-1.05 (m, 4H),0.89 (s,3H). Step 2: (5S,8R,9S,10S,13S,14S)-13-Methyldodecahydro-17H-5,10-methylenecyclopenta[a]phenanthrene-3,17(4H)-diketone [ka] Into a 100 mL single-neck flask, ((8R,9S,10S,13S,14S)-13-methyl-3,17-dicarbonyl-1,2,3,6,7,8,9,11,12,13,14,15,16,17-tetradecahydro-10H-cyclopenta[a]phenanthren-10-yl)methyl 4-methylbenzenesulfonate (7.1 g, 15.5 mmol), acetic acid (300 mL) and water (300 mL) were added and stirred at room temperature for 2 to 3 minutes, after which zinc powder (35 g, 538 mmol) was added and, after completion of the addition, the mixture was reacted at 120°C for 1.5 hours. The reaction mixture was filtered, the filtrate was spin-dried, and the crude product was separated and purified by column chromatography (petroleum ether / ethyl acetate: 35 / 1) to obtain (5S,8R,9S,10S,13S,14S)-13-methyldodecahydro-17H-5,10-methylenecyclopenta[a]phenanthrene-3,17(4H)-diketone (2.5 g, white solid, yield: 56%).

[0255] 1 H NMR (400 MHz, CDCl3) δ 2.56-2.53 (m, 2 H), 2.49-2.27 (m, 2H), 2.14-1.70 (m, 9H),1.55-0.90 (m, 8H), 0.89 (s, 3H),0.55 (d, J = 6.0 Hz, 1H), 0.45 (d, J = 6.0 Hz, 1H). Step 3: (3R,5S,8R,9S,10S,13S,14S)-3-Hydroxyl-3,13-dimethyltetradecahydro-17H-5,10-methylenecyclopenta[a]phenanthrene-17-ketone [ka] Using (5S,8R,9S,10S,13S,14S)-13-methyldodecahydro-17H-5,10-methylenecyclopenta[a]phenanthrene-3,17(4H)-diketone as raw material, and referring to step 3 of Example 1, the product (3R,5S,8R,9S,10S,13S,14S)-3-hydroxyl-3,13-dimethyltetradecahydro-17H-5,10-methylenecyclopenta[a]phenanthrene-17-ketone (white solid, yield 52%) was obtained.

[0256] 1 H NMR (400 MHz, CDCl3) δ 2.47-2.39 (m, 1H), 2.10 - 1.25 (m, 16H), 1.19 (s, 3H), 1.15 - 0.85 (m, 4H), 0.86 (s, 3H), 0.42 (s, 2H). Step 4: (3R,5S,8S,9S,10S,13S,14S)-17-Ethylene-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthrene-3-phenol [ka] Using (3R,5S,8R,9S,10S,13S,14S)-3-hydroxyl-3,13-dimethyltetradecahydro-17H-5,10-methylenecyclopenta[a]phenanthrene-17-ketone as raw material, and referring to step 4 of Example 1, the product (3R,5S,8S,9S,10S,13S,14S)-17-ethylene-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthrene-3-phenol (white solid, yield: 61.5%) was obtained.

[0257] 1 H NMR (400 MHz, CDCl3) δ 5.15-5.08 (m, 1H), 2.40-1.20 (m, 18H), 1.19 (s, 3H), 1.16- 0.87(m, 6H), 086 (s, 3H), 0.43 (d, J = 4.4 Hz, 1H), 0.35(d, J = 4.4 Hz, 1H). Step 5: (3R,5S,8S,9S,10S,13S,14S)-17-(1-hydroxyethyl)-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthrene-3-phenol [ka] Using (3R,5S,8S,9S,10S,13S,14S)-17-ethylene-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthrene-3-phenol as raw material, and referring to step 5 of Example 1, the product (3R,5S,8S,9S,10S,13S,14S)-17-(1-hydroxyethyl)-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthrene-3-phenol (white solid, 100% yield).

[0258] Step 6: 1-((3R,5S,8S,9S,10S,13S,14S,17S)-3-hydroxyl-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthren-17-yl)ethane-1-ketone [ka] Using (3R,5S,8S,9S,10S,13S,14S)-17-(1-hydroxyethyl)-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthrene-3-phenol as raw material, and referring to step 6 of Example 1, product 1-((3R,5S,8S,9S,10S,13S,14S,17S)-3-hydroxyl-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthrene-17-yl)ethane-1-ketone (white solid, yield: 71%) was obtained.

[0259] 1H NMR (400 MHz, CDCl3) δ 2.54 (t, J = 8.0 Hz, 1H), 2.12 (s, 3H), 2.10 - 1.25 (m, 17H), 1.19 (s, 3H), 1.15 - 0.72 (m, 4H), 0.60 (s, 3H), 0.41 (d, J = 4.4 Hz, 1H), 0.36(d, J = 4.4 Hz, 1H). Step 7: 2-Bromo-1-((3R,5S,8S,9S,10S,13S,14S,17S)-3-hydroxyl-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthren-17-yl)ethane-1-ketone [ka] Using 1-((3R,5S,8S,9S,10S,13S,14S,17S)-3-hydroxyl-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material and referring to step 7 of Example 1, product 2-bromo-1-((3R,5S,8S,9S,10S,13S,14S,17S)-3-hydroxyl-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthren-17-yl)ethane-1-ketone (white solid, yield: 100%) was obtained.

[0260] Step 8: 1-(2-((3R,5S,8S,9S,10S,13S,14S,17S)-3-hydroxyl-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-4-carbonitrile [ka] Using 2-bromo-1-((3R,5S,8S,9S,10S,13S,14S,17S)-3-hydroxyl-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material, and referring to step 8 of Example 1, the product 1-(2-((3R,5S,8S,9S,10S,13S,14S,17S)-3-hydroxyl-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-4-carbonitrile (18 mg, white solid, yield: 21.9%) was obtained.

[0261] MS m / z (ESI): 404.2 [M-17] + . 1 H NMR (400 MHz, CDCl3) δ 7.86 (s, 1H), 7.81 (s, 1H), 5.05-4.85 (m, 2H), 2.61 (t, J = 8.8 Hz, 1H), 2.25-2.15 (m, 1H), 2.10-1.95 (m, 2H), 1.90-1.25 (m, 15H), 1.19 (s, 3H), 1.15 - 1.05 (m, 1H), 0.90 - 0.80 (m, 2H), 0.66 (s, 3H), 0.43-0.38 (m, 2H).

[0262] Example 118 1-(2-((3R,5S,8S,9S,10S,13S,14S,17S)-3-hydroxyl-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-3-carbonitrile [ka] Using 2-bromo-1-((3R,5S,8S,9S,10S,13S,14S,17S)-3-hydroxyl-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material and referring to step 2 of Example 2, product 1-(2-((3R,5S,8S,9S,10S,13S,14S,17S)-3-hydroxyl-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthren-17-yl)-2-carbonylethyl)-1H-pyrazole-3-carbonitrile (10.5 mg, white solid, yield 15.4%) was obtained.

[0263] MS m / z (ESI): 404.2 [M-H2O+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 2.4 Hz, 1H), 6.73 (d, J = 2.4 Hz, 1H) 5.10-4.85 (m, 2H), 2.61 (t, J = 8.9 Hz, 1H), 2.24-1.98 (m, 3H), 1.90 - 1.25 (m, 15H), 1.16(s, 3H), 1.15 - 1.05 (m, 1H), 0.90 - 0.80 (m, 2H), 0.67 (s, 3H), 0.43-0.37 (m, 2H).

[0264] Example 119 1-((3R,5S,8S,9S,10S,13S,14S,17S)-3-Hydroxy-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthren-17-yl)-2-(4-(trifluoromethyl)-1H-pyrazol-1-yl)ethane-1-ketone [ka] Using 2-bromo-1-((3R,5S,8S,9S,10S,13S,14S,17S)-3-hydroxyl-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthren-17-yl)ethane-1-ketone as raw material and referring to step 2 of Example 2, product 1-((3R,5S,8S,9S,10S,13S,14S,17S)-3-hydroxyl-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthren-17-yl)-2-(4-(trifluoromethyl)-1H-pyrazol-1-yl)ethane-1-ketone (10.5 mg, white solid, yield: 15.4%) was obtained.

[0265] MS m / z (ESI): 465.2 [M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.72 (s, 2H), 5.10-4.85 (m, 2H), 2.61 (t, J = 8.9 Hz, 1H), 2.26-1.98 (m, 3H), 1.90 - 1.25 (m, 15H), 1.19(s, 3H), 1.15 - 1.05 (m, 1H), 0.90 - 0.80 (m, 2H), 0.67 (s, 3H), 0.43-0.37 (m, 2H).

[0266] Example 120 and Example 121 1-((3R,5S,8S,9S,10S,13S,14S,17S)-3-Hydroxy-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthren-17-yl)-2-(1H-1,2,3-triazol-1-yl)ethane-1-ketone (120) 1-((3R,5S,8S,9S,10S,13S,14S,17S)-3-Hydroxy-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthren-17-yl)-2-(1H-1,2,3-triazol-1-yl)ethane-1-ketone (121) [ka] Using 2-bromo-1-((3R,5S,8S,9S,10S,13S,14S,17S)-3-hydroxyl-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthren-17-yl)ethane-1-ketone as the raw material, and referring to step 8 of Example 6, the product 1-((3R,5S,8S,9S,10S,13S,14S,17S)-3-hydroxyl-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthren- 17-yl)-2-(1H-1,2,3-triazol-1-yl)ethane-1-ketone (120) (7.2 mg, white solid, 12.2% yield) and 1-((3R,5S,8S,9S,10S,13S,14S,17S)-3-hydroxyl-3,13-dimethyltetradecahydro-6H-5,10-methylenecyclopenta[a]phenanthren-17-yl)-2-(1H-1,2,3-triazol-1-yl)ethane-1-ketone (121) (10 mg, white solid, 17.1% yield) were obtained.

[0267] Example 120: MS m / z (ESI): 398.2[M+H] + . 1 H NMR (400 MHz, CDCl3) δ 7.68 (s, 2H), 5.26-5.20 (m, 2H), 2.59 (t, J = 8.0 Hz, 1H), 2.24-1.95 (m, 3H), 1.90 - 1.25 (m, 15H), 1.19(s, 3H), 1.15 - 1.05 (m, 1H), 0.90 - 0.80 (m, 2H), 0.70 (s, 3H), 0.43-0.37 (m, 2H).

[0268] Example 121: MS m / z (ESI): 398.2[M+H] + . 1H NMR (400 MHz, CDCl3) δ 7.76 (s, 1H), 7.65 (s, 1H),5.35-5.10 (m, 2H), 2.66 (t, J = 8.0 Hz, 1H), 2.25-1.97 (m, 3H), 1.90 - 1.25 (m, 15H), 1.20(s, 3H), 1.13 - 1.05 (m, 1H), 0.90 - 0.80 (m, 2H), 0.67 (s, 3H), 0.43-0.36 (m, 2H).

[0269] Biological Test Evaluation The present invention will be further explained and explained by the following test examples, but these examples are not intended to limit the scope of the present invention.

[0270] 1. GABA Compound of the Present Invention A Measurement of receptor binding capacity

[0271] 1.1 Experimental Objective: The purpose of this test example is to measure the inhibitory ability of compounds against the binding of allosteric ion channel blockers (TBPS) to GABA-A receptors. Experimental equipment: [Table 1]

[0272] 1.2 Experimental steps

[0273] 1.2.1 Extraction of cerebral cortex cell membranes: 1. The cerebral cortex of male Sprague-Dawley rats was isolated. 2. Add 10 times the volume of rat cerebral cortex to pre-cooled 0.32 M sucrose solution (add one protease inhibitor per 100 ml), and pulverize in a 50 ml glass tissue homogenizer in several batches to mix uniformly. 3. 4 for 1500g o C for 10 min and the supernatant was collected. 4. 20000g for 4 oC for 30 min and the supernatant was discarded. 5. The pellet was resuspended in pre-chilled PBS (add 1 tablet of protease inhibitor per 100 ml), an average of 4 ml of PBS per rat was added, and mixed uniformly with a glass tissue homogenizer. 6. 4 for 10,000g o C for 10 min and the supernatant was discarded. 7. Steps 5 and 6 were repeated three times. 8. Finally, resuspend the pellet in 4 volumes of PBS, dispense into aliquots, and quickly freeze in liquid nitrogen at -80 °C. o Saved in C. 9. Protein concentration was measured using the BCA method.

[0274] 1.2.2 35S-TBPS binding assay 1. For 1.1 ml deep well plates, add 230 μL of PBS per well. 2. 60 μL of cerebral cortical cell membrane (5 μg / μL) solution was added per well and mixed evenly. 3. Test compounds (3 μL per well) were added and incubated for 5 min at 25° C. The concentration of DMSO was 1%, and the initial concentration of the compound was 1 μM, diluted 3-fold in eight increments with two replicates, with 1% DMSO as the negative control and 10 μM P026-2 as the positive control. 4. GABA was added to a final concentration of 5 μM, and the plate was incubated at 25° C. for 5 minutes. A 1 mM GABA solution was prepared and added at 1.5 μL per well. 5. 35S-TBPS was added to make the final concentration 2 nM and the isotope mother solution concentration 9.7 μM. After diluting 100-fold with PBS, 6 μL of the diluted isotope solution was added per well. 6. Incubate at 4℃ for 20 hours. 7. FilterMate GF / C plates were pretreated with 0.5% PEI and incubated at 4°C for 1 h. 8. Wash the FilterMate GF / C plates twice in the Universal Harvester, using 50 ml of PBS each time. 9. The reaction solution was transferred to a GF / C plate, and each well was washed four times with 900 μL of PBS. 10. After washing, the GF / C plate was dried at 55°C for 10 minutes. 11. 40 μL of scintillation fluid was added per well and CPM values ​​were read on a TopCount.

[0275] 1.2.3 Experimental data processing method: In the experiment, the CPM (counts per minute) values ​​were read using TopCount, and the % inhibition was calculated based on the readings of the High control (DMSO) and Low control (10 uM positive compound) experimental groups using the following formula: % Inhibition=100x(CPM High control -CPM Sample ) / (CPM High control -CPM Low control ) The IC of the compound was calculated using the following four-parameter nonlinear logistic equation: 50 was calculated: Y=Bottom+(Top-Bottom) / (1+10^((LogIC50-X)*HillSlope)) During the ceremony: X is the log of compound concentration; Y is the % Inhibition.

[0276] In the present invention, the inhibition of the TBPS binding activity of the compound was measured in the above experiments. 50 The values ​​are shown in Table 1. [Table 2]

[0277] Conclusion: The compounds according to the present invention have obvious inhibitory effects on TBPS binding activity.

[0278] II. Pharmacokinetics in Balb / C mice 1. Research purpose: Balb / C mice were used as test animals to study the pharmacokinetic behavior in the mouse body (plasma and brain tissue) of the compounds of Examples 2, 5, 7, 12, 18, 23, 26, 38, 41, 50, 51 and 66 when orally administered at a dose of 5 mg / kg.

[0279] 2. Experimental plan:

[0280] 2.1 Test Drugs: Examples 2, 5, 7, 12, 18, 23, 26, 38, 41, 50, 51 and 66 of the present invention prepared in the laboratory

[0281] 2.2 Test animals: Male Balb / c mice were purchased from Shanghai Jiesijie Laboratory Animal Co., Ltd. with the animal production permit number (SCXK(Hu)2013-0006 No.311620400001794).

[0282] 2.3 Administration: Each group consisted of 24 male Balb / C mice, which were administered po at a dose of 50 mg / kg in a volume of 10 mL / kg after an overnight fast.

[0283] 2.4 Sample Collection: Before administration and 0, 0.5, 1, 2, 4, 6, 8, and 24 hours after administration, the mice were killed with CO2, and 0.2 mL of blood was collected from the heart, placed in an EDTA-K2 test tube, centrifuged at 6000 rpm for 6 minutes at 4°C, and stored at -80°C. Whole brain tissue was removed and weighed, then placed in a 2 mL centrifuge tube and stored at -80°C.

[0284] 2.5 Sample Processing: 1) 40 μL of plasma sample was precipitated by adding 160 μL of acetonitrile, mixed, and then centrifuged at 3500 g for 5 to 20 minutes. 2) 30 μL of plasma and brain homogenate samples were precipitated by adding 90 μL of acetonitrile containing an internal standard (100 ng / mL), mixed, and then centrifuged at 13,000 rpm for 8 minutes. 3) 70 μL of water was added to 70 μL of the treated supernatant, and the mixture was vortexed for 10 minutes. Then, 20 μL of the mixture was taken and analyzed by LC / MS / MS for the concentration of the test compound. The LC / MS / MS analysis equipment was AB Sciex API 4000 Qtrap.

[0285] 2.6 Liquid phase analysis ● Liquid chromatography conditions: Shimadzu LC-20 AD pump ● Chromatography column: Agilent ZORBAX XDB-C18 (50 x 2.1 mm, 3.5 μm) Mobile phase: Liquid A is 0.1% formic acid in water, and liquid B is acetonitrile. ● Flow rate: 0.4mL / min ● Elution time: 0-4.0 minutes, elution solution is as follows: [Table 3]

[0286] 3. Experimental Results and Analysis The main pharmacokinetic parameters were calculated using WinNonlin 6.1, and the results of the pharmacokinetic experiments in mice are shown in Table 2 below: [Table 4-1] [Table 4-2]

[0287] As can be seen from the results of the pharmacokinetics experiment in mice in the table, the compounds of the examples of the present invention exhibit good metabolic properties, and the exposure AUC and maximum blood concentration C max Both are good.

[0288] 3. In vivo drug efficacy experiment using mouse forced swimming model 3.1 Purpose of the experiment The antidepressant effects of compounds are evaluated using the mouse forced swimming model.

[0289] 3.2 Main equipment and reagents used in the experiment 3.2.1 Equipment Forced swimming device (JLBehv-FSC-4, Shanghai Jilu Software Science and Technology Co., Ltd.) 3.2.2 Reagents Sodium carboxymethylcellulose (CMC-Na, SLBV9664, Sigma) Tween 80 (BCBV8843, Sigma) 3.2.3 Test Compounds Compounds of Examples 2, 5, 7, 18, 23, 26, and 50 of the present invention prepared in the laboratory

[0290] 3.3 Experimental steps 3.3.1 Adaptation: Before the forced swimming test, male ICR mice (25-35 g) were adapted to the experimental environment for 3 days. 3.3.2 Group Administration: According to the experimental design, the mice were randomly divided into groups according to their body weight on the day before the experiment, with 12 mice in each group. Before the test, the compounds of each example were administered intragastrically based on the brain Tmax time in the mouse pharmacokinetics experiment. The following are the results: 1) Model group (0.5% CMC-Na + 1% Tween 80 solution, po, 10 mL / kg); 2) Compounds of Example 2, Example 5, Example 7, Example 18, Example 23, Example 26 and Example 50 (10 mg / kg, po, 10 mL / kg); At the time of administration, each compound of the Examples was suspended in a 0.5% CMC-Na-1% Tween 80 solution to a desired concentration. 3.3.2 Forced swim test: After 0.5-1 h administration, the ICR mice were placed in a transparent glass drum (18 cm deep, 25-26°C water temperature, 1 mouse per drum) in a forced swimming apparatus and forced to swim for 6 minutes. The floating time of the ICR mice in the forced swimming apparatus was recorded for 6 minutes, and the data for the last 4 minutes was used for data analysis. After the swimming test, the mice were immediately taken out, the water on the mice was wiped off, and they were returned to their original cages.

[0291] NOTE: The criterion for immobility time was that the mouse remained floating in the water without struggling, with only small limbs moving to keep the head above water.

[0292] 3.4 Data Analysis Float time percentage=100*float time / 240s.

[0293] 3.5 Experimental Data: [Table 5]

[0294] 3.6 Experimental results As is clear from the above results, each of the experimental examples of the present invention can significantly shorten the accumulated immobility time in the forced swimming test in mice, and has obvious antidepressant effects.

[0295] Example 2 had a clear difference in the immobility time for the last 4 minutes compared to the model group, and Example 5, Example 23 and Example 50 had a very clear difference in the immobility time for the last 4 minutes compared to the model group.

[0296] 4. Efficacy study in vivo on PTZ-induced epilepsy model in mice 4.1 Purpose of the experiment A PTZ-induced CD-1 mouse epilepsy model is established, and the anti-epileptic effects of the compounds of Example 5 and Example 23 are evaluated using the model.

[0297] 4.2 Experimental Method 4.21 Test Animals Thirty male CD-1 mice purchased from Beijing Weitong Lihua Laboratory Animal Co., Ltd. The test animals were delivered to the animal room of Building 3 of Shanghai Ruizhi Chemical Co., Ltd., and were adapted for 7 days before the formal experiment. The average weight of the animals on the day of the test was 32.2±0.2g. Breeding environment: 5 mice / cage, room temperature 23±2℃, 12 / 12 hours light / dark alternation, food and water available ad libitum.

[0298] On the day of the experiment, the animals were randomly assigned to groups for testing.

[0299] 4.22 Test Compound Test compounds of Example 5 and Example 23 (prepared in the laboratory), test drugs stored in a refrigerator at 4°C.

[0300] [Table 6] 4.2.1 Experimental equipment ● Sterile disposable syringe with 1ml needle (purchased from Zhejiang Kandela Medical Instrument Co., Ltd.) ● Pipette: Eppendorf Research Plus (100~1000μL) ● Vortex mixer: Kylin-Bell Vortex 5 ● Ultrasonic equipment: JL-360 ultrasonic cleaner ● Balance: METTLER TOLEDO XS204 precision balance ● Balance: METTLER TOLEDO XS6002S electronic balance ● Organic glass box: 25cm length * 15cm width * 15cm height, one side wall is designed to be non-translucent, specially customized by Suzhou Feng Laboratory Animal Equipment Co., Ltd. ● 3-channel timer: Oregon / Model NO.WB-388. 4.2.2 Grouping of test animals 1) Vehicle / PTZ: 0.5% CMC-Na + 1% Tween-80 (10ml / kg, po), 0.5hr before PTZ administration, PTZ (120ml / kg, sc), administered before the experiment; 2) 3 mg / kg of example compound / PTZ: Example 5 and Example 23 (3 mg / kg, 10 ml / kg, po), 0.5 hr before PTZ administration, PTZ (120 ml / kg, sc), administered before the experiment.

[0301] 4.3 Experimental steps 4.3.1 Preparation of solvent 1) 0.5% CMC-NA + 1% Tween-80 (administration volume: 10 mL / kg): 1g of sodium carboxymethylcellulose was weighed and placed in a 250mL solvent bottle, and 150mL of double distilled water was added. The mixture was stirred with a magnetic stirrer at room temperature for 4 hours to obtain a uniform, clear solution. 2mL of Tween-80 was gradually added and the mixture was stirred at room temperature for 3 hours to obtain a uniform, clear solution. The solution was gradually transferred to a 200mL volumetric bottle, and double distilled water was added to make the volume 200mL. The solution was then transferred to a 250mL solvent bottle and stirred with a magnetic stirrer for 1 hour to obtain a uniform, clear solution.

[0302] 2) 30% Hydroxypropyl-β-cyclodextrin: 30.6122g of hydroxypropyl-β-cyclodextrin (purity: 98%) was weighed out and placed in a 100mL solvent bottle, and 60mL of double distilled water was added, vortexed for 3 minutes with a vortex mixer, and ultrasonicated for 15 minutes at room temperature to obtain a homogeneous clear solution. Double distilled water was then added to the volume of 100mL, vortexed for 1 minute with a vortex mixer, and ultrasonicated for 5 minutes at room temperature to obtain a homogeneous clear solution.

[0303] 4.3.2 Preparation of test compounds 1) 12mg / mL PTZ (dosage: 120mg / kg, administration volume: 10mL / kg): 248 mg of PTZ was precisely weighed and placed in a 40 mL brown reagent bottle, 20.667 mL of saline was added, and the solution was vortexed for 2 minutes using a vortex mixer, followed by ultrasonic treatment at room temperature for 2 minutes to obtain a homogenous clear solution (concentration: 12 mg / mL).

[0304] 2) 0.3 mg / mL of Example 5 and Example 23 (dosage: 3 mg / kg, dosing volume: 10 mL / kg): A certain amount of 0.5% CMC-Na + 1% Tween 80 was weighed out and placed in a reagent bottle containing a certain amount of Example 5 and Example 23. The solution was vortexed for 3 minutes using a vortex mixer and then ultrasonicated at room temperature for 15 minutes to obtain a uniform suspension (concentration: 0.3 mg / mL).

[0305] 4.3.3 Experimental method 1) The experimental animals were placed in the operating room 1 h before the test to allow them to adapt to the adaptive environment; 2) Randomly assigned to groups, labeled and weighed; 3) Example 5 and Example 23 were administered 1 hour before PTZ administration, or 0.5% CMC-NA+1% Tween-80, Example 5 and Example 23 were administered 0.5 hour before PTZ administration; 4) PTZ (120 mg / kg) was administered subcutaneously before the experimental observation, and this time point was recorded as the starting point of the observation; 5) Immediately after PTZ administration, the animals were placed in the observation box and observed for 30 minutes, and the following were recorded: a) the latency period until the first clonic seizure, b) the latency period until the first generalized tonic-clonic seizure, c) the number of clonic seizures, d) the number of generalized tonic-clonic seizures, and e) the time when the animals died; 6) If the animals did not have epileptic seizures during the 30-minute observation period, the latency period was recorded as 1800 seconds and the number of onsets was recorded as 0. ● Clonic seizure: The skin of the whole animal is seizure-like for more than 3 seconds, accompanied by falling; • Tonic seizures: limbs extend to form 90° with the body; 6) Possible drug-induced side effects after administration can be observed and recorded and divided into four levels: ● None: Normal ● Mild sedation Moderate sedation ● Severe sedation 7) Exam time: 12:00am~16:30pm.

[0306] 4.4 Adaptation to the environment The experimental animals were placed in the operating room 1 h before the test to allow them to adapt to the adaptive environment; 4.5 Group Administration The mice were randomly divided into groups, labeled, and weighed, with 10 mice in each group. The test compounds were orally administered to each mouse 30 to 60 minutes before PTZ administration, with the administration volume being 10 mL / kg.

[0307] 4.6 PTZ model creation and testing Before the experimental observation, PTZ (120mg / kg) was subcutaneously administered and this time point was recorded as the start point of the observation. Immediately after PTZ administration, the animals were placed in the observation box and observed for 30 minutes. The following were recorded: a) the latency period until the first clonic seizure, b) the latency period until the first generalized tonic-clonic seizure, c) the number of clonic seizures, d) the number of generalized tonic-clonic seizures, and e) the time when the animal died. If the animal did not have an epileptic seizure during the 30-minute observation period, the latency period was recorded as 1800 sec and the number of onsets was recorded as 0.

[0308] 4.7 Data Analysis All data are expressed as mean±standard error of the mean (Mean±SEM) and data are analysed using Prism 6.0 statistical software.

[0309] 4.8 Experimental Data: [Table 7]

[0310] 4.9 Experimental results Compared with the control group, each experimental embodiment significantly extended the latency period and frequency of clonic seizures and generalized tonic-clonic seizures, protected 60% of the animals from death, and significantly extended the latency period until death, demonstrating excellent antiepileptic effects.

Claims

1. A compound represented by the general formula (I), a stereoisomer thereof or a pharma- ceutically acceptable salt thereof: 【Chemistry 1】 (In the formula, X is -CR 17 - or -N-; Yは、-CR 23 R 24 -、-S(EH 2 ) n1 -、-P(CH 2 ) n1 -、-O(EH 2 ) n1 -、-(EH 2 ) n1 NR 22 -、 【Chemistry 2】 is selected from R x , R y , R z and R f are the same or different and each independently represent a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a mercapto group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R 23 , -(CH 2 ) n1 OR 23 , -(CH 2 ) n1 S.R. 23 , -(CH 2 ) n1 C(O)R 23 , -(CH 2 ) n1 C(O)OR 23 , -(CH 2 ) n1 S (O) m1 R 23 , -(CH 2 ) n1 N.R. 23 R 24 , -(CH 2 ) n1 C(O)NR 23 R 24 , -(CH 2 ) n1 N.R. 23 C(O)R 24 or -(CH 2 ) n1 N.R. 23 S (O) m1 R 24 wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, a mercapto group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 R 25 , -(CH 2 ) n1 OR 25 , -(CH 2 ) n1 S.R. 25 , -(CH 2 ) n1 C(O)R 25 , -(CH 2 ) n1 C(O)OR 25 , -(CH 2 ) n1 S (O) m1 R 25 , -(CH 2 ) n1 N.R. 25 R 26 , -(CH 2 ) n1 C(O)NR 25 R 26 , -(CH 2 ) n1 C(O)NHR 25 , -(CH 2 ) n1 N.R. 25 C(O)R 26 and -(CH 2 ) n1 N.R. 25 S (O) m1 R 26 may be substituted with one or more substituents selected from Or, R x , R y , R z and R f Any two adjacent, non-adjacent or two identical groups among the above may be bonded to form a cycloalkyl group, a heteroalkyl group, an aryl group and a heteroaryl group, among which the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group may further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 R 23 , -(CH 2 ) n1 OR 23 , -(CH 2 ) n1 S.R. 23 , -(CH 2 ) n1 C(O)R 23 , -(CH 2 ) n1 C(O)OR 23 , -(CH 2 ) n1 S (O) m1 R 23 , -(CH 2 ) n1 N.R. 23 R 24 , -(CH 2 ) n1 C(O)NR 23 R 24 , -(CH 2 ) n1 N.R. 23 C(O)R 24 and -(CH 2 ) n1 N.R. 23 S (O) m1 R 24 may be substituted with one or more substituents selected from Or, R x , R y , R z and R f Any two adjacent groups among R 21 represents a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R 23 , -(CH 2 ) n1 OR 23 , -(CH 2 ) n1 S.R. 23 , -(CH 2 ) n1 C(O)R 23 , -(CH 2 ) n1 C(O)OR 23 , -(CH 2 ) n1 S (O) m1 R 23 , -(CH 2 ) n1 N.R. 23 R 24 , -(CH 2 ) n1 C(O)NR 23 R 24 , -(CH 2 ) n1 N.R. 23 C(O)R 24 or -(CH 2 ) n1 N.R. 23 S (O) m1 R 24 wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 R 25 , -(CH 2 ) n1 OR 25 , -(CH 2 ) n1 S.R. 25 , -(CH 2 ) n1 C(O)R 25 , -(CH 2 ) n1 C(O)OR 25 , -(CH 2 ) n1 S (O) m1 R 25 , -(CH 2 ) n1 N.R. 25 R 26 , -(CH 2 ) n1 C(O)NR 25 R 26 , -(CH 2 ) n1 C(O)NHR 25 , -(CH 2 ) n1 N.R. 25 C(O)R 26 and -(CH 2 ) n1 N.R. 25 S (O) m1 R 26 may be substituted with one or more substituents selected from X is -CR 17 -, R 17 is selected from a bond, a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, a hydroxyl group, an amino group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group, and the heteroaryl group may be further substituted with one or more substituents selected from a deuterium atom, a substituted or unsubstituted alkyl group, a halogen, a hydroxyl group, a substituted or unsubstituted amino group, an oxo group, a nitro group, a cyano group, an alkenyl group, an alkynyl group, an alkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heteroaryl group; Or, R 17 is R x , R y , R z and R f can be bonded to any of the groups listed above to form a cycloalkyl group, a heteroalkyl group, an aryl group, and a heteroaryl group, among which the cycloalkyl group, the heterocyclyl group, the aryl group, and the heteroaryl group can further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 R 23 , -(CH 2 ) n1 OR 23 , -(CH 2 ) n1 S.R. 23 , -(CH 2 ) n1 C(O)R 23 , -(CH 2 ) n1 C(O)OR 23 , -(CH 2 ) n1 S (O) m1 R 23 , -(CH 2 ) n1 N.R. 23 R 24 , -(CH 2 ) n1 C(O)NR 23 R 24 , -(CH 2 ) n1 N.R. 23 C(O)R 24 and -(CH 2 ) n1 N.R. 23 S (O) m1 R 24 may be substituted with one or more substituents selected from R 22 represents a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R 23 , -(CH 2 ) n1 OR 23 , -(CH 2 ) n1 S.R. 23 , -(CH 2 ) n1 C(O)R 23 , -(CH 2 ) n1 C(O)OR 23 , -(CH 2 ) n1 S (O) m1 R 23 , -(CH 2 ) n1 N.R. 23 R 24 , -(CH 2 ) n1 C(O)NR 23 R 24 , -(CH 2 ) n1 N.R. 23 C(O)R 24 or -(CH 2 ) n1 N.R. 23 S (O) m1 R 24 wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 R 25 , -(CH 2 ) n1 OR 25 , -(CH 2 ) n1 S.R. 25 , -(CH 2 ) n1 C(O)R 25 , -(CH 2 ) n1 C(O)OR 25 , -(CH 2 ) n1 S (O) m1 R 25 , -(CH 2 ) n1 N.R. 25 R 26 , -(CH 2 ) n1 C(O)NR 25 R 26 , -(CH 2 ) n1 C(O)NHR 25 , -(CH 2 ) n1 N.R. 25 C(O)R 26 and -(CH 2 ) n1 N.R. 25 S (O) m1 R 26 may be substituted with one or more substituents selected from R 23 , R 24 , R 25 and R 26 are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, a hydroxyl group, an amino group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group may be further substituted with one or more substituents selected from a deuterium atom, a substituted or unsubstituted alkyl group, a halogen, a hydroxyl group, a substituted or unsubstituted amino group, an oxo group, a nitro group, a cyano group, an alkenyl group, an alkynyl group, an alkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group and a substituted or unsubstituted heteroaryl group; m is an integer of 0, 1, 3, 4, 5, 6, 7, 8, 9, or 10; n is an integer of 0, 1, 2 or 3; o is an integer of 0, 1, 2, 3, 4 or 5; p is an integer of 0, 1, 2, 3, 4, 5, or 6; q is an integer of 0, 1, 2, 3, 4, 5, or 6; m 1 is an integer of 0, 1 or 2, and n 1 is an integer of 0, 1, 2, 3, 4 or 5.

2. The compound represented by general formula (I) according to claim 1, which is a compound represented by general formula (II), a stereoisomer thereof, or a pharmacologically acceptable salt thereof. 【Chemistry 3】 (In the formula, R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R 11 , R 12 , R 15a , R 15b , R 16a , R 16b , R 18 and R 19 are the same or different and each independently represent a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R 23 , -(CH 2 ) n1 OR 23 , -(CH 2 ) n1 S.R. 23 , -(CH 2 ) n1 C(O)R 23 , -(CH 2 ) n1 C(O)OR 23 , -(CH 2 ) n1 S (O) m1 R 23 , -(CH 2 ) n1 S(O)NR 23 , -(CH 2 ) n1 N.R. 23 R 24 , -(CH 2 ) n1 C(O)NR 23 R 24 , -(CH 2 ) n1 N.R. 23 C(O)R 23 or -(CH 2 ) n1 N.R. 23 S (O) m1 R 24 wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 R 25 , -(CH 2 ) n1 OR 25 , -(CH 2 ) n1 S.R. 25 , -(CH 2 ) n1 C(O)R 25 , -(CH 2 ) n1 C(O)OR 25 , -(CH 2 ) n1 S (O) m1 R 25 , -(CH 2 ) n1 N.R. 25 R 26 , -(CH 2 ) n1 C(O)NR 25 R 26 , -(CH 2 ) n1 C(O)NHR 25 , -(CH 2 ) n1 N.R. 25 C(O)R 26 and -(CH 2 ) n1 N.R. 25 S (O) m1 R 26 may be substituted with one or more substituents selected from Or, R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R 11 , R 12 , R 15a , R 15b , R 16a , R 16b , R 18 and R 19 Any two adjacent or non-adjacent groups among the above may form one cycloalkyl group, heteroalkyl group, aryl group, and heteroaryl group, and the cycloalkyl group, heteroalkyl group, aryl group, and heteroaryl group formed may further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 R 25 , -(CH 2 ) n1 OR 25 , -(CH 2 ) n1 S.R. 25 , -(CH 2 ) n1 C(O)R 25 , -(CH 2 ) n1 C(O)OR 25 , -(CH 2 ) n1 S (O) m1 R 25 , -(CH 2 ) n1 N.R. 25 R 26 , -(CH 2 ) n1 C(O)NR 25 R 26 , -(CH 2 ) n1 C(O)NHR 25 , -(CH 2 ) n1 N.R. 25 C(O)R 26 and -(CH 2 ) n1 N.R. 25 S (O) m1 R 26 may be substituted with one or more substituents selected from R 3a and R 3b are the same or different and each independently represent a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a mercapto group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R 23 , -(CH 2 ) n1 OR 23 , -(CH 2 ) n1 S.R. 23 , -(CH 2 ) n1 C(O)R 23 , -(CH 2 ) n1 C(O)OR 23 , -(CH 2 ) n1 S (O) m1 R 23 , -(CH 2 ) n1 S(O)NR 23 , -(CH 2 ) n1 N.R. 23 R 24 , -(CH 2 ) n1 C(O)NR 23 R 24 , -(CH 2 ) n1 N.R. 23 C(O)R 23 or -(CH 2 ) n1 N.R. 23 S (O) m1 R 24 wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, a mercapto group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 R 25 , -(CH 2 ) n1 OR 25 , -(CH 2 ) n1 S.R. 25 , -(CH 2 ) n1 C(O)R 25 , -(CH 2 ) n1 C(O)OR 25 , -(CH 2 ) n1 S (O) m1 R 25 , -(CH 2 ) n1 N.R. 25 R 26 , -(CH 2 ) n1 C(O)NR 25 R 26 , -(CH 2 ) n1 C(O)NHR 25 , -(CH 2 ) n1 N.R. 25 C(O)R 26 and -(CH 2 ) n1 N.R. 25 S (O) m1 R 26 may be substituted with one or more substituents selected from X, Y, R 21 ~R 26 , n, m 1 and n 1 is as described in claim 1.

3. The compound represented by general formula (I) according to claim 1, which is a compound represented by general formula (III), a stereoisomer thereof, or a pharmacologically acceptable salt thereof. 【Chemistry 4】 (In the formula, Y, R 1 , R 2 , R 3a , R 3b , R 4 , R 5 , R 6 , R 7 , R 11 , R 12 , R 15a , R 15b , R 16a , R 16b , R 18 , R 19 , R 21 ~R 26 and n are as defined in claim 2.

4. The compound represented by general formula (I) according to any one of claims 1 to 3, which is a compound represented by general formula (IV), a stereoisomer thereof, or a pharmacologically acceptable salt thereof. 【Chemistry 5】 (In the formula, Y is, 【Chemistry 6】 is selected from R 3a is selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a mercapto group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, or an alkynyl group; R 5 is selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, or an alkynyl group; R 15a is selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, or an alkynyl group; R 16a is selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, or an alkynyl group; Or, R 15a and R 16a are bonded to form a cycloalkyl or heteroalkyl group, and the cycloalkyl or heteroalkyl group formed may be further substituted with one or more substituents selected from a hydrogen atom, a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, or a heteroaryl group; R 19 represents a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a mercapto group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a hydroxyalkyl group, -(CH 2 ) n1 OR 23 , -(CH 2 ) n1 S.R. 23 , -(CH 2 ) n1 C(O)OR 23 , -(CH 2 ) n1 S (O) m1 R 23 , -(CH 2 ) n1 S(O)(=NR 23 ) R 24 or -(CH 2 ) n1 C(O)NR 23 R 24 is selected from Or, R 5 and R 19 are bonded to form a cycloalkyl or heteroalkyl group, and the cycloalkyl or heteroalkyl group formed may be further substituted with one or more substituents selected from a hydrogen atom, a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, or a heteroaryl group; R 21 represents a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R 23 , -(CH 2 ) n1 OR 23 , -(CH 2 ) n1 S.R. 23 , -(CH 2 ) n1 C(O)R 23 , -(CH 2 ) n1 C(O)OR 23 , -(CH 2 ) n1 S (O) m1 R 23 , -(CH 2 ) n1 N.R. 23 R 24 , -(CH 2 ) n1 C(O)NR 23 R 24 , -(CH 2 ) n1 N.R. 23 C(O)R 24 or -(CH 2 ) n1 N.R. 23 S (O) m1 R 24 wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 R 25 , -(CH 2 ) n1 OR 25 , -(CH 2 ) n1 S.R. 25 , -(CH 2 ) n1 C(O)R 25 , -(CH 2 ) n1 C(O)OR 25 , -(CH 2 ) n1 S (O) m1 R 25 , -(CH 2 ) n1 N.R. 25 R 26 , -(CH 2 ) n1 C(O)NR 25 R 26 , -(CH 2 ) n1 C(O)NHR 25 , -(CH 2 ) n1 N.R. 25 C(O)R 26 and -(CH 2 ) n1 N.R. 25 S (O) m1 R 26 may be substituted with one or more substituents selected from R 23 , R 24 , R 25 and R 26 are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, a hydroxyl group, an amino group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group may be further substituted with one or more substituents selected from a deuterium atom, a substituted or unsubstituted alkyl group, a halogen, a hydroxyl group, a substituted or unsubstituted amino group, an oxo group, a nitro group, a cyano group, an alkenyl group, an alkynyl group, an alkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group and a substituted or unsubstituted heteroaryl group; n is an integer of 1 or 2; m 1 is an integer of 0, 1 or 2, and n 1 is an integer of 0, 1, 2, 3, 4, or 5.

5. The compound represented by general formula (I) according to any one of claims 1 to 3, which is a compound represented by general formula (III-A), a stereoisomer thereof, or a pharmacologically acceptable salt thereof. 【Chemistry 7】 (In the formula, Z is -CR 23 R 24 -, -(CH 2 ) n1 N.R. 23 -, -(CH 2 ) n1 O (CH 2 ) n2 - or -O-, preferably a methylene group; Ring C is selected from a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, among which the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group, and the heteroaryl group may further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 R 25 , -(CH 2 ) n1 OR 25 , -(CH 2 ) n1 S.R. 25 , -(CH 2 ) n1 C(O)R 25 , -(CH 2 ) n1 C(O)OR 25 , -(CH 2 ) n1 S (O) m1 R 25 , -(CH 2 ) n1 N.R. 25 R 26 , -(CH 2 ) n1 C(O)NR 25 R 26 , -(CH 2 ) n1 C(O)NHR 25 , -(CH 2 ) n1 N.R. 25 C(O)R 26 and -(CH 2 ) n1 N.R. 25 S (O) m1 R 26 may be substituted with one or more substituents selected from R c are the same or different and each represents a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R 23 , -(CH 2 ) n1 OR 23 , -(CH 2 ) n1 S.R. 23 , -(CH 2 ) n1 C(O)R 23 , -(CH 2 ) n1 C(O)OR 23 , -(CH 2 ) n1 S (O) m1 R 23 , -(CH 2 ) n1 S(O)NR 23 , -(CH 2 ) n1 N.R. 23 R 24 , -(CH 2 ) n1 C(O)NR 23 R 24 , -(CH 2 ) n1 N.R. 23 C(O)R 23 or -(CH 2 ) n1 N.R. 23 S (O) m1 R 24 wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 R 25 , -(CH 2 ) n1 OR 25 , -(CH 2 ) n1 S.R. 25 , -(CH 2 ) n1 C(O)R 25 , -(CH 2 ) n1 C(O)OR 25 , -(CH 2 ) n1 S (O) m1 R 25 , -(CH 2 ) n1 N.R. 25 R 26 , -(CH 2 ) n1 C(O)NR 25 R 26 , -(CH 2 ) n1 C(O)NHR 25 , -(CH 2 ) n1 N.R. 25 C(O)R 26 and -(CH 2 ) n1 N.R. 25 S (O) m1 R 26 may be substituted with one or more substituents selected from z is an integer of 0, 1, 3, 4 or 5; n2 is an integer of 0, 1, 3, 4, or 5; and R 3a , R 3b , R 5 , R 19 , R 23 ~R 26 , n, m 1 and n 1 is as described in claim 4.

6. The compound represented by general formula (I) according to any one of claims 1 to 3, which is a compound represented by general formula (V), a stereoisomer thereof, or a pharmacologically acceptable salt thereof. 【Chemistry 8】 (In the formula, Y, R 1 , R 2 , R 3a , R 3b , R 4 , R 5 , R 6 , R 7 , R 11 , R 12 , R 15a , R 15b , R 16a , R 16b , R 17 , R 18 , R 19 , R 21 and n are as defined in claim 2, R 17 is as described in claim 1.

7. The compound represented by general formula (I) according to any one of claims 1 to 6, which is a compound represented by general formula (V-7) and general formula (V-8), a stereoisomer thereof, or a pharmacologically acceptable salt thereof. 【Chemistry 9】 (In the formula, Ring A is selected from a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, among which the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group, and the heteroaryl group can further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 R 25 , -(CH 2 ) n1 OR 25 , -(CH 2 ) n1 S.R. 25 , -(CH 2 ) n1 C(O)R 25 , -(CH 2 ) n1 C(O)OR 25 , -(CH 2 ) n1 S (O) m1 R 25 , -(CH 2 ) n1 N.R. 25 R 26 , -(CH 2 ) n1 C(O)NR 25 R 26 , -(CH 2 ) n1 C(O)NHR 25 , -(CH 2 ) n1 N.R. 25 C(O)R 26 and -(CH 2 ) n1 N.R. 25 S (O) m1 R 26 may be substituted with one or more substituents selected from R a are the same or different and each represents a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R 23 , -(CH 2 ) n1 OR 23 , -(CH 2 ) n1 S.R. 23 , -(CH 2 ) n1 C(O)R 23 , -(CH 2 ) n1 C(O)OR 23 , -(CH 2 ) n1 S (O) m1 R 23 , -(CH 2 ) n1 S(O)NR 23 , -(CH 2 ) n1 N.R. 23 R 24 , -(CH 2 ) n1 C(O)NR 23 R 24 , -(CH 2 ) n1 N.R. 23 C(O)R 23 or -(CH 2 ) n1 N.R. 23 S (O) m1 R 24 wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 R 25 , -(CH 2 ) n1 OR 25 , -(CH 2 ) n1 S.R. 25 , -(CH 2 ) n1 C(O)R 25 , -(CH 2 ) n1 C(O)OR 25 , -(CH 2 ) n1 S (O) m1 R 25 , -(CH 2 ) n1 N.R. 25 R 26 , -(CH 2 ) n1 C(O)NR 25 R 26 , -(CH 2 ) n1 C(O)NHR 25 , -(CH 2 ) n1 N.R. 25 C(O)R 26 and -(CH 2 ) n1 N.R. 25 S (O) m1 R 26 may be substituted with one or more substituents selected from R 19 represents a hydrogen atom, an alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R 23 , -(CH 2 ) n1 OR 23 , -(CH 2 ) n1 S.R. 23 , -(CH 2 ) n1 C(O)R 23 , -(CH 2 ) n1 C(O)OR 23 , -(CH 2 ) n1 S (O) m1 R 23 , -(CH 2 ) n1 S(O)NR 23 , -(CH 2 ) n1 N.R. 23 R 24 , -(CH 2 ) n1 C(O)NR 23 R 24 , -(CH 2 ) n1 N.R. 23 C(O)R 23 , -(CH 2 ) n1 S(O)(=NR 23 ) R 24 or -(CH 2 ) n1 N.R. 23 S (O) m1 R 24 wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 R 25 , -(CH 2 ) n1 OR 25 , -(CH 2 ) n1 S.R. 25 , -(CH 2 ) n1 C(O)R 25 , -(CH 2 ) n1 C(O)OR 25 , -(CH 2 ) n1 S (O) m1 R 25 , -(CH 2 ) n1 N.R. 25 R 26 , -(CH 2 ) n1 C(O)NR 25 R 26 , -(CH 2 ) n1 C(O)NHR 25 , -(CH 2 ) n1 N.R. 25 C(O)R 26 and -(CH 2 ) n1 N.R. 25 S (O) m1 R 26 may be substituted with one or more substituents selected from x is an integer of 0, 1, 3, 4 or 5; Z, R 23 ~R 26 , m 1 and n 1 is as described in claim 5.

8. The compound represented by general formula (I) according to any one of claims 1 to 7, which is a compound represented by general formula (III-B), a stereoisomer thereof, or a pharmacologically acceptable salt thereof. 【Chemistry 10】 (In the formula, R 5 is a hydrogen atom, C 1-6 Alkyl group, C 1-6 Halogenated alkyl group or C 1-6 alkoxy groups, R 19 is a hydrogen atom, C 1-6 Alkyl group, C 1-6 Halogenated alkyl group, C 1-6 Alkoxy group, -(CH 2 ) n1 OR 23 or -(CH 2 ) n1 S.R. 23 is selected from R c is a hydrogen atom, a cyano group or C 1-6 alkyl groups, z is an integer of 0, 1 or 2; and n is 0, 1 or 2.

9. The compound represented by general formula (I) according to any one of claims 1 to 8, which is a compound represented by general formulas (IV-A) and (IV-B), a stereoisomer thereof, or a pharmacologically acceptable salt thereof. 【Chemistry 11】 (In the formula, R 3a is C 1-6 Alkyl group, C 1-6 Halogenated alkyl group or C 1-6 alkoxy groups, R 19 is a cyano group, a halogen, C 1-6 Alkyl group, C 1-6 Halogenated alkyl group, C 1-6 Alkoxy group, -(CH 2 ) n1 OR 23 , -(CH 2 ) n1 S (O) m1 R 23 , -(CH 2 ) n1 S(O)(=NR 23 ) R 24 or -(CH 2 ) n1 S.R. 23 is selected from R a represents a hydrogen atom, a cyano group, a halogen atom, a nitro group, an alkyl group, an alkoxy group, a halogenated alkyl group, a cycloalkyl group, a hydroxyalkyl group, a heterocyclyl group, a heteroaryl group, -(CH 2 ) n1 CR 23 R 24 R 25 , -(CH 2 ) n1 S.R. 23 , -(CH 2 ) n1 C(O)OR 23 , -(CH 2 ) n1 S (O) m1 R 23 , -(CH 2 ) n1 S(O)(=NR 23 ) R 24 , -(CH 2 ) n1 C(O)NR 23 R 24 wherein the alkyl, cycloalkyl, heterocyclyl or heteroaryl group may be further substituted with one or more substituents selected from a hydrogen atom, an alkyl group, a halogen, a cyano group, a hydroxyl group, a cycloalkyl group, a heterocyclyl group and a heteroaryl group; x is an integer of 0, 1 or 2; and R 5 , R 23 , R 24 , m 1 and n 1 is as described in claim 4.

10. The compound represented by general formula (I) according to claim 1 to 3 or 6, which is a compound represented by general formula (VII), a stereoisomer thereof, or a pharmacologically acceptable salt thereof. 【Chemistry 12】 (In the formula, R 1a and R 1b are the same or different and each represents a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R 23 , -(CH 2 ) n1 OR 23 , -(CH 2 ) n1 S.R. 23 , -(CH 2 ) n1 C(O)R 23 , -(CH 2 ) n1 C(O)OR 23 , -(CH 2 ) n1 S (O) m1 R 23 , -(CH 2 ) n1 S(O)NR 23 , -(CH 2 ) n1 N.R. 23 R 24 , -(CH 2 ) n1 C(O)NR 23 R 24 , -(CH 2 ) n1 N.R. 23 C(O)R 23 or -(CH 2 ) n1 N.R. 23 S (O) m1 R 24 wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 R 25 , -(CH 2 ) n1 OR 25 , -(CH 2 ) n1 S.R. 25 , -(CH 2 ) n1 C(O)R 25 , -(CH 2 ) n1 C(O)OR 25 , -(CH 2 ) n1 S (O) m1 R 25 , -(CH 2 ) n1 N.R. 25 R 26 , -(CH 2 ) n1 C(O)NR 25 R 26 , -(CH 2 ) n1 C(O)NHR 25 , -(CH 2 ) n1 N.R. 25 C(O)R 26 and -(CH 2 ) n1 N.R. 25 S (O) m1 R 26 may be substituted with one or more substituents selected from Ring A, Z, Ra, R 23 ~R 26 , m 1 , n 1 and x are as defined in claim 7.

11. The compound represented by general formula (I) according to any one of claims 1 to 9, which is a compound represented by general formula (VIII), a stereoisomer thereof, or a pharmacologically acceptable salt thereof. 【Chemistry 13】 (In the formula, rings A, Z, R a and x are as defined in claim 7.

12. The compound represented by general formula (I) according to any one of claims 1 to 9, which is a compound represented by general formula (IX), a stereoisomer thereof, or a pharmacologically acceptable salt thereof. 【Chemistry 14】 (In the formula, Z is -CR 23 R 24 -, -(CH 2 ) n1 N.R. 23 -, -(CH 2 ) n1 O (CH 2 ) n2 - or -O-, preferably a methylene group; Ring B is selected from a cycloalkyl group, a heterocyclyl group, an aryl group, or a heteroaryl group, of which the cycloalkyl group, the heterocyclyl group, the aryl group, and the heteroaryl group can further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 R 25 , -(CH 2 ) n1 OR 25 , -(CH 2 ) n1 S.R. 25 , -(CH 2 ) n1 C(O)R 25 , -(CH 2 ) n1 C(O)OR 25 , -(CH 2 ) n1 S (O) m1 R 25 , -(CH 2 ) n1 N.R. 25 R 26 , -(CH 2 ) n1 C(O)NR 25 R 26 , -(CH 2 ) n1 C(O)NHR 25 , -(CH 2 ) n1 N.R. 25 C(O)R 26 and -(CH 2 ) n1 N.R. 25 S (O) m1 R 26 may be substituted with one or more substituents selected from R b are the same or different and each represents a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R 23 , -(CH 2 ) n1 OR 23 , -(CH 2 ) n1 S.R. 23 , -(CH 2 ) n1 C(O)R 23 , -(CH 2 ) n1 C(O)OR 23 , -(CH 2 ) n1 S (O) m1 R 23 , -(CH 2 ) n1 S(O)NR 23 , -(CH 2 ) n1 N.R. 23 R 24 , -(CH 2 ) n1 C(O)NR 23 R 24 , -(CH 2 ) n1 N.R. 23 C(O)R 23 or -(CH 2 ) n1 N.R. 23 S (O) m1 R 24 wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 R 25 , -(CH 2 ) n1 OR 25 , -(CH 2 ) n1 S.R. 25 , -(CH 2 ) n1 C(O)R 25 , -(CH 2 ) n1 C(O)OR 25 , -(CH 2 ) n1 S (O) m1 R 25 , -(CH 2 ) n1 N.R. 25 R 26 , -(CH 2 ) n1 C(O)NR 25 R 26 , -(CH 2 ) n1 C(O)NHR 25 , -(CH 2 ) n1 N.R. 25 C(O)R 26 and -(CH 2 ) n1 N.R. 25 S (O) m1 R 26 and y is an integer selected from 0, 1, 2, 3, or 4.

13. The compound represented by general formula (I) according to any one of claims 1 to 3, which is a compound represented by general formula (VIII), a stereoisomer thereof, or a pharmacologically acceptable salt thereof. 【Chemistry 15】 (In the formula, R 21 represents a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R 23 , -(CH 2 ) n1 OR 23 , -(CH 2 ) n1 S.R. 23 , -(CH 2 ) n1 C(O)R 23 , -(CH 2 ) n1 C(O)OR 23 , -(CH 2 ) n1 S (O) m1 R 23 , -(CH 2 ) n1 N.R. 23 R 24 , -(CH 2 ) n1 C(O)NR 23 R 24 , -(CH 2 ) n1 N.R. 23 C(O)R 24 or -(CH 2 ) n1 N.R. 23 S (O) m1 R 24 wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 R 25 , -(CH 2 ) n1 OR 25 , -(CH 2 ) n1 S.R. 25 , -(CH 2 ) n1 C(O)R 25 , -(CH 2 ) n1 C(O)OR 25 , -(CH 2 ) n1 S (O) m1 R 25 , -(CH 2 ) n1 N.R. 25 R 26 , -(CH 2 ) n1 C(O)NR 25 R 26 , -(CH 2 ) n1 C(O)NHR 25 , -(CH 2 ) n1 N.R. 25 C(O)R 26 and -(CH 2 ) n1 N.R. 25 S (O) m1 R 26 may be substituted with one or more substituents selected from R 23 ~R 26 , m 1 and n 1 is as described in claim 1.

14. The compound represented by general formula (I) according to any one of claims 1 to 3, which is a compound represented by general formula (X), a stereoisomer thereof, or a pharmacologically acceptable salt thereof. 【Chemistry 16】 (In the formula, M is -CR 23 - or an oxygen atom, Y is -S(CH 2 ) n1 --, 【Chemistry 17】 is selected from R 21 represents a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, an alkoxy group, a haloalkoxy group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, -(CH 2 ) n1 R 23 , -(CH 2 ) n1 OR 23 , -(CH 2 ) n1 S.R. 23 , -(CH 2 ) n1 C(O)R 23 , -(CH 2 ) n1 C(O)OR 23 , -(CH 2 ) n1 S (O) m1 R 23 , -(CH 2 ) n1 N.R. 23 R 24 , -(CH 2 ) n1 C(O)NR 23 R 24 , -(CH 2 ) n1 N.R. 23 C(O)R 24 or -(CH 2 ) n1 N.R. 23 S (O) m1 R 24 wherein the alkyl group, the halogenated alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group further include a deuterium atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, an oxo group, a nitro group, a cyano group, a hydroxyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkoxy group, a hydroxyalkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, -(CH 2 ) n1 R 25 , -(CH 2 ) n1 OR 25 , -(CH 2 ) n1 S.R. 25 , -(CH 2 ) n1 C(O)R 25 , -(CH 2 ) n1 C(O)OR 25 , -(CH 2 ) n1 S (O) m1 R 25 , -(CH 2 ) n1 N.R. 25 R 26 , -(CH 2 ) n1 C(O)NR 25 R 26 , -(CH 2 ) n1 C(O)NHR 25 , -(CH 2 ) n1 N.R. 25 C(O)R 26 and -(CH 2 ) n1 N.R. 25 S (O) m1 R 26 may be substituted with one or more substituents selected from R 22 ~R 26 , m 1 and n 1 is as described in claim 1.

15. The ring A, ring B and ring C are 【Chemistry 18】 13. The compound represented by the general formula (I) according to any one of claims 5, 7, 10, 11 and 12, a stereoisomer thereof or a pharmacologically acceptable salt thereof, wherein the compound is selected from the group consisting of:

16. The R a , R b and R c is a hydrogen atom, a cyano group, a halogen, a nitro group, C 1-6 Alkyl group, C 2-6 Alkynyl group, C 1-6 Alkoxy group, C 1-6 Halogenated alkyl group, C 3-6 Cycloalkyl group, C 1-6 Hydroxyalkyl groups, 5- to 10-membered heterocyclyl groups, 5- to 10-membered heteroaryl groups, -(CH 2 ) n1 OR 23 , -(CH 2 ) n1 S.R. 23 , -(CH 2 ) n1 C(O)R 23 , -(CH 2 ) n1 C(O)NR 23 R 24 , -(CH 2 ) n1 C(O)OR 23 or -(CH 2 ) n1 S (O) m1 R 23 Among these, C 1-6 Alkynyl group, C 1-6 Alkoxy group, C 1-6 Halogenated alkyl group, C 3-6 Cycloalkyl group, C 1-6 The hydroxyalkyl group, the 5- to 10-membered heterocyclyl group and the 5- to 10-membered heteroaryl group may further include a hydrogen atom, 1-6 Alkynyl group, halogen, cyano group, hydroxyl group, C 3-6 Cycloalkyl group, C 1-6 optionally substituted with one or more substituents selected from hydroxyalkyl groups, 5- to 10-membered heterocyclyl groups, and 5- to 10-membered heteroaryl groups; R 23 and R 24 are each independently a hydrogen atom, C 1-6 The compound represented by the general formula (I) according to any one of claims 1 to 15, a stereoisomer thereof or a pharmacologically acceptable salt thereof, wherein the alkyl group is selected from an alkyl group or a 3- to 8-membered heterocyclyl group.

17. A compound represented by the general formula (I) according to any one of claims 1 to 16, a stereoisomer thereof or a pharma- ceutically acceptable salt thereof. (In the formula, Z is -CH 2 --, --CH 2 NH-, -CH 2 O-, -CH 2 -, -NH- or -NHSO 2 - selected from R 3a is C 1-6 Alkyl group, C 1-6 Halogenated alkyl group or C 1-6 alkoxy groups, preferably C 1-3 Alkyl group or C 1-3 an alkoxy group, more preferably a methyl group or a methoxymethyl group; R 5 is a hydrogen atom, a halogen, a cyano group, C 1-6 Alkyl group, C 1-6 Halogenated alkyl group or C 1-6 alkoxy groups, preferably hydrogen atoms and C 1-3 is an alkyl group, R 19 is a cyano group, a halogen, C 1-6 Alkyl group, C 1-6 Halogenated alkyl group, C 1-6 Alkoxy group, -(CH 2 ) n1 OR 23 , -(CH 2 ) n1 S (O) m1 R 23 , -(CH 2 ) n1 S(O)(=NR 23 ) R 24 or -(CH 2 ) n1 S.R. 23 Preferably, the compound is selected from a cyano group, a halogen, C 1-3 Alkoxy group, C 1-3 Halogenated alkyl groups, -(CH 2 ) n1 S.R. 23 , -(CH 2 ) n1 S (O) m1 R 23 or -(CH 2 ) n1 S(O)(=NR 23 ) R 24 and more preferably halogen. Or, R 5 and R 19 Any two adjacent groups of 3-6 It can form a cycloalkyl group, preferably a cyclopropyl group.

18. 【Chemical 19-1】 【Chemistry 19-2】 【Chemistry 19-3】 【Chemistry 19-4】 【Chemistry 19-5】 【Chemistry 19-6】 【Chemistry 19-7】 【Chemistry 19-8】 The compound represented by the general formula (I) according to any one of claims 1 to 17, its stereoisomer or a pharma- ceutically acceptable salt thereof, selected from the group consisting of:

19. A pharmaceutical composition comprising a therapeutically effective amount of a compound represented by general formula (I) according to any one of claims 1 to 18, a stereoisomer thereof or a pharmacologically acceptable salt thereof, and one or more pharma- ceutically acceptable carriers, diluents or excipients.

20. A compound represented by the general formula (I) according to any one of claims 1 to 18, a stereoisomer thereof or a pharmacologically acceptable salt thereof, or a pharmaceutical composition according to claim 19, A Use in the manufacture of receptor modulators.

21. Use of a compound of general formula (I) according to any one of claims 1 to 18, a stereoisomer thereof or a pharmacologically acceptable salt thereof, or a pharmaceutical composition according to claim 19, in the treatment of a CNS-related disorder selected from sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, memory and / or cognition disorders, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, or tinnitus.

Citation Information

Patent Citations

  • 17-azasteroids substituted on the 21-carbon atom, their use and processes for the preparation thereof

    DE2130282A1

  • 3,3-Disubstituted 19-norpregnan compounds and their uses

    JP2014528485A

  • 19-N-C3,3-disubstituted C21-N-pyrazolyl steroid and method of use

    JP2016517851A

  • Compositions and methods for treating CNS disorders

    JP2017531020A

  • 6beta,19-oxido androstane derivatives

    US3001989A